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MS1 (Myocyte stress 1) is a muscle specific protein, implicated in the development 
of cardiac muscle hypertrophy. In rat models of induced left ventricular 
hypertrophy, MS1 expression is increased 3 times after applying stress signal with a 
peak expression before day 1. It may suggest that MS1 can act as a very important 
stress sensor that correlates external signals with a cellular response, however its 
complete mode of action needs to be further elucidated.   
It is has been proposed that MS1 is indirectly involved in gene expression 
regulation through a mechanism that involves actin dynamics and SRF. However, 
this work will show evidence that MS1 could be directly involved in gene 
expression regulation through a binding of specific DNA sequences. Based on our 
previous structural data it was found that MS1 contains a winged helix-turn-helix 
domain (WHTH), a common DNA binding domain present in transcription factors. 
Consequently, we hypothesised that MS1 could be a DNA binding protein itself and 
potentially it could act as a transcription factor.  
This work shows that MS1 possesses almost all characteristics of a transcription 
factor such as presence of a DNA binding domain, nuclear localisation and binding 
of a specific DNA sequence. In Chapter 3 a detailed subcellular localisation of MS1 
will be characterised and it will provide evidence that MS1 cytoplasmic/nuclear 
localisation is more complex than anticipated and that it depends on a 
developmental stage as well as on environmental conditions such as presence of 
stress factors. In Chapter 4 DNA binding properties of MS1 will be characterised 
and ultimately it will be shown that MS1 binds to a defined DNA sequence in a 
manner typical of a winged helix-turn-helix domain.  
The findings of this thesis expand the present knowledge about MS1 function, 
where apart from its involvement in actin dynamics regulation it binds DNA 
opening up the possibility that it may be directly involved in gene expression 
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Introduction and thesis overview 
 
 
1.1. General introduction 
 
Striated muscle tissue, which builds heart and skeletal muscles, is one of the tissues 
most adaptive to external and internal changes.  
 
Muscle growth (hypertrophy), whether heart or skeletal, is a response to 
biochemical (e.g. hormones, cytokines, growth factors etc.) or mechanical (e.g. 
high pressure, high volume overload) signals, whereas skeletal muscle loss 
(atrophy) can be caused by muscle disuse, biochemical signals (e.g. cytokines, 
catabolic steroids, acidosis etc.) or can be a result of a genetic mutation (Gautel 
2008; Sandri 2008).  
 
Both muscle hypertrophy and atrophy are controlled by highly sophisticated 
signalling pathways, which, in spite of many years of research, are still yet to be 
fully understood. What is known is that the central player of the hypertrophic and 
atrophic signalling pathways is the nucleus. Ultimately, all changes that lead to 
hypertrophy or atrophy, are due to alternate expression of genes that are involved in 
normal myocyte structure and function (Gautel 2008). 
 
The negative consequences of muscle atrophy are not questionable, however 
muscle hypertrophy can have a positive impact. For example, hypertrophy of 
skeletal muscle as a result of exercise or heart hypertrophy in athletes and pregnant 
women are the positive examples of physiological (adaptive) hypertrophy. 
However, we can also distinguish a pathological hypertrophy, which can be 
associated with very serious cardiovascular diseases (CVDs) that may ultimately 
lead to heart failure and death (Schiaffino et al. 2013; Sandri 2008). 
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Currently, cardiovascular diseases account for the highest number of deaths in the 
developed countries. According to the recently published 4th edition of the 
“European cardiovascular disease statistics (2012)” report, CVDs cause 47% of all 
deaths in Europe and 40% in the European Union. Moreover, it is the main cause of 
death in women in all European countries and the main cause of death of men in all 
but 6 countries in Europe (exceptions are France, Israel, the Netherlands, San 
Marino, Slovenia and Spain). In the UK, the numbers are smaller than for the 
Europe (around 32% for both men and women), (Nichols et al. 2013).  
 
In spite of all the efforts that have been made in the recent years, there is still a 
great need to study the molecular mechanisms that control muscle growth and 
development. Understanding the molecular basis of the complex signalling 
pathways controlling muscle mass is essential to the development of novel 
therapeutic treatments for people suffering from myopathies.  
 
Myocyte stress 1 (MS1) is a relatively recently discovered protein (2002), which 
attracted the attention of muscle scientists, especially those working on cardiac 
hypertrophy. It has been identified as an early cardiac stress response protein, as 
well as being a protein expressed early during embryogenesis and subsequently has 
been hypothesised to be crucial in mediating the hypertrophic response (Mahadeva 
et al. 2002).  
 
Although, all the current knowledge about MS1 function is based on its actin 
binding properties (Arai et al. 2002; Fogl et al. 2011), this thesis will provide 
evidence that MS1 can have an alternative function, which is DNA binding. 
 
In this chapter, the currently known mechanisms governing striated muscle growth 
and development will be described, followed by the characterisation of MS1 protein 








1.2. Striated muscle characterisation 
 
Striated muscle tissue, which is responsible for voluntary movement of skeletal 
muscles as well as for the involuntary pumping function of the heart, is built from 
contractile units, called sarcomeres. Sarcomeres are small protein machineries, 
which convert chemical energy into motion and which are built from repetitive, 
highly regular actin and myosin filaments (Figure 1.1). Actin forms thin, whereas 
myosin forms thick filaments, which under the light microscope are seen as 
repetitive light (actin) and dark (myosin) bands. The filaments are cross-linked to 
the M-band (myosin) and the Z-disc (actin) and interact with a wide range of 
proteins, which in turn regulate sarcomere function. For example, the 
tropomyosin/troponin complex on actin filaments regulates muscle contraction, 
whilst myosin filaments contain binding sites for the regulatory myosin-binding 
protein-C, which is also involved in regulation of muscle contraction.  
 
Some of the sarcomeric proteins, such as muscle ankyrin repeat protein (MARP), 
muscle-specific RING-finger proteins (MURFs) or four-and-a-half LIM domain 
protein (FHL), act as molecular communicators between the sarcomere and the 
nucleus (Lange et al. 2006). In response to mechanical signals they translocate to 
the nucleus, where they can affect the gene expression. One example is MURF2, 
which normally is located in the Z-disc or M-band of the sarcomere, but under 
atrophic conditions it translocates to the nucleus, where it interacts with Serum 
Response Factor (SRF). Consequently, this interaction leads to downregulation and 
cytoskeletal relocalisation of SRF, which in turn inhibits SRF-regulated 
transcription of muscle specific genes (Lange et al. 2005).  
 
The sarcomere structure is directly linked to the function of the muscle cell. The 
ultimate role of striated muscle is to generate force via muscle contraction. It is 
achieved by sliding of actin filaments on each end of the sarcomere towards myosin 
filaments and thus, shortening the sarcomere and causing a muscle contraction. It is 
an energy-dependent process and requires adenosine triphosphate (ATP), which is 
produced during glycolysis, oxidative phosphorylation or could be sourced from 






Figure 1.1 Schematic representation of the sarcomere – the contractile unit of 
striated muscles. It contains thin (actin, brown) and thick (myosin, blue) filaments, 
which interact with variety of proteins. Some of the proteins such as MURF or FHL 
translocate to the nucleus in response to appropriate signals. During muscle 
contraction actin filaments slide towards myosin filaments, which results in 




Skeletal and cardiac muscle development begins during early embryogenesis and is 
controlled by a complex network of regulatory proteins, which ensure that the 
correct proteins are expressed at the right time and in the right place. One of the 
most important regulatory proteins during muscle growth and differentiation is 







1.3 Serum Response Factor (SRF) 
 
SRF is a transcription factor that belongs to the MADS box family of transcription 
factors (MCM1, AG, DEFA and SRF). It is expressed in a wide range of tissues and 
is involved in a variety of signalling pathways that regulate gastrulation, 
development of the cardiovascular system and skeletal muscles, function of the 
smooth, cardiac and skeletal muscle cells, vascularisation, development and 
regeneration of the liver, function of T cells, B cells and neuronal cells (Chai and 
Tarnawski 2002). 
 
SRF binds to serum response elements (SRE), which are also known as CArG 
boxes (characterised by the presence of a CC(AT)6GG sequence). They are 
associated with a variety of genes such as early response genes (c-fos, fosB, junB, 
egr-1, egr-2), neuronal genes (nurr1, nurr77) and muscle-specific genes encoding 
actins and myosins. Overall, via regulating expression of the above genes, SRF is 
involved in cell growth and differentiation, muscle growth and function and 
neuronal transmission (Miano 2003; Shore and Sharrocks 1995) 
 
Both cellular signal transduction pathways and interaction with other transcription 
factors regulate SRF activity. For example in response to actin signalling, SRF 
interacts with myocardin or myocardin related transcription factors (MRTFs) and 
activates muscle-specific gene expression (Wang et al. 2002) or through interaction 
with ternary complex factor (TCF) it responds to mitogen-activated protein kinase 
signalling (Buchwalter et al. 2004).  
 
SRF alone is a poor transcription factor and its activity is very often enhanced by 
interaction with its co-activators. For example, it was shown that SRF-mediated 
transcription of cardiac alpha-actin gene requires simultaneous interaction of SRF, 
Sp1 and MydD (Sartorelli et al. 1990) or that it is synergistically increased by 
interaction of SRF with Nkx 2.5 and GATA4 (Sepulveda et al. 2002).  
 
During embryogenesis in vertebrates, SRF mRNA is initially detected mainly in 
striated and smooth muscle lineages, and during later stages of embryogenesis it is 
expressed more ubiquitously in the whole embryo. (Belaguli et al. 1997; Croissant 
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et al. 1996).  
 
Early attempts to establish the role of SRF during muscle development were 
hindered by a high lethality in SRF-deficient mice model. However, subsequent 
studies of the cardiac-specific SRF-deficient mice, showed that SRF is required for 
normal cardiac development. SRF was also found to be a crucial modulator of 
cardiac specific gene expression of genes involved in sarcomerogenesis. On the 
other hand, in skeletal muscles, SRF deficiency causes severe tissue hypoplasia. 
Overall, those findings provide evidence that SRF plays a very crucial role in 
regulation of striated muscle-specific gene expression during development 
(Arsenian et al. 1998). 
 
Apart from the involvement in normal, “healthy” muscle growth and development, 
SRF has been found to be an important regulatory modulator of the cardiac 
hypertrophic response. Over-expression of SRF in hearts causes pathophysiological 
hypertrophy, characterised by chamber dilation, wall thinning and lethality (Zhang 
et al. 2001a; Zhang et al. 2001b). At the level of the individual cardiomyocyte, SRF 
perturbation is sufficient to induce disorganisation of the contractile apparatus, 
stress fibre formation and attenuated expression of sarcomeric genes (Balza and 
Misra 2006; Parlakian et al. 2005). 
 
In the context of MS1, it appears that there is a link between these two proteins 
(SRF-MS1), as knockdown of endogenous MS1 (via RNAi) significantly reduces 
SRF muscle-specific activity (Kuwahara et al. 2005). 
 
 
1.3.1. Myocardin and Myocardin Related Transcription Factors (MRTFs) 
 
Myocardin and MRTFs are co-activators of SRF and they are very important in 
mediating muscle-specific gene expression. MRTFs, which comprise of MRTF-A, 
MRTF-B, and myocardin have been shown to be related, by having similar role and 
structure. Initially, myocardin was identified in a bioinformatics screen for 
unknown cardiac restricted transcripts (Wang et al. 2001). Later, two related to 
myocardin homologous were identified, named myocardin-related transcription 
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factor-A and B (Wang et al. 2002).  
 
Myocardin and MRTFs have a series of conserved domains (Figure 1.2) and thus 
presumably closely related function, however their tissue expression pattern is 
different. Myocardin is expressed specifically in the cardiovascular system (Pipes et 
al. 2006; Parmacek 2007; Wang et al. 2001), whilst MRTFs are expressed in a 
broad range of embryonic and adult tissues (Wang et al. 2002).  
 
All myocardin family members contain RPEL motifs. Myocardin contains 2, while 
MRTF-A and MRTF-B contain 3 RPEL motifs, which regulate their interaction 
with actin. Using those motifs, MRTF-A and MRTF-B bind to G-actin and form 
very stable complexes, which are localised in the cytoplasm. In response to changes 
in actin dynamics, resulting in activating certain signaling pathways e.g. the growth 
pathway, MRTFs dissociate from the G-actins and translocate to the nucleus. In the 
nucleus they associate with SRF and stimulate its activity (Miralles et al. 2003; 
Hirano and Matsuura 2011). Interestingly, MS1 has been shown to stimulate this 
translocation, and therefore transcriptional activity of SRF (Kuwahara et al. 2007).  
 
Myocardin as well as MRTFs have been shown to be very important for normal and 
pathological muscle growth and development. For example, dominant negative 
myocardin prevents cardiac gene expression in Xenopus embryos, whilst conversely 
forced over-expression of wild type myocardin is sufficient to induce cardiac 






Figure 1.2 Schematic representation of the domain architecture and domain 
functions of myocardin and MRTFs. (A) Structural domains of the vertebrate 
(Myocardin, MRTF-A and MRTF-B) and fly (DMRTF) myocardin-related 
proteins. The percentage of the identity between each domain and the 
corresponding domain of myocardin is shown. (B) Functions of the various 
domains of myocardin (black) and their binding interactions (red). The RPEL 
domains mediate cytoplasmic localisation and actin binding only in MRTF-A and 
MRTF-B. Nuclear localisation of MRTF-A requires the basic domain; ++ basic 
region; Q – glutamine-rich region, which mediates interaction with SRF; SAP – 







1.4. Cardiac muscle hypertrophy 
 
Cardiac hypertrophy is a remodelling of the heart muscle, which becomes enlarged 
compared to the normal heart. This is due to an increase in cell size rather than cell 
number. There are two types of cardiac hypertrophy: physiological and 
pathological. In physiological hypertrophy, growth of the heart muscles can occur 
in 3 situations: during normal postnatal growth, during pregnancy and as a response 
to continuous physical exercise. In pathological hypertrophy, enlargement of the 
heart muscles is a response to biomechanical stress (i.e. hypertension and volume 
overload) or biochemical signals (neurohormonal signals e.g. endocrine disorders, 
cytokines, chemokines, growth factors etc.) or can be caused by a genetic mutation 
in sarcomeric or cytoskeletal proteins (Olson and Schneider 2003). 
One of the most common types of cardiac hypertrophy is left ventricular 
hypertrophy (LVH). The signalling pathway leading to LVH starts with a pressure 
or volume overload. In order to accommodate such challenges, the heart increases 
its muscle mass so it can provide more work. At the beginning, the adaptation is 
beneficial, since a larger heart can pump more blood faster, however, in the long-
term it can cause muscle stiffening and other pathological changes that can lead to 
heart failure (Pokharel et al. 2003). 
The molecular and cellular hallmarks of LVH involve enhanced protein synthesis, 
sarcomere reorganization and myocyte size increase. Most of the cellular changes 
are the result of altered gene programming, which is a cellular response to 
environmental signals. There are some known genes, which are expressed in early 
stages of hypertrophic response such as c-fos, c-myc, and c-jun, called early 
response genes. Subsequently, there is an expression of foetal isoforms of 
cytoskeletal proteins such as atrial and natriuretic peptides, foetal α-actinin and β-
myosin heavy-chains and changes in expression of key regulatory proteins that 
modulate intracellular ion homeostasis, specifically, e.g., down-regulation of 
sarcoplasmic reticulum calcium ATPase (SERCA2a) and para-sympathetic and 
sympathetic receptors. In addition, variable up-regulation of the Na2+/Ca2+ 
exchanger and down-regulation of the potassium channel Kv4.3, which causes a 
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prolonged action potential and therefore, subsequent reduction in the transient of 
outward current (Io) density is observed (Lorell and Carabello 2000). 
Summarizing, the cardiac hypertrophic response is characterised by substantial 
changes in myocyte size, fetal gene expression, sarcomeric re-organisation and 
altered Ca2+ handling with the combined effect of these changes ultimately 
resulting in contractile dysfunction and heart failure.  
There are several signaling pathways that control cardiac hypertrophy and they all 
start with the stimulus described above. The most important signaling pathways are 
shown in Figure 1.3. They include proteins such as G protein coupled receptors 
(GPCRs), small G-proteins, mitogen activated protein kinases (MAPKs), PI3K, 
PKB, glycogen synthase kinase-3 and calcinuerin, which are considered to be most 
important in the signaling pathways leading to the development of cardiac 
hypertrophy. Biochemical signals are sensed via a variety of membrane receptors, 
including receptors that have an intracellular tyrosine kinase domain; receptors that 
have an intracellular threonine/serine kinase domain and gp130-linked receptors. 
Biomechanical signals are sensed by intracellular stretch-sensitive receptors, 
however the exact molecular switches need to be further elucidated (Heineke and 
Molkentin 2006). One of the hypothesised stretch-sensing receptors is the small 
LIM-domain protein MLP (muscle LIM protein), which is anchored to specific 
proteins at the Z-disc and is thought to function as an internal stretch sensor through 
forming a complex with transducing proteins (Knoll et al. 2002). In terms of the 
intracellular signaling pathways we can distinguish two principal mechanisms of 
transducing the hypertrophic signal: 1 - protein kinase cascades, where the signal is 
transduced across the cytoplasm and which result in transactivation-dependent 
phosphorylation of nuclear transcription factors and 2 – phosphorylation and 
dephosphorylation of cytoplasmic transcription factors, which subsequently 
translocate to the nucleus, where they regulate downstream gene expression (Clerk 






Figure 1.3 Signalling pathways involved in mediating cardiac hypertrophic 
response (Heineke and Molkentin 2006). Transcription factors include SRF, GATA 
4, MEF2, NF-kB and EGR1, which have been found to be very important mediators 
of hypertrophic gene expression.  
 
 
1.5. RhoA signalling  
 
RhoA protein belongs to the small G protein superfamily, whose  members provide 
a very important link between cell membrane receptors and a variety of intracellular 
signaling pathways. Rho proteins family, which includes RhoA, Rac and cdc42 
proteins, plays a very crucial role in modulating cytoskeletal and sarcomeric 
organization. Moreover, Rho subfamily proteins have been directly implicated in 




RhoA itself regulates numerous cytoskeletal-dependent cell functions including 
focal adhesion formation, myosin-based contractility, F-actin bundling and 
monomeric G-actin polymerization (Yanazume et al. 2002). RhoA stimulates ANF 
expression, which is a typical hypertrophic marker within the heart (Yanazume et 
al. 2002). RhoA has been found to be involved in the development of cardiac 
hypertrophy in response to biomechanical as well as biochemical signals. The most 
important downstream effector of RhoA signaling is SRF. It has been shown that 
RhoA directly activates SRF activity, through a mechanism that involves actin 
dynamics, however the exact mechanism is not known. Recently, it has been shown 
that MS1 may provide a link between RhoA signaling, actin dynamics and SRF 
transcription of hypertrophic genes (Arai et al. 2002).  
 
 
1.6. Skeletal muscle hypertrophy and atrophy 
Skeletal muscle mass is tightly regulated by anabolic and catabolic processes, 
which must be carefully balanced in order to maintain a healthy state of muscles.  
Skeletal muscle hypertrophy is characterised by an increase in muscle mass and it is 
a result of increased protein synthesis, which exceeds protein degradation. There 
are several factors such as resistance training, exercise, diet or hormonal treatment 
that can stimulate skeletal hypertrophy. On the other hand, muscle atrophy, which 
is characterised by a muscle loss, is a result of increased protein degradation, which 
exceeds protein synthesis. It can be also a result of increased muscle cell death 
(Jagoe and Goldberg 2001; Sartorelli and Fulco 2004; Goldspink et al. 1983).  
Whilst skeletal muscle hypertrophy is a rather healthy response to exercise or diet, 
muscle atrophy is observed in neuromuscular diseases such as muscular dystrophies 
or due to lack of exercise (movement), ageing, immobilization or denervation 
(Glass 2003; Goldspink et al. 1983; Sartorelli and Fulco 2004; Jagoe and Goldberg 
2001).  
Several signaling pathways involved in skeletal muscle hypertrophy and atrophy 
development have been identified. One of the most important signaling pathways is 
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the Acute Transforming Retrovirus Thymoma (AKT) signaling pathway. AKT is 
phosphorylated and activated via upstream signalling involving IGF-1 and 
phosphatidylinositol 3-kinase (PI3K). Once activated, AKT has been shown to 
increase protein synthesis via the mammalian target of rapamycin (mTOR) and 
glycogen synthase kinase- 3β (GSK-3β) (Russell 2010; Glass 2005; Léger et al. 
2006). 
 
AKT has been also shown to play a important role in the regulation of signalling 
pathways involved in protein degradation (Russell 2010; Glass 2005; Léger et al. 
2006). For example, inactivation of AKT causes dephosphorylation and subsequent 
activation of Forkhead box (FOXO) transcription factors, FOXO1 and FOXO3a. 
FOXO proteins regulate expression of genes involved in the Ubiquitin Proteasome 
Pathway (UPP), such as Atrogin-1 and muscle RING-finger protein-1 (MuRF1), 
and autophagy such as LC3 and GABA(A) receptor-associated protein like 1 
(Mammucari et al. 2008; 2007). 
 
Other signaling pathways involved in mediating muscle hypertrophy are MAPK 
pathway and the calcineurin/nuclear factor of activated T-cells (NFAT) pathway. 
Muscle atrophy can be controlled by the calpain, the autophagic-lysosomal, the 
caspase/apoptotic protease and the ubiquitin proteasome pathways (Huang and 
Forsberg 1998; Lin et al. 2005; Russell 2010; Banerjee and Guttridge 2012).  
 
Although, some of the signaling pathways are known, there is still a need for more 
research on the intracellular mechanisms that control muscle mass and especially 
the cross-talk between all the proteins involved in them. A better understanding of 
these processes is required for a future identification of major players that can be 
specifically therapeutically targeted in order to minimize or combat the effects of 









MS1 (Myocyte stress 1) also known as STARS (Striated muscle activator of Rho 
signalling) and ABRA (Actin binding Rho activator) is a protein discovered during 
identification of early genes expressed in the rat model of hypertension (Mahadeva 
et al. 2002) and during identification of genes expressed in the early embryonic 
mouse heart tube (Arai et al. 2002).  
Samani et al. (2002) were looking for genes that are upregulated during the early 
stage of pressure-induced LVH (left ventricular hypertrophy) in a rat model of 
aortic banding and they identified a novel gene, which was later named MS1, as one 
of them. MS1 mRNA was upregulated 1 hour after aortic banding, with a peak 
expression before day 1. Further mRNA expression analysis (using RT-PCR) has 
shown that MS1 is expressed specifically in muscle tissue and that it displays a 
development-specific expression pattern. In the left ventricle, MS1 mRNA was 
detected at low level at early embryo stage (E18d) and its expression was 
significantly upregulated from post-natal stage through to adulthood (Mahadeva et 
al. 2002).  
MS1 was also found among other genes in the screen of novel genes expressed in 
the early embryonic mouse heart. Further research has shown that the product of the 
gene is a protein of 375 amino acids and its carboxyl-terminus is conserved 
amongst different species (human, mouse, C.elegans D.melanogaster etc.). The full 
alignment of MS1 for 28 different species is shown in Appendix 1.  
Initially, MS1 was found to be expressed specifically in cardiac and skeletal muscle 
tissues, however some data shows that MS1 could also be expressed in endothelial 
cells, e.g., in collateral blood vessels (Troidl et al. 2009). In terms of subcellular 
localisation, in cardiomyocytes MS1 was found in the I-band, and to a smaller 
extent in the M-band of the sarcomere. However, it has also been reported that MS1 
can localise to the nucleus, although the data was not clearly shown (Arai et al. 
2002) or the findings were not followed up (Troidl et al. 2009; Wallace et al. 2011). 
When overexpressed in non-muscle (Hela or COS) cells as well as in muscle cells, 
MS1 co-localises with the actin cytoskeleton (Arai et al. 2002). 
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The function of MS1 is not yet fully understood and the whole current knowledge 
regarding its functionality is based on its actin-binding properties. Arai et al. (2002) 
have shown that MS1 directly binds actin and stabilises the polymerised form of 
actin and/or enhances actin polymerisation. They mapped the actin-binding region 
of MS1, which seemed to require two separate but co-dependent regions: region 1 
flanked by amino acids 234 to 279, and region 2 encompassed by amino acids 356 
to 375 (Arai et al. 2002). However, our recent results showed absence of any co-
dependency between those two regions in actin binding, as well as the ability of the 
domains containing those regions to bind actin separately (Fogl et al. 2011). Since 
there was no information about the domain organisation of MS1, we have defined it 
using combination of combinatorial domain hunting (CDH), sequence analysis and 
biophysical characterisation. Ultimately, 3 independent parts were identified: an 
unfolded N-terminus and 2 actin-binding domains, named actin-binding domain 1 
(ABD1; 193-296) which is unfolded and actin-binding domain 2 (ABD2; 294-375), 
which in vitro, is the only one folded part of MS1 (Figure 1.4). ABD1, which 
contains region 1,  bound actin with higher affinity than ABD2 (contains region 2) 
(KD = 2.21± 0.47 µM vs. 10.61 ± 0.7 µM, respectively) suggesting that ABD1 can 
fulfil the actin-binding properties on its own, whilst ABD2 may play another role 
(Fogl et al. 2011).  
The N-terminal part of MS1 contains a predicted nuclear localisation sequence 
(NLS), which starts at R153 (PredictNLS (Cokol et al. 2000)). Additionally, using 
the RegPhos server, which provides experimentally confirmed phosphorylation 
sites (Lee et al. 2011), S150 was identified as a likely p38 MAP kinase target 
phosphorylation site. It is common that a NLS can be activated or deactivated by 
phosphorylation of a neighbouring residue, therefore it would be interesting to 
follow this finding. Moreover, using RegPhos another phosphorylation site was 
identified, which is located within the C-terminal part of ABD1. It is Y280, which 
is a possible target of Src-like kinase, however it has to be experimentally 
validated. In this thesis, rat (for bacterial production of protein) and mouse 
(mammalian expression vector) MS1 homologues, which have a high sequence 
similarity to the human MS1 (around 83%) were used. In both cases the protein 





Figure 1.4 Domain organisation of MS1. Only the C-terminal domain of ABD2 is 
folded in solution in vitro. ABD1/2 – actin binding domain 1, 2; NLS – nuclear 
localisation sequence; P1, P2 – potential phosphorylation sites; P1 – S156, p38-like 
MAP kinase target; P2 – Y286, Src-like kinase target.  
 
 
1.7.1. Proposed mode of action of MS1 
Arai et al (2002) proposed that MS1 is involved in SRF-dependent transcription 
through a mechanism that involves Rho signalling and actin dynamics (Arai et al. 
2002). 
Changes in actin dynamics are regulated by members of Rho GTPases family, 
which stimulate actin polymerisation and stress fibre formation in response to 
extracellular signals such as growth factors and stress stimuli (Ridley and Hall 
1992). RhoA protein level has been shown to increase and decrease after work 
overload in skeletal muscles. Additionally, the transcriptional activity of Serum 
Response Factor (SRF) is stimulated in response to changes in actin dynamics and 
Rho signalling, however the mediators between RhoA and SRF were not known 
(Sotiropoulos et al. 1999; Mack et al. 2001). SRF is a MADS-box transcription 
factor, which regulates genes involved in myogenesis, cell proliferation, 
cytoskeletal dynamics and cell migration (Miano 2003), and it controls expression 
of early response genes such c-fos, c-jun, whose expression is increase after high 
pressure or work overload. Transgenic mice with permanently up-regulated SRF 
develop cardiomyopathy, suggesting a very important role for SRF activity in 
ABD1 ABD2 NLS 
1 193 294 375 P1 P2 
Unfolded Folded 
Actin binding sites 
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muscle cells and possibly contribution of SRF to a cardiac hypertrophy (Zhang et 
al. 2001).  
Taking into account that MS1 stabilises polymerised actin and that stabilisation of 
the actin cytoskeleton contributes to SRF-dependent transcription, it was proposed 
that MS1 is a mediator between RhoA and SRF. Using the SM22-luciferase assay, 
in which a construct containing CArG boxes (SRF response elements) was used, it 
has been shown that transfection of MS1 caused 40-fold change in luciferase 
activity, as compared to control. Additionally, mutation in the CArG boxes 
abolished luciferase activity, which indicated a direct involvement of SRF in this 
response (Arai et al. 2002).  
It has also been shown that MS1 activation of SRF transcriptional activity is 
partially mediated by Rho signalling, by comparing the effects of constitutively 
active RhoA mutant (L63) and MS1 on the SM22 promoter activity. The results 
revealed a co-operative role of MS1 and RhoA L63, when expressed together, 
indicated by a higher level activity of the SM22 luciferase reporter assay, than when 
expressed separately (Arai et al. 2002). 
The precise mechanism through which MS1 controls SRF transcriptional activity is 
yet to be elucidated, however it has been shown that MS1 stimulates nuclear 
translocation of MRTF-A and MRTF-B, which are co-activators of SRF (Kuwahara 
et al. 2005). In this proposed model, MS1 enhances actin polymerisation, and 
therefore reduces the available pool of G-actin. This in turn causes the dissociation 
of G-actin monomers from MRTFs and subsequently allows them to translocate to 
the nucleus, where they can associate with SRF and stimulate its transcriptional 
activity (Figure 1.5.), (Kuwahara et al. 2005).  
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Figure 1.5 Proposed mode of action of MS1. In response to signal, MS1 in 
conjunction with RhoA, enhances F-actin polymerisation and/or F-actin 
stabilisation. This reduces the available pool of G-actin and subsequently removes 
its inhibitory effect on SRF co-factors – MRTFs. Subsequently, MRTFs are free to 
translocate to the nucleus, where they associate with SRF and stimulate its 
transcriptional activity.  
 
1.7.2. Regulation of MS1 activity 
It has been shown, that the promoter region of the MS1 gene contains a binding site 
for MEF2 (Myocyte enhancer factor-2); (Kuwahara et al. 2007). MEF2 is a 
transcription factor, whose activity is regulated in response to stress stimuli. It 
controls expression of muscle-specific genes and has been involved in muscle 
development, regulation of striated muscle metabolism and in pathological 
remodelling of the heart (McKinsey et al. 2002). Expression of MS1 is partially 
mediated by MEF2, as in MEF2-full knockout mice the expression of MS1 is 
drastically lowered, however still present. This result suggested that there must be 
other factors that control MS1 expression (Kuwahara et al. 2007).  
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Using comparative in silico analysis of the MS1 promoter, a binding site for MyoD, 
which belongs to myogenic regulatory factors group (MRF) has been identified 
(Ounzain et al. 2008). MRFs are four basic helix-loop-helix E-box binding proteins, 
which are involved in muscle development and myogenesis (Molkentin et al. 1995). 
Further studies have shown, that MyoD regulates expression of MS1 during early 
embryogenesis, whilst MEF2 regulates MS1 expression later. These results are in a 
good agreement with the fact that expression of MEF2 is regulated by MyoD 
(Ounzain et al. 2008). Using a yeast two-hybrid screen, two novel MS1 interacting 
partners were identified, called ABLIM-2 and ABLIM-3 (actin-binding LIM 
protein 2 and 3). ABLIM proteins contain LIM domains, which mediate protein-
protein interaction and which are present in many eukaryotic proteins (Struckhoff 
and Lundquist 2003). In C2C12 cells they were found to co-localise with MS1. It 
has been shown that ABLIM-2 and ABLIM-3 bind actin and stimulate MS1 activity 
in SM22-luciferase reporter assay, which suggests that they may be upstream 
regulators of MS1 activity. Additionally, siRNA-mediated knock-down of ABLIM-
2 and ABLIM-3 inhibits MS1 activity in the SM22-luciferase reporter assay, 
suggesting a very important role of ABLIMs in regulating MS1 downstream 
activity (Barrientos et al. 2007).  
Recently, it has been shown that MS1 expression is controlled by PGC-1α 
(peroxisome proliferator-activated receptor gamma co-activator 1-α) and ERRα 
(oestrogen-related receptor-α). The MS1 promoter contains binding-site for PGC-
1α, which in co-operation with its co-activator ERRα, regulates transcriptional 
expression of muscle-specific genes (Wallace et al. 2011). ERRα and PGC-1α are 
expressed in skeletal muscles following endurance exercises (Wallace et al. 2011), 
and it was reported that MS1 is over-expressed in hypertrophied skeletal muscles 
following resistance exercises (Lamon et al. 2009). Additionally, it was shown that 
overexpression of constitutively active ERRα in C2C12 myotubes increased MS1 
mRNA levels (Wallace et al. 2011). Taking into account that MS1 possibly can 
sense and transduce a pressure overload signal it is possible that the PGC-1α - 
ERRα - MS1 signalling may be very important in mediating hypertrophic response 
in skeletal muscles. Recently, it has been also shown that MS1 can regulate its own 
transcription via a feed-forward mechanism that requires SRF binding to the CArG 
boxes on the MS1 promoter (Chong et al. 2012) and that MS1 is repressed in 
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embryonic, neonatal, and adult hearts by GATA4 (Ounzain et al. 2012). It was also 
demonstrated that pathological depletion of GATA4 (in type1 1/type 2 diabetic 
model) upregulates MS1 expression and activity (Ounzain et al. 2012). 
 
1.7.3. Involvement of MS1 in cardiac hypertrophy 
It has been reported that 1 hour after applying high-pressure stimuli in LVH model 
in rats, MS1 mRNA was up-regulated, with a peak expression 4 hours post banding. 
The densitometric analysis of MS1 mRNA expression indicated three-fold increase 
after banding. The increased MS1 mRNA expression returned to its basal level 
before 24 hours post banding (Mahadeva et al. 2002). This early upregulation of 
MS1 mRNA can suggest a potential involvement of MS1 in early mediation of the 
hypertrophic response (Figure 1.6). Moreover, MS1 has been shown to be up-
regulated in several models of cardiac hypertrophy. It was reported that MS1 is 
expressed in a mouse model of cardiac hypertrophy and in failing human hearts as 
well as being upregulated by MEF2 (Kuwahara et al. 2007). MEF2 causes 
transcription of muscle-specific genes in response to stress signals, which is in line 
with the fact that activation of MS1 by MEF2 causes stimulation of SRF-dependent 
transcription of the early response genes. 
It has been shown that overexpression of MS1 in H9c2 cells causes hypertrophy, 
where cells size was 55% increased compared to the control (Koekemoer et al. 
2009). The precise mechanism by which MS1 caused the hypertrophy was not 
established, however it was shown that MS1 did not affect cell proliferation and 
that it protected the cells from staurosporine-induced apoptosis. The precise 
mechanism of this protection is not known, however, it was shown that 
overexpression of MS1 in H9c2 cells up-regulated Nol3, which is a known 
cardioprotective gene (Koekemoer et al. 2009).  
Together, all these findings indicate that MS1 plays a very important role in cardiac 
function and that it is involved in the development of cardiac hypertrophy, but at 
the same time it may have a cardioprotective role as shown by the attenuation of 





Figure 1.6 Schematic representation of the mechanism of MS1 involvement in the 
development of cardiac hypertrophy. In response to stress signal such as high 
pressure, MS1 in conjunction with RhoA and ABLIMs stimulates F-actin 
polymerisation and subsequent SRF transcriptional activity. SRF activates 
expression of early response and hypertrophic genes, which results in increased 
protein synthesis and sarcomeric re-organisation, ultimately leading to increase in 









1.7.4. Involvement of MS1 in skeletal muscle hypertrophy 
 
Apart from the role in the heart, MS1 is found to be very important for skeletal 
muscle mass maintenance. MS1 mRNA level was found to be significantly 
increased in the Vastus lateralis muscle following 8 weeks of hypertrophy-inducing 
resistance exercise training in humans (Lamon et al. 2009). Similarly, MS1 gene 
expression was increased in postmenopausal women following 12 months of 
hypertrophy-inducing power training (Pöllänen et al. 2010). Moreover, MS1 gene 
expression was found to be 10 times increased when measured 3 h after eccentric 
exercise (Macneil et al. 2010) and MS1 mRNA and protein levels were increased 3 
h following an acute bout of single-leg endurance exercise, and returned to their 
basal level 24 hours post-exercise (Wallace et al. 2011). It all suggests, that MS1 is 
indeed involved in the development of the skeletal hypertrophy and its expression is 
increased in response to a mechanical signal/stress.  
 
In agreement with this statement, hind limb suspension decreased MS1 mRNA 
expression in rat soleus muscle within the first 24 hours, which remained 
suppressed for 48 hours, followed by muscle weight loss (Giger et al. 2009). 
Whether the decrease in MS1 mRNA is a cause or a consequence of muscle wasting 
is yet to be investigated. In contrast, 20 days of limb suspension in humans, 
resulting in a 10% loss in muscle mass, did not reduce MS1 mRNA levels (Sakuma 
et al. 2008), however Lamon et al. (2009) found that cessation of exercise training 
for 8 weeks resulted in a loss of muscle mass as well as in reduction in MS1 mRNA 
(Lamon et al. 2009). 
 
Overall, those finding suggest that MS1 is very important for maintaining skeletal 
muscle mass and that it plays a key role in the detection and transmission of 
mechanical signals in skeletal muscle cells. Knowing that, MS1 may be a future 
therapeutic target for enhancing muscle growth and regeneration for the treatment 






1.8. Aims and approaches used in this study 
MS1 has been shown to play an important role in cardiac and skeletal muscle 
function, however its complete mode of action is not fully understood. The main 
aim of this project is to investigate MS1 function in heart and skeletal muscles as 
well as to understand how it contributes to the development of cardiac and skeletal 
muscle hypertrophy. It is known that MS1 is over-expressed 1 hour after applying a 
stress signal and in hypertrophic hearts and/or skeletal muscles, thus it is possible 
that MS1 could act as a molecular controller that senses the overpressure and 
mediates hypertrophic response. However the exact mechanism needs to be 
elucidated. It is also known that MS1 stimulates SRF-dependent transcription of 
hypertrophic genes, however, in this work we would also like to address the 
possibility of MS1 being directly involved in muscle specific gene expression. 
Recently, we defined the domain architecture and solved the structure of MS1, 
which revealed the presence of 3 independent parts (Figure 1.4), (Fogl et al. 2011). 
Only ABD2 was folded in solution and its three-dimensional NMR solution 
structure was determined (pdb code: 2KRH; Figure 1.7 B).). Using DALI software 
(Holm et al. 2008) we identified proteins structurally similar to ABD2 and most of 
the all 100 hits with a known function were transcription factors or were associated 
with DNA binding function (Table 1.1 shows the first 20 hits, all hits are shown in 
(Appendix 2). All top 10 proteins identified in DALI contained a winged helix-
turn-helix domain, which is a typical DNA-binding domain (Gajiwala and Burley 
2000; Teichmann et al. 2012; Aravind et al. 2005).  
Winged helix-turn-helix domains belong to a family of helix-turn-helix domains, 
which are usually found in transcription factors. They are formed by three alpha-
helices and can also be involved in mediating protein-protein interaction (Wong et 
al. 2000) or form a part of large enzymes (Zheng et al. 2002).  
The major distinguishing feature of winged helix-turn-helix domains is a beta-
strand hairpin located in its C-terminal. The loop between beta strands is 
reminiscent of a “wing”, justifying the domain nomenclature (Brennan 1993).   
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Further comparison has shown that ABD2 contains all features characteristic of a 
typical winged helix-turn-helix DNA binding domain. In a typical winged helix-turn-
helix domain the N-terminus contains three alpha-helices (H1, H2 and H3) and three 
beta-strands (S1, S2 and S3). In ABD2 these are found at the following residues, H1 = 
R302 to M314, H2 = F327 to S338, H3 = V341 to H351. The first beta-strand is 
located between H1 and H2, S1 = I323 to F327, while the S2 = V354 to E357 and S3 = 
V370 to L372. S2 and S3 are separated by loop, which forms the wing.  Additionally, 
there is a high level of residue conservation in helix 3, which is the recognition part and 




PDB code Z-score Function/Description 
1 3Q5F-A 4.9 Transcriptional regulator SLYA  
2  4LMY-A 4.6 Peroxide regulator PERR, FUR family 
3  1G3T-A  4.6 Diphtheria toxin repressor  
4  1Q1H-A 4.5 Transcription factor E 
5  4HX8-A  4.5 Transcriptional regulator MNTR 
6  4ETS-B  4.5 Ferric uptake regulation protein  
7  4BGR-O 4.5 Proteasome subunit beta type-1 
8  1P6R-A 4.4 Penicillinase repressor 
9  2RGV-B 4.3 Peroxide operon regulator 
10  1YQA-A 4.3 Histone 1 
11  2QWW-A 4.2 Transcriptional regulator MARR 
12  LU6G-A 4.2 Cullin homolog 1 
13  2XV4-S 4.2 DNA-directed RNA polymerase III subunit 
14  3EYI-B 4.2 Z-DNA-binding protein 1 
15  3NQO-A 4.1 MARR-family transcriptional regulator 
16  1DPU-A 4.1 Replication protein A (RPA32) 
17  LOKR-A 4.1 Methicillin resistance regulatory protein MECI 
18  1W1W-H 4.1 Structural maintenance of chromosome 1 
19  3R4K-A 4.1 Transcriptional regulator, ICLR family  
20  3CTA-A 4.1 Riboflavin kinase 




Figure 1.7 MS1 contains typical features of a winged helix-turn-helix domain. A). 
Schematic representation of the topology of a typical winged helix-turn-helix 
domain, which contains 3 alpha helices and 3 parallel beta strands. The name 
“wing” comes from the loop present between the second and third beta strands. The 
recognition helix 3 is coloured in red (Gajiwala and Burley 2000). B). NMR 
solution structure of ABD2 (pdb code: 2KRH). The domain topology contains all 
features characteristic of a winged helix-turn-helix domain. C). Sequence alignment 
of helix 3 residues from MS1 and other winged helix-turn-helix domain containing 
proteins, which were identified in DALI. 2D45 - the MecI-MecA repressor-operator 
complex, 2P7X:B - B. Lichenformis BlaI monomeric form in complex with the 
BlaP half-operator, 1SAX - S. Aureus methicillin-resistance regulating 









Since the ABD2 structure contains a winged helix-turn-helix domain, which is 
commonly found in DNA binding proteins, we will investigate the hypothesis that 
MS1 is a DNA binding protein itself. As the winged helix-turn-helix domain is 
often found in transcription factors we will also provide initial characterisation of 
this probable function. To classify a protein as a transcription factor it has to 
possess 4 characteristics: 1) it has to be localised in the nucleus, at least during 
some stage, 2) it has to contain a DNA binding domain, 3) it has to bind DNA in a 
sequence specific manner, and 4) it has to have an effect on transcription, either 
through enhancement or repression.  
In this work, the first 3 points will be addressed  by answering the following 
questions: 
1. Does MS1 go to the nucleus? 
2. Does MS1 bind DNA in vitro?  
3. Does MS1 bind a specific DNA sequence?  
So far, MS1 has been identified as a cytoplasmic protein. However, if it is indeed a 
transcription factor, we would expect it to be localised in the nucleus. Interestingly, 
there are few reports stating that MS1 was seen in the nucleus, although the data 
was not clearly shown or the functionality of this localisation was not followed up 
(Arai et al. 2002; Troidl et al. 2009; Wallace et al. 2011). Moreover, we identified 
within the N-terminus of MS1 a predicted nuclear localisation sequence (NLS), 
which is responsible for protein nuclear translocation and is commonly found in 
transcription factors (Figure 1.8). Add to that, we identified a potential 
phosphorylation site next to the NLS, which may provide a regulatory mechanism 
of its function via activating or deactivating it. It all suggests that MS1 may indeed 
translocate to the nucleus at some point, however, what exactly is the role of MS1 
in there, e.g., whether it is involved in gene transcription or other function such as 






Figure 1.8. MS1 contains a predicted NLS. The identified NLS is coloured in red. 
The NLS was found using PredictNLS software (Cokol et al. 2000).  
 
 
As a result, we will investigate the localisation of endogenous as well as 
overexpressed MS1 in cardiomyocytes freshly isolated from adult rat and neonatal 
rat hearts (ARCs – adult rat cardiomyocytes and NRCs – neonatal rat 
cardiomyocytes). ARCs and NRCs will be used as a model of fully differentiated 
and not completely differentiated muscle cells, respectively. The MS1 localisation 
will also be studied under hypertrophic and non-hypertrophic conditions in order to 
determine whether stress factors have effect on its subcellular localization. In order 
to look at the endogenous MS1, we will prepare and validate a new antibody 
against MS1, as currently there are no good commercially available antibodies 
against this protein.  
The DNA binding properties of MS1 will be assessed using a gel shift assay and if 
the binding is positive we will further investigate whether MS1 binds a specific 
DNA sequence, as would be expected for a transcription factor. This will be 
achieved using the SELEX assay (Systematic Evolution of Ligands by Exponential 
Enrichment) 
If SELEX identifies a specific DNA motif for MS1, we will characterise the 
interaction between MS1 and the DNA motif using EMSA, fluorescence, NMR and 








Chapter 2  
 





2.1. Recombinant protein production 
 
All protein constructs were cloned into pLEICS vectors (kindly provided by 
University of Leicester). They were designed to contain a N-terminal poly-histidine or 
N-terminal GST-tag. All protein constructs were expressed in E. coli expression 
strains, either BL21* or Arctic Express1. A detailed description of all constructs used 
















D3ZBQ1 150-250 11.5 BL21* Kanamycin 
GST-FOXO3a 
DBD 
D3ZBQ1 150-250 11.5 BL21* Kanamycin 
His-ABD2_C1 Q8K4K7 250-375 14.8 Arctic 
Express1 
Kanamycin 
His-ABD2_C2 Q8K4K7 270-375 12.4 Arctic 
Express1 
Kanamycin 
His-ABD2_C3 Q8K4K7 281-375 11.1 Arctic 
Express1 
Kanamycin 
His-ABD2_C4 Q8K4K7 287-375 10.5 Arctic 
Express1 
Kanamycin 
N-term MS1  Q8K4K7 1-120 16 BL21* Kanamycin 
MSD1 Q8K4K7 1-118 15 BL21* Kanamycin 
MSD2 Q8K4K7 40-196 24 BL21* Kanamycin 
TEV protease P04517 1-304 28 Arctic 
Express1 
Carbenicillin 
ABD1 Q8K4K7 193-294 17 BL21* Kanamycin 
ABD2 Q8K4K7 294-375 9.6 Arctic 
Express1 
Kanamycin 
TANDEM Q8K4K7 193-375 21.5 Arctic 
Express1 
Kanamycin 
1- Arctic Express contains internal gentamycin-resistant plasmid, so whenever this host strain was 
used for expression, gentamycin was added to the medium (60ng/ml).  
 
Table 2.1 Protein constructs used in this thesis. 
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2.1.1. Transformation of constructs into expression strains  
 
DNA encoding for each protein construct was transformed into either BL21* or 
Arctic Express bacterial expression strains. 5-10 ng of DNA was incubated with 25 
µl of competent cells for 30 minutes on ice. The mixture was then heat shocked at 
42ºC for 45 seconds and put back on ice for 10 minutes. To recover the cells, 500 µl 
of pre-warmed LB medium (Appendix 3 contains all media recipes) was added and 
the mixture was incubated in the shaker for 1.5 hours at 37ºC. To select transformed 
cells, 30 µl of the transformation mixture were plated on appropriate antibiotic-
containing plates and were left overnight in the incubator at 37ºC. 
 
 
2.1.2. Protein expression 
 
The next day, successful colonies were picked up and grown for 8 hours in 10 ml of 
LB + appropriate antibiotic. When the cells density reached OD600 = 0.7, glycerol 
stock was prepared by mixing 500 µl of the day culture and 500 µl of 50% glycerol. 
The glycerol stock was stored at -80ºC and was used as a start up culture for protein 
expression.  
 
To express the protein 10 µl of glycerol stock was inoculated in 10 ml of fresh LB + 
appropriate antibiotic and grow for 8 hours at 37ºC in the shaker. 1 ml of this 
culture was then transferred into 200 ml of fresh LB + antibiotic and grown 
overnight. The next day, 20 ml of the overnight culture was transferred into 1L of 
fresh LB + appropriate antibiotic and grown until bacteria reached the stationary 
phase (OD600 = 0.7). Protein expression was induced by adding freshly prepared 
IPTG to a final concentration of 750 µM and incubation further carried on either 
overnight at 15ºC or for 3.5 hours at 37ºC. After the expression time elapsed, cells 
were harvested, resuspended in FF6 Wash buffer (Appendix 4 contains all buffers 







2.1.2.1. Preparation of isotopically labelled protein (15N or 15N/13C) 
 
To produce isotopically labelled proteins for NMR experiments, bacteria were 
grown in M9 minimal media (Appendix 3) where the only source of nitrogen (and 
of carbon when double labelled proteins were prepared e.g. for backbone 
assignment) was the added isotope-labelled ammonium chloride (glucose). Prior to, 
bacteria were grown in standard LB medium, then spun down for 5 minutes at 9000 
rpm and washed in 1 x M9 salts. After the wash step, the pellet was resuspended in 
M9 minimal medium supplemented with the appropriate antibiotic and left to grow 
at 37ºC for 1 hour. After that, freshly prepared IPTG was added to a final 
concentration of 750 µM of to induce the protein expression. The protein 
expression was carried out, either overnight (around 16 hours) at 15ºC or for 3.5 
hours at 37ºC. After that, cells were spun down, resuspended in the FF6 Wash 
buffer and stored at -80ºC.  
 
 
2.1.3. Protein purification 
 
All proteins were purified using affinity chromatography. Two PD10 columns 
containing Nickel Sepharose 6 Fast Flow or Glutathione Sepharose resin were 
equilibrated with FF6 Wash or GST Wash buffer, whilst cells were lysed using a 
sonicator. In order to remove the cell debris, the mixture was centrifuged for 90 
minutes at 18000 rpm. The supernatant was loaded onto the column and the flow-
through was collected for further analysis. In order to remove the contaminants, the 
loaded columns were washed with 100 ml of FF6 Wash or GST Wash buffer. Flow-
through from the wash step was also collected for further SDS-PAGE analysis. 
Finally, the proteins were eluted from the column with 10 ml of FF6 Elution or 
GST Elution buffer.  
 
 
2.1.3.1. TEV protease preparation 
 
Protein constructs were designed to contain poly-histidine or GST tag in order to 
ease their purification. However, for further experiments it was necessary to remove 
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the tag as it could influence some protein functional assays (e.g. EMSA). pLEICS 
vectors encode for a TEV protease cleavage site between the poly-histidine or GST 
tag and the first amino acid of the cloned protein. A construct encoding for the TEV 
protease was kindly provided by Alexander Alexandrovich and TEV protease was 
prepared as described in 2.1.2 and 2.1.3 except that different buffers were used for a 
wash and elution step (TEV Wash and TEV Elution buffer). The yield of TEV 
protein after purification was high (15-20 mg/ml form 1L of final culture). The 




2.1.3.2. TEV cleavage and second round of protein purification 
 
After the protein of interest was eluted in a first round of purification, 2 mM of 
DTT was added. DTT is required for a full TEV protease activity. After that, 5 µl 
(from 15-20 mg/ml stock) of TEV protease was added and the mixture was 
incubated at room temperature for 1.5 hour. To remove the imidazole or reduced 
glutathione and allow further protein purification, the mixture was dialysed 
overnight against 3L of FF6 Wash or GST Wash buffer. The next day, two PD10 
nickel columns were equilibrated with FF6 Wash buffer and the protein mixture 
was further purified as described in 2.1.3 The pure protein of interest was expected 
to be in the first flow-through, hence that fraction was treated with a special care. 
The columns were washed with 50 ml of FF6 Wash buffer and the TEV protein and 
his-tags were eluted with FF6 Elution buffer. Each fraction was kept for further 
SDS-PAGE analysis.  
 
 
2.1.3.3. Visualisation of proteins by SDS-PAGE  
 
Protein purity was assessed by SDS-PAGE (sodium dodecylsulphate 
polyacrylamide gel electrophoresis). 5 µl of each protein fraction was mixed with 5 
µl of gel loading buffer and samples were run on 4-20% gradient gels (NuPage – 
Invitrogen). After 35 minutes of running at 200V, gels were stained with 
InstantBlue protein stain for 20 minutes and the protein purity was assessed. In 
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order to identify protein’s molecular weights, protein marker was run at the same 
time on the gel (Mark12 – Invitrogen). 
 
 
2.1.4. Buffer exchange and protein concentration determination 
 
As the protein after purification was in FF6 Wash buffer, it was necessary to change 
the buffer for subsequent experiments (DNA binding assay, SELEX, NMR, 
fluorescence, MST). It was done by dialysis using Spectrapore membrane with a 
molecular cut off of 3 or 5 kDa depending on the protein used. After the protein 
was in an appropriate buffer, it was concentrated using Viva spin (GE Healthcare) 
with a molecular cut off of 3 or 5 kDa. Protein concentration was measured using a 
NanoDrop 2000 and samples were run again on SDS-PAGE gel to assess their 
purity and stability.  
 
 
2.1.5. Protein unfolding and refolding  
 
The protein unfolding and refolding protocol was used in order to recover double-
labelled (15N-13C-labelled) ABD2(C3) protein. The protein tends to precipitate 
extensively after a short time during the NMR experiment resulting in a substantial 
loss of sample ruling out acquiring additional experiments with the same sample. 
The sample preparation is expensive hence it is advisable to try to recover the 
protein sample if possible. In order to do that, the precipitated protein was spun 
down and the pellet was resuspended in 20 ml of NMR buffer with 8M urea. The 
solution was incubated at 4°C for 16 hours. The next day it was dialysed 
sequentially against NMR buffer containing 6M, 4M, 2M and 1M urea, 
respectively. Later, 1D 1H NMR spectrum was recorder to assess whether the 








2.2. Biophysical characterisation of proteins 
 
2.2.1. Circular Dichroism 
 
Circular Dichroism spectroscopy was used to assess secondary structure of different 
protein constructs as well as to assess protein stability and to study protein-DNA 
interactions. All experiments were performed by Dr. Tam Bui at the Biomolecular 
Spectroscopy Centre at King’s College London. For all experiments protein and 
dsDNA samples were dialysed into CD buffer.  
 
UV and CD spectra of proteins or/and dsDNA were acquired on the Applied 
Photophysics Chirascan and Chirascan Plus spectrometers (Leatherhead, UK).  
1mm and 0.5mm Suprasil rectangular cells were employed in the region 320-
195nm or 260-195nm. The instruments were flushed continuously with pure 
evaporated nitrogen throughout the experiment. The following parameters were 
employed: 1nm or 2nm spectral bandwidth, 1nm stepsize and 1.5s instrument 
time/step.  
 
To assess the thermal stability of protein and DNA samples, the UV and CD spectra 
of proteins or/and dsDNA were recorded at room temperature (20oC), cooled to 
6oC, then heated to high temperature (90oC) and re-cooled to 6oC and 20oC after 
heating and cooling. The multi–wavelength melting profiles were recorded during 
the heating process. The instrument was equipped with a Quantum NorthWest 
TC125 Peltier unit set to change temperature from 6→90oC & from 90oC→6oC at 
1oC per minute rate with 2oC step size. A 1.42s and 1.5s time-per-point CD 
measurement time and 1nm step-size were employed in the 320-195nm or 260-
195nm regions respectively. A 1mm or a 0.5mm rectangular cell pathlengths were 
employed. The temperature was measured directly with a thermocouple probe in 
the sample solution. Melting temperatures were fitted using a Levenberg–
Marquardt algorithm (LMA) based on the modified Gibbs-Helmholtz equation 
(Equation 1.1; Greenfield 2006, Razvi and Scholtz 2006; and Global Analysis T-
ramp Version 1 built 19, Applied Photophysics Ltd, 2007-2009). 
 
 (E1.1)  ΔG(T) = ΔHM (1 - T/TM) – ΔCp ((TM – T) + Tln (T/TM)) 
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where: ΔG(T) – free energy at a temperature T 
            ΔHM – change in enthalpy at TM 
            ΔCp – change in heat capacity associated with the unfolding of the protein 
            TM – melting temperature of the protein 
 
 
2.2.2. NMR spectroscopy 
 
All experiments were acquired using Bruker Avance 500-MHz and 700-MHz 
spectrometers, equipped with 5-mm triple resonance cryoprobes with z-gradients at 
the NMR Facility at King’s College London. All NMR samples were prepared in 
NMR buffer (Appendix 4) containing 10% D2O (v/v). Table 2.2 and Table 2.3 




Experiment  Sample Conc. [µM] Ligand  Conc. [µM] pH Field  
1H-15N HSQC 15N-ABD2 50 - - 7.2 500 
1H-15N HSQC 15N-ABD2 50 Motif 1 150 7.2 500 
1H-15N HSQC 15N-ABD2 50 Motif 2 150 7.2 500 
1H-15N HSQC 15N-ABD2 50 Motif 3 150 7.2 500 
1H-15N HSQC 15N-ABD2 50 36mer 50 7.2 500 
1H-15N HSQC 15N-ABD2 50 Sel1_GT 150 7.2 500 
1H-15N HSQC 15N-ABD2_C4 50 - - 7.2 500 
1H-15N HSQC 15N-ABD2_C3 70 - - 7.2 500 
1H-15N HSQC 15N-ABD2_C2 80 - - 7.2 500 
1H-15N HSQC 15N-ABD2_C1 80 - - 7.2 500 
1H-15N HSQC 15N-ABD2_C3 70 AT_DNA 35 7.2 700 
1H-15N HSQC 15N-ABD2_C3 70 AT_DNA 70 7.2 700 
1H-15N HSQC 15N-ABD2_C3 70 AT_DNA 105 7.2 700 
1H-15N HSQC 15N-ABD2_C3 70 - - 6.5 500 
1H-15N HSQC 15N-ABD2_C3 70 - - 6.0 500 
1H-15N HSQC 15N-FOXO3a 100 - - 7.2 700 
1H-15N HSQC 15N-FOXO3a 100 FOX 100 7.2 700 
1H-15N HSQC 15N-ABD2_C3 70 Motif 1 210 7.2 500 
1H-15N HSQC 15N-ABD2_C3 70 Motif 2 210 7.2 500 
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1H-15N HSQC 15N-ABD2_C3 70 Sel1_GT 210 7.2 500 
1H-15N HSQC 15N-ABD2_C3 70 36mer 70 7.2 500 
1H-15N HSQC 15N-ABD2_C3 70 WT 70 7.2 500 
1H-15N HSQC 15N-ABD2_C3 70 WT 140 7.2 500 
1H-15N HSQC 15N-ABD2_C3 70 WT 210 7.2 500 
1H-15N HSQC 15N-ABD2_C3 70 WT 280 7.2 500 
1H-15N HSQC 15N-ABD2_C3 70 WT 350 7.2 500 
1H-15N HSQC 15N-ABD2_C3 70 A7G 140 7.2 500 
1H-15N HSQC 15N-ABD2_C3 70 Scramble 140 7.2 500 
1H-15N HSQC 15N-ABD2_C3 70 AT_WT 140 7.2 500 
1H-15N HSQC 15N-ABD2_C3 70 WT_core 210 7.2 500 
1H-15N HSQC 15N-ABD2 50 WT 250 7.2 500 
1H-15N HSQC 15N-ABD2_C2 80 AT_WT 40 7.2 500 
1H-15N HSQC 15N-ABD2_C2 80 AT_WT 80 7.2 500 
1H-15N HSQC 15N-ABD2_C2 80 AT_WT 120 7.2 500 
1H-15N HSQC 15N-ABD2_C2 80 AT_WT 160 7.2 500 
 
Table 2.2 Conditions used for NMR titration experiments.  
 
Experiment Sample Conc. [µM] pH Field 
15N-13C HNCA 15N-ABD2_C3 420 7.2 500 
15N-13C HNCACB 15N-ABD2_C3 420 7.2 500 
15N-13C HNCA 15N-ABD2_C3 350 6.5 500 
15N-13C HNCACB 15N-ABD2_C3 350 6.5 500 
15N-13C HNCOCA 15N-ABD2_C3 350 6.5 500 
15N-13C HNCOCACB 15N-ABD2_C3 350 6.5 500 
 
Table 2.3 Conditions used for the backbone resonance assignment of ABD2_C3. 
 
Typically, a 1D 1H NMR spectrum was recorded for every sample in order to verify 
whether the protein was correctly folded and to assess labelling efficiency for the 
double-labelled protein (15N-13C labelling). A 2D 1H-15N HSQC spectrum was 
recorded for DNA interaction experiments and for the backbone resonance 
assignment as a reference spectrum. Additionally, the following spectra were 
recorded for the sequential backbone resonance assignment: HNCBCA, HNCA, 
HNCOCACB, HNCOCA, HNCO. The assignment was done using CCPN Analysis 
2.1.5 software (Vranken et al. 2005).  
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Chemical shift provides valuable information about the electronic environment and 
the surroundings chemistry of a nucleus. In fact, the distance to and the type of 
neighboring nuclei have a direct impact on the resonance frequency of such 
nucleus. Any chemical environment changes, whether caused by a ligand binding 
or conformational changes, will result in changes of the resonance frequency of the 
affected nuclei.  
 
To characterize the binding between MS1 and DNA oligonucleotides, the chemical 
shift perturbations and/or peak intensity changes analysis were performed. In fact, 
the interaction between a protein and a ligand results in chemical shifts changes for 
both molecules. This information may be used as a qualitative indicator of binding 
or it may be interpreted quantitatively to determine the binding affinity and also 
structural data. The binding interface between the molecules is located by mapping 
the observed affected nuclei on the molecules structures. However, such molecular 
interaction may also lead to changes in the structure at sites that are not part of the 
binding site, i.e presence of allosteric process, which will also induce chemical shift 
changes and thus could be mistaken for another binding site.  
 
The changes in chemical shifts of a residue in a protein, as a result of ligand 
binding, depend on the thermodynamic binding kinetics, namely the on and off 
rates (kon and koff), and the properties of the nuclei involved. The interaction 
between two molecules can be characterized by its chemical exchange regime, a 
process where a nucleus switches between two states A and B at resonance 
frequencies νA and νB (like free and bound states). A nucleus chemical exchange 
regime is characterised by its chemical exchange rate kex, which is related to the kon 
and koff rates of this interaction. Depending on kex magnitude as compared to NMR 
experiment time range (usually ~ ms timescale) there are three chemical exchange 
regimes.  
 
Slow exchange mode: In case when both states are equally populated and kex is 
slow compared to the duration of the NMR experiment (kex << |νA - νB|) then two 
separate peaks will be visible in the NMR spectrum, representing state A and B 
(half of the molecule will be in free and half in bound state). The slow exchange 
mode of the protein-ligand system exhibits a characteristic ‘peak disappearance and 
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appearance’ pattern in the spectra on gradual addition of ligand. 
 
Fast exchange mode: If kex is fast (kex >> |νA - νB|) and the two states are equally 
populated, the molecule will swap between state A and B many times during the 
duration of the NMR experiment. Consequently, a new average of A and B state 
chemical shift will be observed, which represents weighted average of bound and 
unbound state. The apparent observed average chemical shift can be written as a 
function of each state fraction fA and fB : 
 
νobs = fA νA + fB νB        where fA + fB = 1 
 
The fast exchange mode of the protein-ligand system exhibits a characteristic ‘peak 
walking’ pattern in the spectra on gradual addition of ligand and the averaged 
chemical shift depends on fractional saturation.  
 
Intermediate exchange mode: In case of intermediate exchange, where kex ~ |νA - 
νB|, the individual peak lines gradually broaden (lose their intensities) and 
eventually it may even disappear.  
 
Note that increasing the NMR experiment magnetic field, BO, can be used as a 
diagnostic way to assess the true chemical exchange mode the nuclei are 
undergoing. In fact, increasing BO can shift a fast to slow chemical exchange mode 
due to the increase of resolution of the NMR line shape. Additionally, depending on 
the nuclei chemical exchange rate, the NMR peak intensity can be proportional to 












2.3. Protein-DNA interaction studies 
 
2.3.1. Electrophoretic Mobility Shift Assay (EMSA) 
 
To test DNA-binding properties of MS1, EMSA was performed. Depending on the 
experiment, different DNA probes were used such as: dsDNA oligonucleotides 
(preparation described in 2.3.1.1), random dsDNA library (preparation described in 
2.3.2.) or plasmids. Protein in EMSA buffer was incubated with 1 µM or 2 µM of 
DNA in a total volume of 20 µl. Protein concentration ranged from 1 µM to 100 
µM depending on the experiment. The mixture was incubated for 30 minutes at 
room temperature and then 2 µl of 80% glycerol was added and the samples were 
loaded onto a 1.6% agarose gel prepared with SYBRSafe stain. Gels were run for 
30 minutes at 80V and no further staining was necessary. Samples were visualised 
under UV light. 
 
2.3.1.1. Preparation of dsDNA oligonucleotides 
 
Complementary pairs of ssDNA were purchased from Biomers or Sigma-Aldrich. 
Equal molar amounts of each oligonucleotide were mixed and the solution was 
heated for 15 minutes at 95°C in the thermocycler. After that, the sample was left to 
cool down gradually to room temperature for 5 hours. Concentration of the 
annealed oligonucleotide was re-checked and re-calculated. In order to verify 
whether the annealing was successful, samples were run on 5% polyacrylamide gel 
and visualised using SYBRSafe stain.  
 
 
2.3.2. Systematic Evolution of Ligands by Exponential Enrichment (SELEX)  
 
SELEX is a technique, which allows identification of high-affinity nucleic acids 
(called aptamers) for a wide range of molecules such as proteins or even for a 
whole cell lysate (Tuerk and Gold 1990; Stoltenburg et al. 2007; Xie et al. 2011; 
Dwivedi et al. 2010). SELEX combined with sequencing allows identification of 
DNA motifs bound by a protein (Reiss and Mobley 2011; Someya et al. 2011; 
Kubota et al. 2013; Zhang et al. 2011; Cui and Leng 2007; Fonfría-Subirós et al. 
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2012) The SELEX procedure involves several rounds of selection, partitioning and 
amplification of random library of single or double stranded DNA or RNA. The 
library members contain a random region, which is flanked by fixed sequences 
allowing amplification of the library in PCR. During the first round of selection a 
random library is incubated with an investigated protein at appropriate ratios, and 
then unspecific oligonucleotides are washed out and bound sequences are amplified 
and used as in another round of selection. The selection/amplification process is 
conducted until no change in affinity is observed. After this stage, a randomly 
selected pool of the amplified DNA is cloned and sequenced, and sequencing data 
is analysed for the presence of a significant DNA motif. 
 
 
2.3.2.1. Random ssDNA library design 
 
The random ssDNA library was purchased form Gene Link. It was designed to 
contain a region of 18 or 36 random nucleotides (N18 or N36), which was flanked by 
sites of known sequences (fixed regions - 25 nucleotides each site). Primers 
complementary to each fixed site were designed and used to amplify the library. 
Additionally, each fixed site contains a restriction enzyme recognition site (EcoRI 
and BamHI for reverse and forward fixed site, respectively), which were further 
used for cloning (Figure 2.1).  
 
 
         
 
 
Figure 2.1 Schematic representation of the random ssDNA library. A random 
region of N = 18 or 36 ((N)18/36) is flanked on both sites by regions of known 
sequences (fixed regions) GGATCC represents the recognition site for BamHI 





  5'-­‐ATCGGATCCTTGATCAAGCTGCA	  (N)18/36	  CGACATGTATCGATGAATTCGAC-­‐3' Fixed	  region Fixed	  region 
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The following primers were used to amplify the library: 
 
Forward primer (BamHI primer):  5' - ATCGGATCCTTGATCAAGCT - 3' 
Reverse primers (EcoRI primer):   3' - GTACATAGCTACTTAAGCTG – 5' 
 
 
2.3.2.2. dsDNA library preparation 
 
The random ssDNA library (MW = 25.255 kDa, TM = 65.2°C; yield after 
synthesis: 17.8 nmols) was resuspended in 357 µl to obtain 50 µM stock.  
 
To produce the dsDNA library, 380 pmol of the ssDNA random library was 
annealed with 650 pmol of reverse primer (EcoRI primer) in 20 µl of 
TE/100mMNaCl buffer (5 minutes at 95 °C, then 30 minutes at 30°C). The 
extension reaction was run overnight (around 16 hours) at 30°C in a Klenow buffer 
in the presence of 2.5 mM dNTPs, 40 µg BSA and 1 unit of Klenow fragment in a 
total volume of 80 µl. After the incubation, Klenow enzyme was deactivated by 
heating at 85°C for 15 minutes and the dsDNA library was purified using the 
QIAquick PCR purification kit (Qiagen) or PureLink Quick Gel Extraction Kit 




2.3.2.3. Optimisation of the binding assay and partitioning step 
 
The selection step of the SELEX procedure must be optimised in order to find the 
most suitable method for the MS1 system. In order to do that, two methods have 
been checked and optimised: 1. An immobilised protein (column based) selection 







2.3.2.3.1. Column based selection method 
 
In this method, his-tagged protein was prepared as described in 2.1.3. except that no 
TEV cleavage was done. 20 pmols of pure his-tagged protein in SELEX buffer A 
was immobilised on 100 µl Nickel Sepharose 6 Fast Flow resin and equilibrated 
with the same buffer. 200 pmols of the random dsDNA library was added and the 
mixture was left to incubate for 30 minutes at room temperature. In order to remove 
non-specific DNA, 500 µl of SELEX buffer A was added (1 column volume) and 
the fraction, labelled 1 Wash – 1W, was saved for further PCR analysis. The wash 
step was repeated 2 more times: 2W with SELEX buffer A and 3W with SELEX 
buffer B. After that, the bound protein+DNA complex was eluted in 100 µl of FF6 
Elution buffer. To recover the bound DNA, phenol extraction and ethanol 
precipitation was performed. Later on, each fraction obtained from the pull-down 
was subjected to PCR. Table 2.4 shows the PCR set up.  
 
 






- forward primer (BamH1) 1 [10 µM] 
reverse primer (EcoRI) 1 [10 µM] 
dNTPs 1 [10 mM] 
Taq Polymerase buffer 5 10 x 
Taq Polymerase 0.25 5000 U/ml 
ddH2O 41.25 - 
 
Table 2.4 Concentration of reagents used for PCR amplification during SELEX 
procedure.  
 
Thermocycling was done according to the following protocol: 
 
93 °C – 3 mins  
92 °C – 30 sec. 
56 °C – 30 sec.       20 cycles  
72 °C – 60 sec.  
72 °C – 5 mins  
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The overall number of PCR cycles was 20, however, in order to compare the 
amount of obtained PCR product, for each fraction, 5 µl of PCR product was taken 
after every 5 cycles of PCR. This sampling was done in order to verify whether the 
wash steps were sufficient to remove the non-specific DNA. If they were, we would 
expect no PCR product in the final 3W step and large amount of PCR product in the 
eluted fraction. It would mean that the protein bound this DNA specifically, or at 
least with a higher affinity. After PCR, all fractions were run on a 1.6 % agarose gel 
and electrophoresed at 80 V for 40 mins in 0.5X TBE buffer. The gel was prepared 
with SYBR(R) Safe DNA gel stain in 0.5X TBE buffer (Invitrogen). No further 
staining was necessary. 
 
 
2.3.2.3.2. Gel shift assay partitioning method 
 
This is the final method that was used for the full SELEX.  
 
In this method, the purified dsDNA library was incubated with different MS1 
constructs or FOXO3a in SELEX buffer A (20 mM NaPO4, 100 mM NaCl, 0.01 % 
Triton X-100, pH 7.5) or SELEX buffer B (20 mM NaPO4, 150 mM NaCl, 0.01 % 
Triton X-100, pH 7.5) for 10-30 minutes depending on the number of SELEX 
round (Table 2.7). For the first round of SELEX, 20 pmols of purified dsDNA 
library was incubated with 200 pmols of protein in a total volume of 20 µl 
(concentration of protein and DNA for the subsequent rounds of SELEX can be 
found in Table 2.7). After that, 1.5 µl of 80% glycerol was added and samples were 
loaded onto a 1.6 % agarose gel and electrophoresed at 80 V for 30 minutes in 0.5X 
TBE. The gel was prepared with SYBR(R) Safe DNA gel stain in 0.5X TBE 
(Invitrogen). No further staining was necessary. Shifted DNA was cut out and 
purified using the QIAquick Gel Purification Kit (Qiagen) according to the 
manufacturers protocol. Later, the selected and purified DNA was amplified in 







2.3.2.3.2.1. PCR amplification of selected sequences (enrichment step) 
 
To amplify sequences selected in the first and subsequent rounds of SELEX, PCR 
was performed. It was done according to the protocol shown in Table 2.4.  
 
After 20 cycles of PCR, samples were purified using the QIAquick PCR 
purification kit and eluted with 50 µl of TE. Typically 8 PCR samples were purified 
together and it yielded in about 1 µg (20 pmol) of PCR product.  
 
 
2.3.2.3.2.1.1. PCR amplification optimisation 
 
In order to enhance the amount of PCR product to be used for the next round of 
SELEX, the following protocol was used:  
 






- forward primer (BamH1) 1 [10 µM] 
reverse primer (EcoRI) 1 [10 µM] 
dNTPs 1 [10 mM] 
Taq Polymerase buffer 5 10x 
Taq Polymerase 0.25 5000 U/ml 
PCR Enhancer Solution (Invitrogen) 15 3x 
MgSO4 1.5 [10 µM] 
ddH2O 24 - 
 
Table 2.5 Concentration of reagents used for PCR optimisation. 
 









2.3.2.3.2.2. Subsequent SELEX rounds  
 
As the SELEX progressed, the stringency was increased in order to reduce the 
amount of non-specific binders. It was done by alternating one or more of the 
following factors: protein concentration (decrease), salt concentration (increase), 
incubation time (decrease). Table 2.6 represents conditions used for the binding 
assay for each round of selection. After each binding assay, samples were run on 2 
% agarose gel at 80 V for 30 minutes at room temperature and shifted bands were 
cut out, purified and amplified as described in 3.2.3.2.1. 
 
 










Selex1 20 200 A 30 
Selex2 20 100 A 30 
Selex3 20 20 A 20 
Selex4 20 2 A 20 
Selex5 20 2 A 15 
Selex6 20 0.2 B 15 
Selex7 20 0.1 B 10 
Selex8 20 0.1 B 10 
 





After the 8th round of selection, the shifted DNA was cut out, purified and amplified 
in a large scale PCR. 2 strategies for cloning inserts were used: 1. sticky-ends 
cloning and 2. TA cloning.  
 
2.3.2.3.2.3.1. Sticky ends cloning 
 
2.3.2.3.2.3.1.1. Insert preparation 
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The previously purified PCR product was first double digested with EcoRI and 









20 ng/ µl 
- Tango buffer 10 2x 
EcoRI 1 [10 u/ µl] 
BamHI 2 [10 u/ µl] 
ddH2O 7 - 
 
Table 2.7 Conditions used for insert digestion. 
 
 
The reaction mix was incubated at 37 °C for 3 hours and then the enzymes were 
inactivated by heating at 65°C for 20 minutes and by adding EDTA to achieve a 
final concentration of 20 mM. EcoRI can be deactivated by heating at 65°C for 20 
minutes, however only a small fraction of BamHI can be deactivated by heating, 
hence addition of EDTA is necessary. Due to fact that EDTA was added to inhibit 
the BamHI, it was necessary to purify double digested inserts in order to minimize 
possible inhibition of the ligase in the subsequent ligation reaction. The double 
digested inserts were purified using the QIAEX II Gel Extraction Kit (Qiagen) 
following the manufacturer’s protocol.  
 
 
2.3.2.3.2.3.1.2. Vector preparation 
 
pBluescript II KS (-) was prepared by digesting with EcoRI and BamHI. Table 2.8 












500 ng/ µl 
- Tango buffer 10 2x 
EcoRI 1 [10 u/ µl] 
BamHI 2 [10 u/ µl] 
ddH2O 6 - 
 
Table 2.8 Conditions used for vector digestion. 
 
The double digest reaction was done as described for the inserts, except that after 
the enzyme inactivation, the double digested vectors were run on a 0.8% agarose 





The ligation of vector and insert was prepared according to the conditions shown in 
Table 2.9.  
 
 






 Vector 1 50 ng/µl 
T4 ligase buffer 2 10x 
T4 ligase 0.25 [5 u/µl] 
ddH2O 6.75 - 
 
Table 2.9 Conditions used for ligation reaction. 
 
The mixture was incubated at room temperature for 1 hour, then the T4 ligase was 







2.3.2.3.2.3.1.4. Transformation of TOP10 and blue/white screening 
 
Chemically competent TOP10 cells were thawed on ice and 5 µl of the ligation 
mixture was added to 50 µl of cells. It was then incubated on ice for 30 minutes and 
heat shocked at 42°C for 50 seconds. After that, cells were put back on ice for 10 
minutes. Meanwhile fresh SOC media was warmed up. To recover transformed 
cells, 250 µl of pre-warmed SOC media was added to the cells and then they were 
incubated in the shaker for 1 hour at 37°C at the maximum speed of shaking.  
 
To select appropriate transformants, 30 µl of cells were plated on carbenicillin and 
X-gal-containing plates and left to grow for 16 hours. The plates were prepared by 
adding carbenicillin to a final concentration of 50 mg/L to a freshly autoclaved LB 
agar, while 80 µl of 40 mg/ml X-gal was spread onto the agar plates and left to 
diffuse for at least 1 hour before plating the cells. When TOP10 cells are used, there 
is no need to add IPTG to perform the blue/white screening. The next day white 
colonies were picked and colony PCR was run in order to verify presence of the 
inserts.  
 
2.3.2.3.2.3.2. TA cloning 
 
TA cloning was performed when the shorter library (N18) was used for SELEX. It 
was done using the TA Cloning Kit (Invitrogen) following the manufacturer’s 
protocol.  
 
2.3.2.3.2.3.2.1. Transformation  
 
Transformation of TOP10 cells was done as described in 2.3.2.3.2.2.1.4. 
 
 
2.3.2.3.2.4. Colony PCR 
 
To identify the presence of the cloned inserts, a colony PCR employing M13 
primers was run. The expected size for the PCR product-containing insert was 280 
(for sticky ends cloning of the longer library) or 295 bp (for the TA-cloning of the 
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shorter library), whilst for a PCR product without the insert - 227 bp. After PCR, 
samples were run on 2.6% agarose gel. The colony PCR was run according to the 
protocol shown in Table 2.10.  
 
 






- M13 forward primer (-20) 1 [10 µM] 
M13 reverse primer (-22) 1 [10 µM] 
dNTPs 1 [10 mM] 
Taq Polymerase buffer 5 10 x 
Taq Polymerase 0.25 5000 U/ml 
ddH2O 41.25 - 
 
Table 2.10 Conditions used for colony PCR. 
 
Thermocycling was done according to the following protocol: 
 
93 °C – 5 mins  
92 °C – 30 sec. 
56 °C – 30 sec.       20 cycles  
72 °C – 60 sec.  





To increase chances of finding the motif bound by MS1, 96 PCR products obtained 
from colony PCR were sequenced using M13 primers at Beckman Coulter 
Genomics facilities. Prior to sequencing, PCR products were purified using SPRI 
technology. Samples were sequenced using the Sanger method and the BigDye 
Terminator v3.1 cycle sequencing kit. After the reaction, the dye was removed 





2.3.2.3.2.6. Data analysis  
 
The sequencing results were aligned using the fixed sequences on both sites of the 
designed library, and the random regions were extracted. To search for a 
significantly represented motif within the data set, the MEME (Multiple Em for 
Motif Elucidation) suite was used. MEME is a free web server 
(http://meme.nbcr.net) that provides the user with different tools for analysis of 
large DNA sequence data sets, including motif discovery. It also contains a tool 
(called TOMTOM) that allows the user to compare the new discovered motif with 
known transcription factors motifs or to associate the found motif with a putative 
function using a Gene Ontology-based tool called GOMO (Bailey and Elkan 1994; 
Bailey et al. 2009).  
 
 
2.3.3. NMR titration using 1H-15N HSQC experiment  
 
1H-15N HSQC is one of the most frequently used experiments in the field of protein 
NMR, especially when studying protein-ligand interaction. It shows every proton-
nitrogen correlation within the molecule. The recorded spectrum contains peaks 
(chemical shifts) representing the backbone amide group of each amino acid, except 
of prolines, which contain imino groups instead of an amide group. In addition to 
the backbone amide peaks, there are extra observable peaks coming from the 
nitrogen-bound protons in glutamine, asparagine and tryptophan side-chains and, if 
working at low pH, of arginine and lysine. As the resulting 1H-15N HSQC spectra 
contains 1 peak per residue  (except the cases explained above) it has been used as a 
sort of  “fingerprint” of a protein. It is the very first spectrum recorded to assess the 
protein characteristics such as its fold and provides a reference for further 
experiments e.g. backbone assignment or ligand binding.  Using triple resonance 
experiments with 13C -15N labelled protein, each amide peak is assigned in a 
sequential manner to provide information as to which residue it belongs.  
 
In order to study the ligand binding, first a 1H-15N HSQC spectrum of the apo-form 
is recorded. Then, an increasing amount of the ligand is added and for each addition 
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the 1H-15N HSQC spectrum is recorded. If the ligand is bound, there will be 
changes between the apo and bound-form in the chemical shifts of the resonances 
(of each amino acid) involved in the binding as a result of changes in their chemical 
environment cause by the binding event. Analysis of the chemical shift changes 
(perturbation) can provide qualitative information about the binding (indicate the 
binding site) and/or quantitative details about the binding affinities. However, this 
analysis depends on the nature of the interaction, whether it is in the fast or slow 
exchange mode on the NMR time scale.  
 
For the MS1-DNA interaction, a variety of protein constructs were used (Table 
2.1). The samples were prepared as described in 2.2. The reference spectrum was 
recorded before each titration and then, increasing amounts of DNA were added. 
After each addition of DNA, the sample pH was checked and adjusted to ensure the 
same pH throughout the whole titration. All conditions used for all experiments are 
listed in Table 2.2. 
 
After the experiments were finished and the spectra processed using Topspin 
software, they were further analysed in CCPN software using the Follow Chemical 
Shift Changes tool, which calculates chemical shifts perturbation (CSP) values 
between the apo and bound form. A plot of CSP for each assigned residue was 
created and residues that exhibit higher CSP than the average CSP value and/or 
average CSP + 1SD were mapped onto the protein surface and visualised using 




2.3.4. Tryptophan fluorescence 
 
Tryptophan fluorescence was used to measure the affinity between different MS1 
constructs and DNA sequences. All experiments were performed in the 
Measurement buffer using a FluoroMax4 spectrofluorometer (Horiba) at 20°C in a 
total volume of 50 µl. A concentration of 2.5 µM of protein was titrated with a 
stock solution of  >300 µM DNA (depending on the DNA used). After each 
addition, the sample was left to equilibrate for 5 minutes prior to recording their 
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emission spectra 3 times. The 3 spectra were averaged to produce the final 
spectrum. Emission spectra were recorded in the region of 280 nm – 450 nm at an 
excitation wavelength of 290 nm. The slit width for the excitation and emission 
beam was set to 4.5 nm. The maximum fluorescence at 354 nm and 348 nm was 
used in determining the dissociation constants for MS1 constructs and FOXO3a, 
respectively. For the KD calculations all spectra were corrected for the solvent 
effects by subtracting the emission spectra of the Measurement buffer recorded 
across the full emission range as well as compensating for dilution effects. To 
calculate dissociation constants, the corrected fluorescence intensity (Y) was 
plotted against the concentration of the ligand added and fitted to the quadratic 
equation based on 1:1 binding model using Prism software (Equation 1.2) (André 
et al. 2004).  
 
 
(E1.2)   Y = {(Ltot + Kd + Ptot) – [(Ltot + Kd + Ptot)2 – 4 Ptot Ltot]0.5} / (2 Ptot) 
 
where:  Ptot = [PL] + [P] 
             Ltot = [PL] + [L] 
    and:  Ltot – total ligand  
             Ptot – total protein 
             KD – dissociation constant  
 
 
2.3.5. MST (Microscale Thermophoresis)  
 
All experiments were performed using a Monolith NT.115 instrument (NanoTemper 
Technologies GmbH). Microscale thermophoresis is a recent technology developed 
by NanoTemper that allows analysis of biomolecular interactions, including binding 
event detection and quantification of biophysical parameters such as binding 
affinity, stoichiometry and binding energetics (free energy ΔG, enthalpy ΔH and 
entropy ΔS) (Zillner et al. 2012; Jerabek-Willemsen et al. 2011). Microscale 
thermophoresis works on the premise that in temperature gradients molecules will 
migrate and that movement is dependent on the size, shape and hydration shell of a 
 
61 
certain molecule. Any changes in their hydration shell (e.g. due to binding event or 
oligomerisation etc.) affect their migration along the temperature gradient and can 
be used to determine the binding affinity, kinetics etc. In practice, a fluorescently 
labelled molecule (or tryptophan) is used and its movement in the temperature 
gradient generated inside a capillary by an-IR laser is measured by monitoring the 
fluorescence as a function of position.  
 
To determine the binding affinities of MS1 constructs or FOXO3a for DNA, a serial 
dilution of ligand was prepared, whilst the fluorescently labelled protein was kept at 
a constant concentration. Proteins were fluorescently labelled with L001 
Monolith™ NT.115 Protein Labeling Kit RED-NHS (Amine Reactive) kit 
(NanoTemper) according to the manufacturer’s protocol. In a typical experiment, 
16 samples were prepared, each containing a different concentration of ligand, 
covering the range from 0.02 – 600 µM and 0.01 – 400 µM for MS1 constructs and 
FOXO3a, respectively. Then, 2 µM or 0.2 µM of fluorescently labelled MS1 
construct or FOXO3a was added, respectively. After that, samples were left to 
incubate for 10 minutes at room temperature and loaded into standard capillaries. 
Prior to each thermophoresis scan, fluorescence of each sample was checked and 
samples were adjusted when the fluorescence reading differed between samples by 
10%. The thermophoresis measurement was conducted for 3 different laser powers 
(20%, 40% and 80%) and each scan was repeated 3 times. To analyse the data and 




2.4. Antibody production and localisation studies 
 
2.4.1. Antibody production 
 
To generate antibodies against MS1, 3 different MS1 constructs were prepared: N-
terminal (1-99 aa), ABD1 (193-295 aa) and ABD2 (294-375 aa). They were 
expressed and purified as described in 2.1. 10 mg/ml of each protein was sent for a 
rabbit immunisation to 2 different companies (Absea and Bioscience). After around 
2 months, rabbit sera which showed presence of the antibody against MS1 antigen 
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(based on ELISA test) were received. The obtained sera were further tested for a 
specificity using Western blot and immunofluorescence. The serum that gave the 
best results as judged by initial western blots was further validated using 
overexpression studies and immunofluorescence. As a control for specificity the 
antibody was preabsorbed with the immunizing antigen and then used on western 
blots and in immunofluorescence.  
 
 
2.4.2. Constructs and point mutation 
 
A mouse myc-tagged (pcDNA3.1(+)) mammalian expression MS1 construct was 
kindly provided by Dr. A. Koekemoer. For point mutation the QuikChange Site 
Directed Mutagenesis kit was used (Agilent Technologies). Primers carrying the 
desired mutation were designed using the QuikChange Primer Design software 
(http://www.genomics.agilent.com/primerDesignProgram.jsp). Mutagenesis was 
performed following the manufacturer’s protocol. DNA from successful colonies 




2.4.3. Western blot 
 
Protein samples were prepared by scraping cells from the dish using a cell scraper 
and by subsequent lysis in a protein loading buffer at 90°C for 10 minutes. Protein 
samples were separated by SDS-PAGE using pre-cast NuPage 4-12% Bis Tris gels 
(Invitrogen) and blotted onto PVDF membrane (Milipore). After the transfer, 
membranes were blocked in TBST buffer supplemented with 5% milk (Sigma-
Aldrich) for 1 hour at room temperature, followed by overnight (around 16 hours) 
incubation with primary antibody at 4°C. The following antibodies diluted in TBST 
+ 5% milk were used: polyclonal rabbit anti-MS1 (aABD2chn, 1:25000) polyclonal 
rabbit anti-actin (Sigma-Aldrich, 1:200), polyclonal rabbit anti-beta-actin 
(GeneTex, 1:500), polyclonal rabbit anti-lamin A (Sigma-Aldrich, 1:200). After 
that, membranes were washed 3 times in TBST + 5 % milk and HRP-conjugated 
anti-rabbit or anti-mouse Igs secondary antibody was added (1:5000 dilution, Santa 
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Cruz). The secondary antibody was incubated for 1 hour at room temperature, 
followed by 3 washes in TBS buffer. To detect the antibody, chemiluminescent 
reagent (Invitrogen) was added and the blots were exposed to X-ray film.  
 
 
2.4.4. Cells  
 
For the antibody validation Hela cells were used (kindly provided by Dr Stephen 
Terry). To study MS1 cellular localisation as well as for antibody validation NRC 
(Neonatal Rat Cardiomyocyte) and ARC cells (Adult Rat Cardiomyocyte) were 
used. NRCs were provided by Dr. Ay Lin Kho and ARCs by Dr. Shiney Reji. NRCs 
and ARCs were produced from Sprague-Dawley rats as described previously 
(Zhang et al. 2006; Iskratsch et al. 2013). Rats were aged 1-2 days for NRCs and 6 
months for ARCs.  
 
 
2.4.5. Tissue lysate preparation 
 
A variety of rat tissues were isolated from Sprague-Dowley rats and were provided 
by Dr Ay Lin Kho. To prepare samples for Western blot analysis, the tissues were 
minced and sonicated for 3 minutes in PBS buffer with the pulse 3 seconds on 
followed by 3 second off. After that, samples were centrifuged for 15 minutes at 4 




2.4.6. Cell Transfection 
 
Hela cells were plated on 12 mm glass cover slips in 6-well plate format. They were 
transfected with myc-tagged MS1 construct using Lipofectamine 2000 (Invitrogen). 
For each well with a cover slip, a mixture of 1µg of plasmid plus 5 µl of 
Lipofectamine in DMEM medium was added. Cells were incubated overnight, and 
the next day the medium was changed into a fresh DMEM medium + 10% FCS. 
The transient transfection was carried out for the next 48 hours. After that, cells 
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were fixed with 4% paraformaldehyde (Agar Scientific) in PBS for 10 min. for 
immunofluorescence or lysed for Western blot analysis.  
 
NRCs were plated onto collagen-coated 35 mm culture dishes (PureCol; Inamed 
Biomaterials). Transfection was done as for the Hela cells, except that Escort III 
(Sigma-Aldrich) and different media were used depending on the experiment. To 
study cells in the presence of a hypertrophic stimulus, the next day, the transfection 
medium (68% DME, 16% medium M199, 10% horse serum, 5% fetal calf serum, 4 
mM glutamine) was changed into maintenance medium (78% DME, 20% medium 
M199, 4% horse serum, 1% penicillin–streptomycin, 4 mM glutamine, and 0.1 mM 
phenylephrine [Sigma-Aldrich]). To study cells in the absence of a hypertrophic 
stimulus, transfection medium was used for the whole experiment. After 48 hours 
cells were fixed with 4% PFA in PBS for immunofluorescence or lysed for Western 
blot analysis.  
 
 
2.4.7. Cellular fractionation 
 
Cellular fractionation was performed using the Subcellular Protein Fractionation kit 
for Cultured Cells (Thermo Scientific) following the manufacturer’s protocol. 
Cellular fractionation was performed for Hela, NRC and ARC cells yielding 
cytoplasmic, membrane, soluble nuclear, chromatin-bound and cytoskeletal protein 
fractions. Later on, each fraction was analysed for the presence of MS1 protein 





The following cell types were used for immunofluorescence: Hela, NRCs and 
ARCs. The immunofluorescence protocol used was the same for all of them except 
that Hela cells were plated on glass coverslips and NRCs and ARCs onto collagen-
coated 35 mm culture dishes. Briefly, cells were fixed for 10 minutes with 4% 
paraformaldehyde in PBS and permeabilised for 5 minutes with 0.1% TX-100 in 
PBS, following by 1 wash in PBS.  After that, they were blocked in the blocking 
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reagent (Hela in 1%BSA in PBS, NRCs and ARCs in MAXblock, Activ Motif) for 
1 hour at room temperature. Later, the cells were incubated in the primary antibody 
solution for 1 hour at room temperature (ARCs were incubated overnight at 4 °C), 
followed by 3 washes in PBS and incubation in secondary antibody solution for 1 
hour at room temperature (or 5 hours at room temperature for ARCs). Primary and 
secondary antibodies were diluted in 1% BSA in PBS. The following primary 
antibodies were used: polyclonal rabbit anti-MS1 (aABD2chn, 1:2000), monoclonal 
mouse anti-sarcomeric alpha-actinin, clone EA-53 (Sigma-Aldrich, 1;500), 
monoclonal mouse anti-c-myc (Roche, 1:500). Polyclonal rabbit anti-titin (M8 
epitope) was kindly donated by Mathias Gautel (King’s College London, UK). 
Primary antibodies were visualised using Alexa488-conjugated anti-mouse Igs and 
Cy-5-conjugated anti-rabbit Igs (Jackson ImmunoResearch Laboratories, Inc.) To 
visualise actin AlexaFluor488- or AlexaFluor568-conjugated phalloidin was used 
(Invitrogen). For the nucleus staining DAPI (Sigma-Aldrich) was used. Cells were 
mounted in 0.1 M Tris-HCl/glycerol (3:7) and 50 mg/ml N-propylgallate, pH 9.5 
and photographed using a Nikon microscope at 60x magnification (Ar1 confocal). 




























MS1 has been identified mainly as a cytoplasmic protein, however, there are also 
some reports stating that it was seen in the nucleus, although the data was not 
clearly shown or the finding was not followed up (Arai et al. 2002; Troidl et al. 
2009; Wallace et al. 2011).   
As it was found that MS1 contains a winged helix-turn-helix domain, a typical 
DNA binding domain present in transcription factors, the subcellular localisation of 
MS1 will be here investigated to verify whether MS1 can go to the nucleus. 
In this chapter, as there is no good commercially available one, a new antibody 
against MS1 will be validated and the localisation of endogenous as well as 
transiently overexpressed MS1 in muscle cells will be investigated. 
Cardiomyocytes freshly isolated from adult rat and neonatal rat hearts (ARCs – 
adult rat cardiomyocytes and NRCs – neonatal rat cardiomyocytes) will be used as 
a model of adult, fully differentiated and not completely differentiated muscle cells, 
respectively.  
Moreover, as the expression of MS1 has been shown to be affected by stress signals 
(Mahadeva et al. 2002), the expression of MS1 under hypertrophic and non-
hypertrophic conditions will be studied.  
Finally, using point mutation, the relevance of the predicted nuclear localisation 
sequence (NLS) as well as the predicted phosphorylation sites of MS1 (S150, 




3.2. Anti-MS1 antibody (aABD2ch) validation 
 
To generate a better antibody against MS1 than those currently available, 3 different 
MS1 constructs were prepared: N-terminal (1-99 aa), ABD1 (193-295 aa) and 
ABD2 (294-375 aa). They were expressed and purified as described in 2.1 and sent 
for a rabbit immunisation to two different companies (Absea, China and 
Bioscience, Germany). The antibody that gave best signals (as judged by initial 
Western blot with purified recombinant MS1), generated with the ABD2 antigen 
and obtained from Absea was further validated using overexpression studies and 
immunofluorescence. It will subsequently be referred to as aABD2ch antibody.  
 
First, myc-tagged MS1 was overexpressed in COS cells and the protein was 
detected using Western blots of the cell lysates (Figure 3.1). The aABD2ch 
antibody recognised only the overexpressed myc-MS1, which was subsequently 
confirmed by detection of the overexpressed myc-MS1 with the anti-myc antibody. 
Both antibodies detected the same, approximately 43 kDa protein, which is in a 
good agreement with the calculated molecular weight of MS1 (43 kDa).  
 
To further characterise the aABD2ch antibody, Western blots with different rat 
tissue lysates were performed. MS1 was detected only in muscle tissues (soleus, 
heart, TA and EDL muscles; no MS1 was detected in liver and stomach), which is 
in good agreement with the previously published data (Arai et al. 2002). The 
detection signal was abolished when antibody pre-absorbed with the immunizing 
antigen was used, confirming specificity of this antibody (Figure 3.2).  
 
To validate the use of the aABD2ch antibody in immunofluorescence, Hela cells, 
which do not express MS1, were transiently transfected withe myc-MS1 plasmid. 
The aABD2ch antibody detection pattern was consistent with the one of anti-myc 
antibody, confirming the specificity of the aABD2ch antibody. Additionally, no 
signal was detected for untransfected Hela cells, which further confirmed its 
specificity (Figure 3.3).  
 
Subsequent cellular fractionation of untransfected Hela cells and Hela cells 
transiently transfected with myc-MS1 plasmid, confirmed cellular localisation of 
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overexpressed MS1, which was found in the cytoskeleton fraction. It also further 
validated the specificity of the aABD2ch antibody, as no signal was visible in any 
of the untransfected Hela cells fractions (Figure 3.4).  
 
Overall, the aABD2ch antibody seemed to be specific and appropriate for the 









Figure 3.1 Characterisation of the anti-MS1 antibody (aABD2ch) (1). Myc-
tagged MS1 was overexpressed in COS cells and Western blots with cell lysates 
were performed. To detect MS1, anti-MS1 (aABD2ch) and anti-myc antibody were 
used. As a negative control, cell lysates with overexpressed GTP-Rock were used. 
The immunoblot analysis reveals that the anti-MS1 antibody (aABD2ch) 










Figure 3.2 Detection of the endogenous MS1 in different rat tissues. The first 
lane (MS1) contains overexpressed myc-MS1 in COS cell samples and the 
following lanes contain rat tissue lysates from: soleus, liver, stomach, TA and EDL 
muscle and heart, respectively. The bottom figure shows on immunoblot probed 
with antibody pre-absorbed with the immunizing antigen. The immunoblot analysis 
confirms the specificity of the anti-MS1 antibody (aABD2ch), as demonstrated by a 
lack of the detection signal, when pre-absorbed antibody was used. Additionally, 
MS1 was found only in muscle tissues, which is in a good agreement with the 
previously published data (Mahadeva et al. 2002).  
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Figure 3.3 Characterisation of the aABD2ch antibody (2). Hela cells, which 
normally do not express MS1 were transfected with c-myc-MS1 plasmid and were 
subsequently incubated with anti-c-myc (A.) or aABD2ch (B.) antibody. Both 
antibodies recognised MS1 only when it was overexpressed. Note that for the 
aABD2ch antibody there was no staining for the non-transfected cells, which 
supports the specificity of the aABD2ch antibody. Moreover, the general features of 
the aABD2ch antibody detection pattern are in good agreement with the anti-myc 







Figure 3.4. Cellular fractionation performed for untransfected Hela cells and Hela 
cells transiently transfected with myc-MS1 plasmid. Immunoblots were incubated 
with the aABD2ch antibody (top figure) and anti-beta-actin antibody (bottom figure) as 
a cytoskeletal marker. The aABD2ch antibody specifically recognises a protein only 
when MS1 is overexpressed. Moreover, the localisation of MS1 is mainly cytoplasmic, 
which is in a good agreement with the previously published data (Arai et al. 2002). The 
presence of MS1 in the chromatin-bound fraction is very likely due to contamination 
between fractions (according to the Subcellular Protein Fractionation kit for Cultured 
Cells from Thermo Scientific separated subcellular compartments should have less than 
15% contaminations from other fractions. C -cytoplasmic fraction, M – membrane 
fraction, SN – soluble nuclear fraction, CH – chromatin-bound fraction, CS – 




3.3. Subcellular localisation of MS1 in NRCs  
 
 
To determine endogenous MS1 localisation in muscle cells, freshly isolated 
neonatal rat cardiomyocytes (NRC) were used. Interestingly, MS1 was found in the 
nucleus in form of a “speckled pattern”, which is characteristic for transcription 
factors (Figure 3.5). This speckled pattern is reminiscent of PML nuclear bodies 
(NB), which are spheres of 0.1–1.0 µm in diameter found in most cell-lines and 
many tissues and, which belong to the nuclear matrix structure proposed to anchor 
and regulate many nuclear functions, including DNA replication, transcription, or 
epigenetic silencing (Lallemand-Breitenbach and de Thé 2010). To determine the 
phenotype of the overexpressed MS1, NRCs were transiently transfected with myc-
MS1 plasmid, and the fixed cells were incubated with the aABD2ch antibody. As 
seen in Figure 3.5, overexpressed MS1 also localises to the nucleus. To confirm 
that the staining was specific to MS1, aABD2ch antibody blocked with the 
immunizing antigen was used. Figure 3.6 shows that pre-absorption with the 
immunizing antigen abolished the nuclear signal.                            
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Figure 3.5 Subcellular localisation of endogenous and overexpressed MS1 in 
NRCs. Untransfected NRC cells and NRC cells transfected with myc-MS1 were 
stained with the aABD2ch antibody. The immunofluorescence analysis revealed 
that the protein is localised to the nucleus, in a characteristic speckled pattern for 




        
 
Figure 3.6 Validation of the aABD2ch antibody specificity in NRC cells. NRCs 
transfected with myc-MS1 were stained with normal and with pre-absorbed with 
the immunizing antigen aABD2ch antibody. The immunofluorescence analysis 
confirms that the aABD2ch nuclear detection of MS1 is specific, as the blocked 








Previous results showed that endogenous as well as overexpressed MS1 localised to 
the nucleus. As the medium used for this experiment contained phenylephrine 
(maintenance medium), it was possible that the protein translocated to the nucleus 
in response to a hypertrophic signal. Phenylephrine is an agent that stimulates 
myocyte contractility, therefore it mimics hypertrophic conditions when used for a 
sufficient amount of time (Benfey and Carolin 1971; Liu et al. 2011).  
 
To determine whether the nuclear localisation of MS1 was a result of the 
phenylephrine stimulation, a medium without phenylephrine (transfection medium) 
was used for the subsequent experiment. As seen in Figure 3.7, endogenous MS1 
localised to the nucleus regardless of the medium used. However, overexpressed 
MS1 localised to the nucleus only under hypertrophic conditions. In non-stimulated 
cells, the overexpressed MS1 was localised specifically to the cytoplasm.  
 
Sequence analysis of MS1 predicted a nuclear localisation sequence. To determine 
whether this sequence, which in MS1 starts at R153A, is indeed involved in the 
regulation of the nuclear localisation of MS1, the first two arginines 
(RR153AA_MS1) were mutated in this putative NLS and the mutant was 
overexpressed in NRCs under hypertrophic conditions. Interestingly, the nuclear 

















Figure 3.7 Subcellular localisation of MS1 in NRCs under hypertrophic and 
non-hypertrophic conditions. To mimic hypertrophic conditions, medium with 
phenylephrine (maintenance medium) was used 12 hours post-transfection or for 
endogenous MS1 detection. For non-hypertrophic conditions medium without 
phenylephrine was used (transfection medium). Endogenous MS1 localises to the 
nucleus regardless of the medium used (top 2 figures), whilst when overexpressed, 
it localises to the nucleus only in stimulated with phenylephrine medium (bottom 2 
figure). In non-hypertrophic medium, MS1 localises to the cytoplasm, when 
overexpressed. The overexpressed MS1 under non-hypertrophic conditions was 
detected using anti-myc antibody in order to pick up the signal only from the 















Figure 3.8 Subcellular localisation of the NLS-mutant of MS1 
(RR153AA_MS1). The RR153AA_MS1 overexpressed mutant localises to the 
sarcomere as opposed to the wild type MS1. The NLS-mutant was detected using 
anti-myc antibody in order to not pick up the signal from the endogenous MS1. 
 
 
3.4. Subcellular localisation of MS1 in ARCs  
 
 
In order to determine localisation of MS1 in adult cardiomyocytes, fully 
differentiated freshly isolated ARCs cells were used. With respect to the in vivo 
myocardium, it is more advisable to study adult cardiac cells, as there are some 
differences, e.g., in expression of ion channels and contractile protein isoforms 
between different stages of development, which may influence the overall protein 
function and localisation (Mitcheson et al. 1998).  
 
As seen in Figure 3.9, in ARCs, MS1 localised to the sarcomere, specifically to the 
I-band, where it partially co-localised with alpha-actinin. The results were further 
validated using a cellular fractionation assay, where MS1 was found in the nuclear 
fraction in NRCs cell lysates, whilst in ARCs cell lysates it was found in the 








Figure 3.9 Subcellular localisation of MS1 in NRCs vs. ARCs. Endogenous MS1 
was detected using the aABD2ch antibody A). Immunofluorescence images of the 
ARCs vs. NRCs. In ARCs, MS1 localises to the sarcomere, whilst in NRCs it 
localises to the nucleus, suggesting developmental control of its expression and 
localisation. B). Cellular fractionation performed for NRCs and ARCs. Actin and 
lamin C were used as a cytoskeletal and nuclear fractions marker, respectively. The 
results from cellular fractionation confirmed results obtained from 
immunofluorescence, where MS1 localises to the nucleus in NRCs, whilst in the 
sarcomere in ARCs. C-cytoplasmic fraction, M – membrane fraction, SN – soluble 








3.5. Subcellular localisation of S150 and Y280 phosphorylation mutants in 
Hela cells  
 
Two potential phosphorylation sites: S150 – possibly phosphorylated by p38-like 
MAP kinase and Y280 – very likely a Src-like kinase target, were identified within 
the MS1 sequence. S150 is located near the predicted NLS, which starts at R153. It 
is known that phosphorylation of a residue near an NLS can serve as a regulatory 
mechanism of its function (reviewed in Jans and Hubner 1996, and Poon and Jans 
2006), therefore it is possible that the S150 may be  important for MS1 function. 
 
To test whether this is the case for MS1, S150 and Y280 were mutated to alanine 
and the constructs were transfected into Hela cells. Interestingly, no change in 
phenotype between wild type and the S150A_MS1 was observed (both showed 
cytoplasmic localisation), whilst Y280A_MS1 localised partially to the nucleus 





Figure 3.10 Subcellular localisation of the S150A and Y280A_MS1 mutant in Hela 
cells. Hela cells were transfected with myc-MS1 plasmid and the overexpressed protein 
was detected using the anti c-myc  antibody. The Y280A_MS1 mutant localised partially to 
the nucleus as opposed to WT and S150A_MS1, which localised mainly to the cytoplasm. 
This may indicate a potential regulatory function of this phosphorylation site.  
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3.6. Conclusions  
 
 
In this chapter a new antibody against MS1 was successfully validated (aABD2ch). 
In neonatal rat cardiomyocytes, endogenous MS1 was found in the nucleus 
regardless whether hypertrophic or non-hypertrophic conditions were used. On the 
other hand, in adult rat cardiomyocytes MS1 was found in the cytoplasm, in the I-
band of the sarcomere. Together all these findings suggest a complex 
spatiotemporal regulation of MS1 localisation.  
 
When overexpressed in NRC, MS1 localised to the nucleus only under hypertrophic 
conditions, whilst when non-stimulated, it localised to the cytoplasm. The predicted 
NLS was found to be involved in the regulation of MS1 localisation, as the NLS-
mutant localised to the cytoplasm, when overexpressed under hypertrophic 
conditions.  
 
Finally, the cellular localisation of potential MS1 phosphorylation mutants in Hela 
cells was tested and it was found that Y280A shown a partial nuclear localisation as 
opposed to the wild type MS1, which localised to the cytoplasm. Localisation of 

























Since the NMR structure of ABD2 revealed that it is a winged helix-turn-helix 
domain, a typical DNA binding domain, we wanted to explore further whether MS1 
could bind DNA, whether this interaction is sequence-specific and what is the 
significance of this interaction.  
In this chapter the DNA binding properties of MS1 will be presented. First, the 
DNA binding properties of different MS1 constructs were characterised using gel 
shift assay and the result suggested that this interaction could be sequence-
dependent. In order to identify the DNA sequence bound by MS1 a SELEX assay 
was performed. The interaction between different MS1 constructs and DNA motifs 
found in the SELEX analysis were later characterised in greater detail using variety 
of biophysical techniques such as NMR, fluorescence and MST. Ultimately, best 
DNA motif, which is bound by MS1 with a moderate affinity was identified and the 
interaction characterised using EMSA, NMR, fluorescence, MST and point 
mutation. 
In this chapter, it will also be shown that ABD2 requires an N-terminal extension to 
its winged helix-turn-helix domain in order to bind DNA. The extension contains a 
protein motif called the AT-hook, which binds AT-rich DNA sequences. Together, 
all these findings confirm that MS1 binds DNA in vitro with a moderate affinity  
(best KD was found at 7 ± 0.9 µM), which suggests that this interaction may be 
relevant in vivo.  
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4.2. Production of different MS1 constructs (ABD1, ABD2 and TANDEM of 
ABD1 and ABD2)  
Constructs encoding different parts of MS1 were previously prepared by Dr. 
Claudia Fogl. Table 4.1 shows constructs and their characteristics used in this 
study.  
 
Construct name Residues MW [kDa] 
ABD1 193-295 12 
ABD2 294-375 9.6 
TANDEM of ABD1 and ABD2  193-375 21.6 
Table 4.1 Constructs used in this study  
 
ABD1 (actin binding domain 1) and ABD2 (actin binding domain 2) are separate, 
functional domains of MS1 that are able to bind actin with different affinity (KD = 
2.21± 0.47 µM vs. 10.61 ± 0.7 µM for ABD1 and ABD2, respectively (Fogl et al. 
2011). The NMR solution structure of ABD2 adopts the fold of a winged helix-
turn-helix domain, which is a typical DNA binding domain, therefore we would 
expect this part to bind DNA. We also carried out the DNA binding assay on ABD1 
and TANDEM of ABD1 and ABD2..  
 
4.2.1. ABD1 production 
 
 The ABD1 fragment of MS1 was expressed in BL21* for 3-4 hours at 37°C. The 
expression level and the purity were high, however after both the first and second 
rounds of purification there was a persistent extra band at a molecular size of 36 
kDa (before cleavage with TEV) and 24 kDa (after TEV cut). Addition of DTT 
causes disappearance of the band  (Figure 4.1. C), which suggested that ABD1 
forms disulphide-linked dimers. For further purification, DTT was added to reduce 
cysteines (ABD1 contains 1 cysteine) and prevent formation of disulfide bonds. 
Overall, the two-step purification yielded a high protein concentration (12 mg/ml 
produced from 4 litres of bacterial culture).  
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  A).        B).                C). 
 
 
Figure 4.1 ABD1 purification. A). First round of IMAC purification. B). Second 
round of purification after TEV cleavage. C). Gel showing that incubation of ABD1 
with DTT reduces its dimers. PL = protein ladder, FT = flow through taken after 
loading supernatant on the column. W = wash factions, E = eluted fractions; red 
arrows show protein band with expected size of 18 kDa (before cut with TEV) and 
12 kDa (after cut with TEV); green arrows show dimers of ABD1 (36 kDa before 
cut with TEV and 24 kDa after cut with TEV).  
 
 
4.2.2. ABD2 and TANDEM of ABD1 and ABD2 production 
 
ABD2 as well as TANDEM were expressed in Arctic Express cells at 15°C for 16 
hours. Overall, the expression and purification procedure yielded a high purity and 
concentration of proteins (12 – 20 mg/ml form 4 litres of bacterial culture), (Figure 






Figure 4.2. ABD2 purification. Left figure = first round of IMAC purification. 
Right figure = second round of purification after TEV cleavage. PL = protein 
ladder, FT = flow through taken after loading supernatant on the column. W = wash 
factions, E = eluted fractions. Red arrows show protein band with expected size of 







Figure 4.3. TANDEM purification. Left figure = first round of IMAC purification. 
Right figure = second round of purification after TEV cleavage. PL = protein 
ladder, FT = flow through taken after loading supernatant on the column. W = wash 
factions, E = eluted fractions. Red arrows show protein band with expected size of 
28 kDa (before cut with TEV) and 22 kDa (after cut with TEV).  
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4.3. DNA binding properties of different MS1 constructs 
 
To study the DNA-binding properties of different parts of MS1, a gel shift assay 
(EMSA) was performed. In the first experiment (Figure 4.4) plasmid DNA 
(pETM11 – 6 kbp) was used as a probe. As a negative control (non-binding protein) 
an SH3 domain was used as well as the ABD1 and TANDEM fragments of MS1. 
The SH3 domain is known for mediating protein-protein interaction and it does not 
have DNA-binding properties (Kay 2012). 1 µM of plasmid DNA was incubated 
with 10 µM of protein and electrophoresed on an agarose gel. The control plasmid 
(lane 4) migrated as normal, however when the plasmid was mixed with the MS1 
constructs, its migration was retarded (lane 5, 6 and 7 for ABD1, ABD2 and 
TANDEM, respectively). Surprisingly, all MS1 constructs had an effect on the 
plasmid migration suggesting that they are somehow involved in the DNA binding. 
It is worth noticing that the ABD1 and TANDEM shifted more DNA than ABD2. 
In case when the plasmid was incubated with the SH3 domain, there was no 





Figure 4.4 DNA binding properties of different MS1 constructs. All 3 MS1 
constructs cause plasmid DNA retardation as opposed to SH3 domain. Lane 1, 2, 3 
– 10 µM of ABD1, ABD2 and TANDEM, respectively, lane 4 - 1 µM of pETM11 
plasmid, lane 5, 6, 7 – 1 µM of pETM11 plasmid + 10 µM of ABD1, ABD2 and 
TANDEM, respectively, lane 8 - 10 µM of SH3 domain, lane 9 - 1 µM of pETM11 
plasmid + 10 µM of SH3 domain.  
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As the previous gel shift experiment suggested differences in DNA affinities for 
MS1 constructs, we decided to perform titration experiment with increasing 
concentration of proteins in order to characterise the affinities more precisely. A 
double stranded 42-bp long oligonucleotide, which is a part of the BACH1 gene was 
used as a probe. This sequence was not expected to be bound specifically by MS1 
and it was chosen as at the time of the initial characterisation of the DNA binding 
properties of MS1 it was available in the laboratory. Also, it was chosen due to fact 
that as opposed to plasmid DNA, its migration in a gel is linear and therefore the 
quantitative analysis is more straightforward than for the coiled plasmid DNA. The 
DNA sequence of this fragment was: 5'-
GTTGAGCACAGCAGTGCTGAGTCATGCTGAGTCATGCTGAG-3'.  
 
For the experiment, 1 µM of dsDNA was incubated with increasing concentration 
of protein (1, 30 and 100 µM) and run on a gel. As seen on the Figure 4.5 the 
strongest DNA binding was observed when TANDEM of ABD1 and ABD2 was 
incubated with the DNA. ABD2 did not bind this DNA fragment at all, whilst 
ABD1 started to shift the DNA at 30:1 [protein:DNA] ratio TANDEM at 30:1 
[protein:DNA] ratio shifted almost all DNA. 
  
One of the possible explanations of the strongest DNA binding by TANDEM could 
be that part of ABD1 is needed for the DNA binding, perhaps the residues located 
within its C-terminus. It is possible that during designing the ABD2 boundaries 
some residues were missed. Also, it is important to consider that some winged 
helix-turn-helix domains have an extra wing at their N-terminus (Kitano et al. 2010; 
Clark et al. 1993), therefore the C-terminus of ABD1 could act as the second wing. 
Indeed, when analysing the sequence of ABD1 
(DMEERPEQDVAQVAAARIKRPLHSQANRYSETLNCKAHRKYSQVDNLKG
QQWADEHIQSQKLNPFSDEFDYDLAMSTRLHKGDEGYGRPKEGSKTAERA
KR) there is a high number of positively charged residues, especially those located 
within its C-terminus (highlighted in red). Positive residues such as arginines and 
lysines are known for binding the negatively charged phosphate backbone of DNA 
either in a sequence specific or non-specific manner. However, it is also possible 
that those residues bind non-specific DNA due to electrostatic interactions. As can 
be seen in Figure 4.5, ABD1, which was not expected to bind DNA at all, bound 
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DNA stronger than ABD2. Most likely this interaction is a result of non-specific 
electrostatic interaction and will be further investigated.  
 
On the other hand, ABD2 did not bind that particular DNA fragment at all, which 
could mean that its DNA motif was not present in this sequence (the DNA probe 
used in this experiment was 42bp long), which would suggest a preference for a 
specific DNA motif. However, it could also mean that indeed it needs the N-
terminal extension in order to fulfil its DNA binding properties and without which 







Figure 4.5 DNA binding properties of different MS1 constructs. 1 µM of 
dsDNA was incubated with increasing concentration of different MS1 constructs 
and electrophoresed on an agarose gel. The strongest DNA binding was observed 
for TANDEM of ABD1 and ABD2, suggesting that a part of ABD1 may be needed 
for the DNA binding or that the binding is caused by non-specific interaction 
between positively charged residues of ABD1 and negatively charged phosphate 
backbone of DNA. ABD2 did not bind this DNA sequence suggesting that it may 
need a sequence specific DNA or that indeed it needs an N-terminal extension to 
fulfil its DNA binding function. 
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4.4. Identification of DNA motif bound by ABD2 – SELEX results 
In order to find a specific DNA sequence bound by ABD2, a SELEX assay was 
performed. However, first it was necessary to optimise its selection step in order to 
find the most suitable method for the ABD2 system.  
 
 
4.4.1. Optimisation of SELEX protocol 
Two methods have been checked and optimised: 1. Immobilised protein (bead-
based) selection method and 2. Gel shift assay partitioning method.  
 
 
4.4.1.1. Bead-based selection protocol 
In this method his6-tagged ABD2 was immobilised on Nickel Sepharose column 
and incubated with the random dsDNA library. To remove non-specific DNA 3 
washes were performed and DNA-protein complexes were eluted. The bound DNA 
sequences were extracted and subjected to a further analysis by PCR. As it can be 
seen in Figure 4.6 each fraction yielded PCR products. The overall number of PCR 
cycles was 20, however, in order to compare the amount of obtained PCR product 
for each fraction, 5 µl of PCR product was taken after every 5 cycles of PCR. It was 
done in order to verify whether the wash steps were sufficient to remove the non-
specific DNA. If they were, we would expect no or much less PCR product in the 
final 3W step and a large amount of PCR product in the eluted fraction. It would 
mean that the protein bound this DNA specifically, or at least with a higher affinity. 
In order to determine the background binding, an empty (-ABD2) Nickel Sepharose 
column was used. Unfortunately, there was a high non-specific binding to the resin 
(Figure 4.6 A), which was not entirely unexpected as the DNA may bind to the 
nickel cations non-specifically. 
In order to find a different, more suitable resin for the assay, glutathione and 
amylose resin was checked. Unfortunately, there was also a high level of non-





Figure 4.6 Optimisation of the bead-based selection step of SELEX. ABD2 was 
used as bait and random dsDNA library was added. Agarose gels show PCR 
product obtained after every 5 cycles of PCR thermocycling, performed for 3 wash 
fractions (W1, W2, W3) and the elution fraction (E). A). Negative control – as a 
PCR template, DNA collected from pull-down without the immobilised protein was 
used. B). As a PCR template, DNA collected from pull-down with ABD2 as bait 
was used. There is a high level of background DNA binding to the beads as even in 
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Figure 4.7 Optimisation of the bead-based selection step of SELEX. Amylose 
and Glutathione resin were checked for a background DNA binding. Both agarose 
gels show results for 3 wash fractions (W1, W2, W3) and the elution fraction. A). 
Results for amylose resin; B). Results for glutathione resin. There is a high 
background DNA binding for both types of resin.  
 
 
In order to reduce the non-specific binding to the resin, different buffers containing 
from 50-500 mM of NaCl (SELEX buffer A, SELEX buffer B, FF6 Wash buffer) as 
well as larger wash volumes were used. Unfortunately, the background DNA 
binding was still very high. Despite of that, we carried out the SELEX assay up to 
round 6 and performed a binding assay. The binding assay was performed using 
EMSA and the aim of this experiment was to see whether there is an increase in 
binding of the DNA by ABD2. If yes, it would mean that the specific DNA bound 
by ABD2 was successfully pulled-down from the library and amplified. In order to 
perform this experiment, eluted fractions from pool 1, 2, 4 and 6 were amplified by 
PCR to obtain a large amount of DNA, purified and subjected to EMSA with 
increasing concentration of ABD2. Figure 4.8 shows that there was no difference in 
DNA binding between fractions from round 1 and 6 suggesting that no DNA bound 
by ABD2 was pulled down from the random library. 
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Figure 4.8 Binding experiment performed after the 6th round of SELEX using 
the bead-based selection step. A). Gel showing PCR product obtained for each 
fraction from the last round of pull-down (round 6). The eluted fraction contains 
much more product than the Wash 3 (W3) fraction, consistent with a potential 
enrichment of the specific DNA sequence bound by ABD2. Yellow colour describes 
fractions obtained from the last round of SELEX. White colour describes amplified 
fractions for each eluted fraction from round 1-6 (E1, E2, E3, E4, E5, E6). B). 
Binding assay performed using EMSA. Increasing concentrations of ABD2 (1 µM – 
100 µM) were incubated with amplified elution fractions from round 1, 2, 4 and 6. 
There was no difference in DNA binding between fraction from round 1 and 
fraction 6 suggesting that no DNA bound by ABD2 was amplified. 
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4.4.1.2. Gel-shift assay selection protocol 
 
The gel shift assay has been previously used as a selection step of SELEX (Tsai and 
Reed 1998; Kubota et al. 2013). To check whether this method will be suitable for 
our system, we performed EMSA for ABD2 and a random dsDNA library. We ran 
the sample on agarose and polyacrylamide gels and the results were much better for 
the agarose gel as the shifted DNA bands were more defined. However, in some 
cases, there was a shifted DNA band located outside the well, which very likely 
represented formation of non-specific oligomers. The effect of this on the SELEX  
procedure will be discussed later in Discussion chapter. Figure 4.9 shows the first 
round of SELEX performed for ABD2 on the agarose gel.  
 
 
                
 
Figure 4.9 First round of SELEX. 20 pmols of ABD2 was incubated with 200 
pmols of random dsDNA library and run on agarose gel. Top 3 red arrows indicate 
complex bands formed during electrophoresis. Free probe (unbound DNA) bands 
are located at the bottom of the gel. The first lane contains only free probe (random 
dsDNA library). Lanes 2, 3 and 4 contain 20 pmols of ABD2 plus 200 pmols of 
random dsDNA library. The last lane contains 20 pmols of ABD2.  
 
 
The complex bands were cut from the gel, purified and subjected to PCR in order to 
amplify the bound fraction. PCR was optimised in order obtain a high yield of PCR 
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product which will be later combined and used for the second round of SELEX. We 
also checked the effect of the addition of the PCR Enhancer Solution (Invitrogen), 







Figure 4.10 Optimisation of PCR protocol. PCR was run with or without the PCR 
Enhancer Solution. Lanes 1, 2 – 10 µl of PCR product without the PCR Enhancer 
Solution, Lanes 3, 4 - 10 µl of PCR product with the PCR Enhancer Solution. PCR 
Enhancer Solution does not improve the yield of the PCR product.  
 
 
Further rounds of SELEX were performed using gel shift assay for the selection 
step and the pulled-down DNA was amplified as described in Materials and 
Methods (2.3.2.3.2.1.). Subsequent rounds of SELEX were performed as described 
in Table 2.7 (Materials and Methods). After the final 8th round, ABD2-bound DNA 
sequences were cloned into pBluescript  II KS (-). To verify the presence of cloned 
inserts, blue-white screening and colony PCR were performed. Colony PCR 
showed that statistically about 80% of the blue colonies contained the inserts 
(Figure 4.11).  
    M        1        2        3         4 




Figure 4.11 Colony PCR performed with blue colonies. Expected PCR product size 
= 280 bp. PCR done using M13F/M13R primers. 
 
 
Overall, 96 colonies were picked, colony PCR with M13F/M13R primers was run 
on each, and the PCR product were sequenced using the M13F primer.  
 
 
4.4.2. SELEX results 
 
53 sequences out of 96 sequences sent were suitable for further analysis. 43 
sequences were discarded due to: a) absence of the flanking region, b) presence of 
extra nucleotides within the random region (sometimes even up to 200 bp) c) some 
simply failed the sequencing reaction. For further analysis, 53 sequences were 
aligned according to the flanking region. All alignments were done using JalView 
software. After aligning the flanking regions, sequences were sorted according to 
the similarity level within the random region. Two sets of data emerged, named 
Data A and Data B. Figure 4.12 shows the two data sets. Data A consists of almost 
identical DNA sequences whilst Data B is more random, however it is worth to note 
that they both are GT-rich. The reason why all the sequences of Data A are identical 
could be that either they were specifically enriched during SELEX procedure or, 
which is more likely, is that they were overamplified during PCR and subsequently, 
all clones contained this sequence.  
 
To analyse the sequencing data for a presence of a significant motif, MEME tools 
were used. MEME algorithms were run for those two data sets and the found motifs 







Figure 4.12 SELEX results for ABD2. The sequencing data was divided into 2 
data sets: one (left figure, Data A) represented almost identical sequences, whilst 
the other one contained more random sequences (right figure, Data B). Note that 













Figure 4.13 DNA motif found for Data A using MEME. 29 sequences were 
analysed. The search parameters were: a) minimum width – 6 bp; b) maximum 
width – 12 bp; c) number of motif to be found – 3. All motifs (Motif 1, Motif 2, 












Figure 4.14 DNA motif found for Data B using MEME. 24 sequences were 
analysed. The search parameters were: a) minimum width – 6 bp; b) maximum 
width – 12 bp; c) number of motif to be found – 3. Motif 1 was found at 18 sites, 




The whole SELEX procedure was repeated and the results are shown in Figure 
4.15. They were further analysed for a presence of a significant motif and the 




                              
Figure 4.15 SELEX results for ABD2 obtained from a repeat. Note that only one 
5’-3’ strand is shown. 
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Figure 4.16 DNA motifs found for a data generated from repeated SELEX. 
MEME. 34 sequences were analysed. The search parameters were: a) minimum 
width – 6 bp; b) maximum width – 12 bp; c) number of motif to be found – 3. Motif 
1 was found at 16 sites, Motif 2 – 5 and Motif 3 - 3 sites. Motifs are shown for both 
5’-3’ strands.  
 
Comparing all most significant motifs obtained from both SELEX experiments, a 
consensus DNA sequences can be found. It is worth notice that the motif is CA/GT-
rich (Figure 4.17).  
 
Oligonucleotides containing the most significant motifs will be later characterised 





                       
Figure 4.17 Comparison of most significant motifs obtained from results for 
Data A (Motif 1, SELEX1, Data A – M1-S1A); Data B (Motif 1, SELEX1, Data 
B – M1-S1B) and SELEX 2 (Motif 1, SELEX2 – M1-S2). Comparing all motifs a 




4.5. Characterisation of the binding between ABD2 and DNA motifs found in 
SELEX using gel shift assay and NMR spectroscopy 
 
To test whether ABD2 binds to motifs found in SELEX, gel shift assay and NMR 
titration were used. Sequences of the oligonucleotides used in this study can be 
found in Table 4.2.  
First, motifs found in SELEX 1 for Data A were tested for the binding. They were 
found in each of the analysed sequences, therefore they were most significant and 
very likely bound by ABD2. To test the binding, a gel assay was run. As seen in 
Figure 4.18, ABD2 bound Motif 1 and Motif 2, however it did not bind Motif 3. 
The interaction seemed to be very weak as ABD2 started to shift the DNA only at 
1:30 [DNA:protein] ratio. If one of the sequences were specific for ABD2, we 
would expect much stronger binding. Typically, binding affinities for transcription 
factor-DNA interactions are usually found in a range of pM-nM (Jaeger et al. 2010; 
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Badis et al. 2009; Wang et al. 2011). Based on the EMSA results it seems that the 
binding affinity for MS1-DNA is much lower  ( >30 µM). However, there are some 
known transcription factors that bind DNA with much lower that pM-nM affinity 
e.g. AsH2L protein (KD = 3.7 ± 0.9 µM) (Sarvan et al. 2011; Chen et al. 2011) or 
other DNA binding proteins that bind DNA with affinity in a range of µM,  e.g., 
AT-hook motifs from Tip5 protein (KD = 20 µM for 1 AT-hook motif and KD = 4 
µM for a tandem of 2 AT-hook motifs), (Tanay 2006; Segal et al. 2008; Zillner et al. 
2012).  
 
To further test the interaction between ABD2 and the found motifs, NMR titrations 
were performed. For each experiment 50 µM of 15N-labelled ABD2 was mixed with 
150 µM or 50 µM of unlabelled oligonucleotide (to obtain 3:1 or 1:1 [DNA:protein] 
ratio) and HSQC was recorded. The obtained spectrum was superimposed with a 
reference spectrum of 50 µM of 15N-labelled ABD2, which was recorded prior to 
the complex experiment and the chemical shift perturbations (CSP) were 
calculated. As shown on the Figure 4.19, 4.20 and 4.21 none of the motifs found in 
SELEX 1 (Motif 1, 2 and 3) caused any significant changes to the position of the 
peaks when compared to the reference spectrum.  
 
One of the possible reasons why there was no detectable binding, could be that 
ABD2 may need a longer DNA oligonucleotide. For the NMR experiment, a 12bp 
long oligonucleotide was chosen, however in the SELEX experiment a library of 
82bp long oligonucleotides was used. Additionally, the random region consist of 
36bp, therefore there was a possibility that for the DNA binding, a longer DNA 
oligonucleotide is required. To test this hypothesis, a 36mer, which consists of 
Motif 1, Motif 2 and Motif 3 was used for the NMR experiment. As shown on the 
Figure 4.22 there were a mild differences in some peaks position after addition of 
the 36mer as compared to the reference spectrum. The residues affected by the 
addition of the 36mer oligonucleotide are localised within helix 1 and loop (wing) 
after helix 3. However, the binding seemed to be very weak as the chemical shifts 
perturbations are very small throughout the titration. Additionally, we designed 
another oligonucleotide (Sel_GT/CA), which consisted only of GT/CA bases as the 
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sequencing results suggested that ABD2 might bind a GT/CA-rich sequence. 
Figure 4.33 shows binding of Sel_GT/CA by ABD2. Similarly to 36mer, there are 
small CSPs, also affecting residues from helix 1, as well as to the loop and 
additionally helix 2.  
 
 
DNA oligonucleotide 5’-3’ sequence 
MOTIF 1 (M1) ACTTAGGTGTGA 
 MOTIF 2 (M2) TCCACAACACTT 









Figure 4.18 EMSA showing the binding between ABD2 and Motif 1, 2 and 3. 1 
µM of each motif was incubated with increasing concentration of ABD2 (1, 10 and 
30 µM) and run on an agarose gel. Motif 1 and Motif 2 was weakly bound by 
ABD2, however Motif 3 was not.  
ABD2	   






Figure 4.19 Binding between ABD2 and Motif 1. A). Superimposition of HSQC 
spectra of 15N-labelled ABD2 with (red) and without (black) Motif 1 
oligonucleotide. 50 µM of ABD2 and 150 µM of DNA were used. B). Plot of 
Chemical Shift Perturbation (CSP) vs. residue number. The dashed line indicates 
<Δδtot> + 1σ level. Residues: G291, A292, H299, Y301, R318, R319, R336, I337, 
E359 were not assigned. Addition of the DNA does not cause any significant 






Figure 4.20 Binding between ABD2 and Motif 2. A). Superimposition of HSQC 
spectra of 15N-labelled ABD2 with (blue) and without (black) Motif 2 
oligonucleotide. 50 µM of ABD2 and 150 µM of DNA were used. B). Plot of 
Chemical Shift Perturbation (CSP) vs. residue number. The dashed line indicates 
<Δδtot> + 1σ level. Residues: G291, A292, H299, Y301, R318, R319, R336, I337, 
E359 were not assigned. Addition of the DNA does not cause any significant 







Figure 4.21 Binding between ABD2 and Motif 3. A). Superimposition of HSQC 
spectra of 15N-labelled ABD2 with (green) and without (black) Motif 3 
oligonucleotide. 50 µM of ABD2 and 150 µM of DNA were used. B). Plot of 
Chemical Shift Perturbation (CSP) vs. residue number. The dashed line indicates 
<Δδtot> + 1σ level. Residues: G291, A292, H299, Y301, R318, R319, R336, I337, 
E359 were not assigned. Addition of the DNA does not cause any significant 









Figure 4.22 Binding between ABD2 and 36mer. A). Superimposition of HSQC 
spectra of 15N-labelled ABD2 with (red) and without (black) 36mer 
oligonucleotide. 50 µM of ABD2 and 50 µM of DNA were used. B). Plot of 
Chemical Shift Perturbation (CSP) vs. residue number. The dashed line indicates 
<Δδtot> + 1σ level. Residues: G291, A292, H299, Y301, R318, R319, R336, I337, 
E359 were not assigned. Addition of the DNA causes mild difference in the 







Figure 4.23 Binding between ABD2 and Sel_GT/CA. A). Superimposition of 
HSQC spectra of 15N-labelled ABD2 with (magenta) and without (black) Sel1 GT 
oligonucleotide. 50 µM of ABD2 and 150 µM of DNA were used. B). Plot of 
Chemical Shift Perturbation (CSP) vs. residue number. Residues: G291, A292, 
H299, Y301, R318, R319, R336, I337, E359 were not assigned. Addition of the 
DNA causes mild differences to the position of the peaks. The dashed line indicates 
<Δδtot> + 1σ level.  
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In summary, the binding between most significant motifs found in SELEX and 
ABD2 was tested using EMSA and NMR. EMSA results indicated a very weak 
binding for Motif 1 and Motif 2 and no binding for Motif 3. However, NMR results 
shown no binding for all 3 motifs. As there was a possibility, that ABD2 need a 
longer DNA sequence for the binding, a combination of those 3 motifs, called 
36mer, was used. The addition of the 36mer oligonucleotide had a bigger effect 
than the single motifs 1, 2 and 3 on some residues, however due to very small 
chemical shift perturbations it seemed that the binding is of a very low affinity. The 
residues affected by the binding are localised to helix 1 and the loop between helix 
3 and second beta-strand. The canonical binding site of winged helix-turn-helix 
domains is localised to the helix 3, therefore it is possible that the found motif in 
SELEX is not the sequence-specific one and the interaction between these two is 
driven via unspecific electrostatic interactions.  
 
We have also checked a GT/CA-rich DNA sequence for the binding as the 
sequencing results clearly indicated a GT/CA-rich motif. Again, the addition of the 
oligonucleotide caused very small CSPs and residues affected involve those from 
helix 1, loop and helix 2. There are significant changes in the peak position of 
Tyr334 and Val335, which are localised to helix 2 and it is worth noting that after 
Val336 there are Arg337 and Ile338, which have not been assigned due to lack of 
sufficient data from the triple-resonance experiments. It is therefore likely that this 
region binds DNA in an unspecific manner.  
 
The results of these experiments (i.e. failure to bind the SELEX-identified 
sequences with a high affinity and similarly weak binding to a random short 
GT/CA-rich sequence) leaves open the possibility that ABD2 requires an unknown 
specific DNA sequence for high affinity binding. Additionally, as the preliminary 
EMSA results showed that TANDEM of ABD1 and ABD2 bound DNA stronger 









4.6. Design and preparation of the extended constructs of ABD2 
 
As the ABD1 or part of ABD1 seemed to be important for the DNA binding 
properties of ABD2, new extended constructs of ABD2 were prepared. Figure 4.24 
A). shows domain boundaries of the new constructs. The new constructs were 
cloned and prepared by overexpression in E.coli. The protein yield after purification 
was high for C4 and C3 constructs (around 20mg/ml from 1L of E.coli culture) and 
slightly lower for C2 and C1 constructs (around 5 – 10 mg/ml). Overall, the 







   
Figure 4.24 Design and preparation of the N-terminal extended constructs of 
ABD2. A). Schematic diagram showing domain boundaries for ABD1, ABD2, 
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TANDEM of ABD1 and ABD2 as well as for the new ABD2 constructs. B). SDS-
PAGE gel showing yield and purity of ABD2 and its new constructs.  
4.6.1. Biophysical characterisation of the extended constructs of ABD2 using 
CD and NMR spectroscopy 
 
To assess the new construct’s fold and stability, CD spectroscopy was used. All 
constructs were correctly folded as shown in Figure 4.25.  
   
     
 
 
Figure 4.25 Characterisation of ABD2 and its new constructs fold using far-UV 
CD spectroscopy. Far UV-CD spectra of ABD2 and the extended constructs.  
 
 
To assess the stability of ABD2 and its extended constructs, thermal denaturation 
experiments were performed. The thermal melting curves monitored by the CD 
signal at 222 nm are shown in Figure 4.26 along with the calculated melting 
temperatures (table). All proteins were stable and the new constructs had slightly 
higher melting temperature than the original ABD2. Construct ABD2(C4) had a 
very similar melting temperature to ABD2 (63.3 ± 0.1 vs. 64.0 ± 0.1), whilst 
ABD2(C3) and ABD2(C2) had slightly higher melting temperatures (67.4 ± 0.1 and 
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70.9 ± 0.2, respectively). The longest construct ABD2(C1) had a lower melting 
temperature than ABD2(C2) construct (65.0 ± 0.1 vs. 70.9 ± 0.2).  
To further assess the fold and to see whether the assignment of new constructs 
would be feasible, the 1H-15N HSQC spectrum for each protein construct was 
recorded. The results are shown in Figure 4.27, 4.28, 4.29 and 4.30 for ABD2(C4), 
ABD2(C3), ABD2(C2) and ABD2(C1) respectively. Overall, the spectra are similar 
suggesting comparable to ABD2 fold of the main domain. Furthermore, comparing 
each new spectrum with the original ABD2 1H-15N HSQC spectrum (black 
spectrum on each figure) it seems that the extended parts for each new construct are 
unfolded, as the new peaks are mainly localised in the random coil region of the 1H-
15N HSQC spectrum.  
 
In terms of the future assignment of the new constructs, in case when the extension 
will be found important and crucial for the DNA binding properties, there could be 
some potential problems with assigning all of the additional peaks. For ABD2(C4)  
(contains additional 7 residues) there are only 4 additional peaks when compared to 
the ABD2 spectrum. For ABD2(C3) there are around 10 new peaks out of 14 added 
amino acids and for ABD2(C2) around 18 new peaks out of 24. In case of 
ABD1(C1), the 1H-15N HSQC spectrum is of a much worse quality than for the 
other constructs and the additional peaks seem to be heavily overlapped in the 
random coil region.  
 
Although, there are some missing peaks for each construct in the 1H-15N HSQC 
spectrum, the final conclusion whether it is possible to assign those peaks will 









    
 
Figure 4.26 Characterisation of ABD2 and its new extended constructs 
stability using thermal denaturation. Thermal unfolding was assessed by 
monitoring the CD signal at 222 nm. Denaturation curves are shown for ABD2 and 
its new constructs. The data were fitted (red line indicates best fit) using a 
Levenberg–Marquardt algorithm (LMA) based on the Gibbs-Helmholtz equation 
(Equation 1.1) and the calculated melting temperatures are shown in the Table in 
the right bottom corner.  
 
Protein Tm (oC) 
ABD2 63.3 ± 0.1 
ABD2(C1) 65.0 ± 0.1 
ABD2(C2) 70.9 ± 0.2 
ABD2(C3) 67.4 ± 0.1 
ABD2(C4) 64.0 ± 0.1 !
















































































































































Figure 4.30 Superimposition of 1H-15N HSQC spectrum of ABD2 (black) and 





4.6.2. Identification of an AT-hook motif within the C-terminus of ABD1  
 
During designing new construct boundaries, an interesting feature in the MS1 
protein sequence was identified. The C-terminus of ABD1 seemed to contain an 
AT-hook motif, which is characterised by a presence of a core “GRP” amino acid 
sequence flanked by positive residues on both sides (Aravind and Landsman 1998). 
AT-hook motifs bind short stretches of AT-rich sequences in the minor groove of 
DNA. CD and NMR spectroscopy studies showed that in the absence of DNA, AT-
hook motifs have no defined secondary or tertiary structure. However, when they 
bind to an AT-rich minor groove of DNA they adopt a defined “hook-like” 
conformation (Cui and Leng 2007; Cui et al. 2005; Fonfría-Subirós et al. 2012).  
 
AT-hook motifs are involved in gene regulation by serving as accessory proteins 
that anchor chromatin-associated proteins to certain DNA sequences or by being 
involved in cooperative DNA binding with other proteins in the assembly of 
transcriptional complexes (Aravind and Landsman 1998). It was also shown that 
they are present in proteins with another DNA binding domain for example in 
Estrogen Releated Receptor-2 protein (hERR2) (Gearhart et al. 2003) or in TdIF1 
(Kubota et al. 2013).  
 
Figure 4.31 shows a motif logo for identified AT-hook motifs compared to the MS1 
sequence. MS1 contains the “GRP” motif, which is flanked by a C-terminal lysine, 






Figure 4.31 Identification of an AT-hook like motif within the C-terminus of 
ABD1. The figure shows sequence logo of all identified AT-hook motifs in 
Aravind et al. study (1998). All AT-hook motifs contain the conserved “GRP” core 
motif as shown by its high occupancy among all identified AT-hook motifs. MS1 
also contains the core “GRP” motif within the C-terminal sequence of ABD1 as 
well as some other conserved residues (highlighted in red). Only part of the MS1 





To test whether the AT-hook motif identified in MS1 is functional, NMR titration 
experiments were performed. To begin, ABD2(C3) was used for the study as it 
previously produced a good 1H-15N HSQC spectrum, it contains the “GRP” AT-
hook core motif and would have a potentially easy backbone assignment to conduct 
when needed.  
For the experiment an AT-rich dsDNA sequence  (5’-CGAATTAATTCG-3’) was 
used, which was previously published by Campos et al. as being bound by the AT-
hook of HMGA1 protein (Fonfría-Subirós et al. 2012).   
Figure 4.32 shows a titration of 70 µM of ABD2(C3) with increasing 
concentrations of the AT-rich sequence ( to obtain 1:05, 1:1 and 1:2 [protein:DNA] 
ratio). It is worth noting that there are only 3 peaks that experienced significant 
changes in their position after the ligand addition. Comparison with 1H-15N HSQC 
spectrum of ABD2 showed that those peaks most likely belong to the extended part 




peaks indeed belong to the AT-hook motif, which confirmed that MS1 contains a 
functional AT-hook motif.  
 
To verify which residues they were, a backbone assignment of the ABD2(C3) was 
performed. In order to do so, first HNCA and HNCACB spectra of the 15N-13C 
labelled ABD2(C3) at pH 7.2 were recorded. Those spectra allow the identification 
of alpha (HNCA, HNCACB) and beta  (HNCACB) carbons of each amino acid as 
well as identification of specific type of residues by analysing their chemical shifts. 
Overall, about 50% of alpha and about 30% of beta carbons were identified from 
those experiments.  
 
To test whether reduction of the sample pH will improve quality of the data, HSQC 
at pH 6.5 and pH 6.0 were recorded. Figure 4.33 shows both spectra. The spectrum 
recorded at pH 6.5 is of a better quality than the one recorded at pH 6.0, where the 
peaks intensity is much lower. Additionally, in the spectrum at pH 6.5 there are 
extra peaks when compared to the spectrum at pH 7.2 (Figure 4.34), which were 
later assigned to belong to the extended part.  
 
To improve the ABD2(C3) assignment, HNCA, HNCACB were repeated at pH 6.5 
and it significantly improved the data quality. Additionally, HNCOCA and 
HNCOCACB spectra were recorded to sequentially connect the residues. Overall, 
almost all 14 added residues were assigned (except for the first glycine, which is 






Figure 4.32 Identification of the AT-hook like motif within the C-terminus of 
MS1. 70 µM of ABD2(C3) was titrated with increasing concentration of AT-rich 
DNA sequence and 1H-15N HSQC spectrum was recorded at each concentration. 
Superimposed spectra indicate that only 3 peaks were affected by the ligand 
addition. Interestingly, those peaks, belong to the extension of ABD2(C3) and were 
later assigned to belong to the AT-hook (R282) or near the AT-hook motif (K284 










Figure 4.34 Comparison of ABD2(C3) 1H-15N HSQC spectrum at pH 7.2 
(black) and pH 6.5 (blue). There are more peaks in the pH 6.5 HSQC spectrum, 







Figure 4.35 shows chemical shift perturbation plot against number of assigned 
residues of ABD2(C3) for the titration experiment with the AT-rich DNA sequence. 
It confirms that the residues, which were affected by the addition of the ligand, 
belong to the extension of ABD2(C3) as well as to the core “GRP” motif. The 
hypothetical AT-hook motif in ABD2(C3) was suspected to consist of G281, R282, 
P283 and K284. Indeed, the R282 residue, which is central in the “GRP” motif, 
1H	  (ppm) 
ABD2(C3)	  pH	  7.2 









experienced the biggest chemical shift perturbation. The flanking G281 and P283 
were not visible in the spectrum, while K284 also experienced a substantial 
chemical shift perturbation as compared to the noise level (<Δδtot> + 1σ). 
Summarising, the above experiment provides sufficient evidence to confirm that the 




   
 
 
Figure 4.35 Plot of chemical shift perturbation vs. residue number of 
ABD2(C3). Upon addition of the AT-rich DNA sequence, residues from the AT-
hook motif show significant changes in their position, which indicates that this 
motif is functional. The dashed line indicates <Δδtot> + 1σ level. * - indicates 
unassigned residues (G279, K294, H299, Y301, H317, R318, R319, D320, R336, 
I337, E359); * - indicates residues invisible in HSQC (G281, P283, G286, S287, 
K288, T289).  
 
 
4.7. Characterisation of DNA binding properties of the new ABD2 constructs 
using EMSA and NMR spectroscopy 
 
To test the DNA binding properties of the new ABD2 constructs, gel shift assays 
were performed. As a probe, random dsDNA library was used. It contains 1015 
possible combination of the 18bp random region and therefore it is very likely that 
the DNA sequence bound by MS1 will be present, which should help establish any 
 
121 
differences in the DNA binding affinities of the new constructs, if there are any, 
e.g., if the extended part contributes significantly to the DNA binding, the binding 
should be much higher than the binding of ABD2 alone. Also, to help assess the 
strength of the DNA binding, a positive control for the assay, FOXO3a was 
prepared.  
 
FOXO3a is a well-characterised transcription factor, which, similarly to ABD2, also 
contains a winged helix-turn-helix domain. Its structure has been solved by both 
solution state NMR and X-ray crystallography (Tsai et al. 2007; Wang et al. 2008). 
The specific DNA sequence bound by FOXO3a has been studied extensively and a 
consensus motif is known. Similarly to ABD2, it also contains a winged helix-turn-
helix domain. All of these characteristics make FOXO3a a good control for the 
DNA binding studies, both in gel shift assays as well as for the SELEX experiment. 
The DNA binding domain of FOXO3a (FOXO3a-DBD) was cloned and it is about 
the same size as ABD2 and its new constructs (MW of FOXO3a-DBD – 11 kDa, vs. 
10 – 16 kDa of the new ABD2 constructs). As the consensus sequences is known, it 
will be useful to conduct SELEX experiment for FOXO3a to verify how adequate 
and reliable the assay is. This will be described later in this thesis.  
 
Figure 4.36 shows preparation of the DNA binding domain of FOXO3a. For the 
cloning, a rat homolog of FOXO3a was used. The DNA was cloned into a pLEICS 
vector containing a His6-tag and the protein was overexpressed in E.coli. 
Unfortunately, it did not produce a sufficient amount of pure protein. To resolve this 
problem, a GST-tag version of FOXO3a-DBD was overexpressed in E.coli and 
purified using glutathione resin. It yielded a very pure protein at high concentration 
(around 20 mg/ml from 1L of bacterial culture). The protein was later tested for its 
DNA binding properties using EMSA and NMR and it was confirmed that the 








Figure 4.36 Preparation of FOXO3a. A). SDS-PAGE gel showing purification of 
FOXO3a-DBD. FT-flow through, W-washes, B- GST-tagged bound fraction on the 
glutathione beads. B). EMSA gel showing binding of the target sequence by DBD-
FOXO3a. Increasing concentration of FOXO3a-DBD (1, 5, 10, 20 and 30 µM 
respectively) was incubated with 1 µM of its target DNA sequence and separated on 
an agarose gel. At high concentration of the protein, the DNA migration is retarded. 
C). 1H-15N HSQC spectrum of FOXO3a-DBD with (red) and without (black) 
addition of its target DNA sequence. There are substantial changes in peaks 
position after addition of the ligand confirming that the prepared protein is fully 
active.  
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In order to characterise the DNA binding properties of the new ABD2 constructs, a 
gel shift assay was performed. 1 µM of random dsDNA library was incubated with 
increasing concentration of the protein and the samples were electrophoresed on an 
agarose gel. As it can be seen in Figure 4.37, ABD2(C3) and ABD2(C2) bound the 
DNA much stronger than ABD2 did alone. Interestingly, the strength of the binding 
is comparable to the FOXO3a-DBD DNA binding (for all 3 proteins at 10:1 
[protein:DNA] ratio  all DNA probe was shifted). In case of ABD2 alone, there was 
only a small smear of DNA, confirming previous results that it binds DNA with a 
very low affinity. Interestingly, in case of ABD2(C4) the DNA shifts were almost 
invisible. It could have been caused by a technical problem with EMSA as 
sometimes it was observed that some of the DNA probe diffused into the buffer 
(explained in discussion). ABD2(C1) shifted only a small fraction of the DNA 
probe indicating a very low DNA binding of this construct.  
 
Overall, the 2 new middle length constructs (ABD2(C3) and ABD2(C2)) bound 
DNA with a higher affinity than ABD2 alone, which indicates the importance of the 
sequence extension in DNA binding. They both contain the AT-hook motif, and it 
is highly likely that this motif specifically improved the DNA binding as 
ABD2(C4) although it contains an extra 7 residues, it does not include the AT-hook 
motif and it failed to bind the DNA with the same strength as ABD2(C3) or 
ABD2(C2).  
 
Possibly, one may argue that the binding in EMSA may have been caused by the 
AT-hook alone, and therefore to verify it, a SELEX experiment will be repeated for 
one of the longer constructs. However, it is worth noting that the longest construct 
ABD2(C1) also contains the AT-hook motif but it bound DNA with a very low 
affinity. One explanation of that could be that the extension of the ABD2(C1), 
which is quite flexible, somehow inhibits the winged helix-turn-helix domain thus 













Figure 4.37 DNA binding properties of the new ABD2 constructs. 1 µM of 
random dsDNA library was incubated with increasing concentration of each protein 
construct and separated on an agarose gel. Top gel shows results for ABD2 and 
FOXO3a-DBD (positive control). Middle gel shows results for ABD2(C4) and 
ABD2(C3). Bottom gels show results for ABD2(C2) and ABD2(C1). The strongest 
DNA binding was observed for ABD2(C3) and ABD2(C2). The strength of the 
binding is comparable with the strength of DNA binding by FOXO3a-DBD. M – 
DNA marker, DNA – free dsDNA random library probe.  
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For further investigation the ABD2(C3) construct was chosen as the NMR 
backbone assignment was already done and also because it showed a very good 
binding in previous EMSA experiment. To further test its DNA binding properties, 
NMR titration with DNA sequences found in the first and the second SELEX 
(performed for ABD2) were performed. It was also done to test whether the 
addition of the extension will improve the binding of those sequences, which 
previously were not bound by ABD2. Prior to that experiment, we assessed whether 
the addition of the extension caused any drastic differences in the conformation of 
the winged helix-turn-helix domain (ABD2). As seen in Figure 4.38 there are 
almost no significant differences in the position of the peaks of the winged helix-
turn-helix domain of ABD2(C3), except for 2 residues on its N-terminus, which 
very likely represent the interaction of the extended linker with the residues from 







Figure 4.38 Influence of the addition of the extension on the winged helix-turn-
helix domain. Plot shows chemical shift perturbation vs. residue number of the 
winged helix-turn helix domain after addition of the extension. To plot the graph, 
CSP were calculated between ABD2 and ABD2(C3) spectra. The dashed line 
indicates <Δδtot> + 1σ level. Residues above the dashed line show significant 
changes to the peaks position. * - indicates unassigned residues (G291, A292, 





Figure 4.39, 4.40, 4.41 and 4.42 show binding of Motif 1, Motif 2, Sel_GT/CA and 
36mer, respectively by ABD2(C3). Similarly to ABD2, ABD2(C3) did not bind 
Motif 1 (Figure  4.19, 4.20, 4.23 and 4.22 show binding of Motif 1, Motif 2, 
Sel_GT/CA and 36mer by ABD2, respectively). Although, there are few chemical 
shifts perturbations higher than the noise level, they are very mild, randomly 
distributed and they do not form any cluster of residues. Therefore, it is very 
unlikely, that those CSP were caused by the binding event and most probably they 
are result of the experimental noise. 
 
The binding of Motif 2 by ABD2(C3) seemed to be improved when compared to 
the binding by ABD2. Previously, there was no significant CSP of ABD2 after 
addition of the ligand, however when the extended construct is used, there are some 
peaks moving after the addition of DNA. Those are localised to the N-terminus and 
part of helix 1 of MS1. 
 
Interestingly, the binding of Sel_GT/CA and 36mer by ABD2(C3) seemed to be 
much more improved from the binding by ABD2. In case of Sel_GT/CA, 
previously, addition of the DNA oligonucleotide caused only mild changes in the 
position of peaks belonging to helix 1, helix 2 and the loop after helix 3. When 
ABD2(C3) is used instead of ABD2, the CSP for helix 1 residues are much higher 
and they form a distinctive cluster of residues, suggesting that indeed they are 
involved in the binding. This is also true for the binding of 36mer by ABD2(C3), 
where introduction of the extension increases the CSP of residues from helix 1.  
 
Overall, ABD2(C3) has DNA binding properties better than ABD2 alone, however 
it does not bind any of the above sequence with a high affinity. It seems that the 
binding is non-specific, as we would expect the helix 3 to be involved in the 
binding if it was specific (canonical mode of DNA binding by winged helix-turn-
helix domains). It could also be possible that the specific sequence of ABD2(C3) 
was not present in the studied DNA sequences, and therefore SELEX will be 





Figure 4.39 Binding between ABD2(C3) and Motif 1. A). Superimposition of 
HSQC of the 15N-labelled ABD2(C3) with (red) and without (black) Motif 1 
oligonucleotide. 70 µM of ABD2 and 210 µM of DNA were used. B). Plot of 
Chemical Shift Perturbation (CSP) vs. residue number. The dashed line indicates 
<Δδtot> + 1σ level. Addition of the DNA does not cause any significant changes to 
the position of the peaks. * - indicates unassigned residues (G279, K294, H299, 
Y301, H317, R318, R319, D320, R336, I337, E359); * - indicates residues invisible 
in HSQC (G281, P283, G286, S287, K288, T289). Experiment was performed at 




      
Figure 4.40 Binding between ABD2(C3) and Motif 2. A). Superimposition of 
HSQC of the 15N-labelled ABD2(C3) with (red) and without (black) Motif 2 
oligonucleotide. 70 µM of ABD2 and 210 µM of DNA were used. B). Plot of 
Chemical Shift Perturbation (CSP) vs. residue number. The dashed line indicates 
<Δδtot> + 1σ level. Addition of the DNA causes mild changes to the position of 
some peaks. * - indicates unassigned residues (G279, K294, H299, Y301, H317, 
R318, R319, D320, R336, I337, E359); * - indicates residues invisible in HSQC 






Figure 4.41 Binding between ABD2(C3) and Sel_GT/CA. A). Superimposition 
of HSQC of the 15N-labelled ABD2(C3) with (red) and without (black) Sel_GT/CA 
oligonucleotide. 70 µM of ABD2 and 210 µM of DNA were used. B). Plot of 
Chemical Shift Perturbation (CSP) vs. residue number. The dashed line indicates <
Δδtot> + 1σ level. Addition of the DNA causes mild changes to the position of 
the peaks from helix 1, helix 2 and the loop between helix 3 and beta strand 2. * - 
indicates unassigned residues (G279, K294, H299, Y301, H317, R318, R319, 
D320, R336, I337, E359); * - indicates residues invisible in HSQC (G281, P283, 





Figure 4.42 Binding between ABD2(C3) and 36mer. A). Superimposition of HSQC of the 15N-
labelled ABD2(C3) with (red) and without (black) 36mer oligonucleotide. 70 μM of ABD2 and 70 
μM of DNA were used. B). Plot of Chemical Shift Perturbation (CSP) vs. residue number. The 
dashed line indicates <Δδtot> + 1σ level. Addition of the DNA causes significant changes to the 
position of the peaks within helix 1. * - indicates unassigned residues (G279, K294, H299, Y301, 
H317, R318, R319, D320, R336, I337, E359); * - indicates residues invisible in HSQC (G281, 
P283, G286, S287, K288, T289). Experiment was performed at pH 7.2.  




In order to identify the specific DNA sequence bound by ABD2(C3), a SELEX 
procedure was performed. To increase the probability of finding the right motif 
bound by ABD2(C3), a few changes were introduced to the SELEX procedure. 
First, a different SELEX library was used, where instead of 36 bp, an 18 bp random 
region was used. It was done to minimise any artefacts during the selection 
procedure and to simplify the search of the motif. Secondly, a binding assay was 
run before deciding to stop the cycles of SELEX and to sequence the last pool of 
pulled-down DNA. This assay was done to check the enrichment of the DNA 
sequence bound by ABD2(C3) between 1st and the last round of SELEX. As shown 
in Figure 4.43, ABD2(C3) was incubated with random DNA obtained from cycle 1 
and cycle 8 of SELEX (which was amplified in PCR and purified prior that 
experiment) and electrophoresed on agarose gel. DNA from cycle 8 was shifted 
more than DNA from cycle 1 by ABD2(C3), which indicated that pool 8 contains 
more specific DNA for ABD2(C3). As the enrichment of the DNA bound by 
ABD2(C3) was shown, pool 8 was cloned and the samples were sent for the 
sequencing.  
Figure 4.44 A). shows sequences of the successful clones. Similarly to the previous 
results for ABD2, they were CA/GT-rich (only one 5’-3’ strand is shown). To 
identify a significant motif within those sequences, MEME software was used. 
Figure 4.44 B). shows the most significant motif logo found for this data set.  
Finally, the SELEX procedure was run for FOXO3a-DBD in order to verify how 
adequate the procedure is and what is the level of artefacts generated during the 
selection step. Figure 4.45 shows SELEX results for FOXO3a-DBD. The general 
motif bound by FOXO3a is 5’-(G/A)(T/C)(A/C)AA(C/T)-3’, therefore there are a 
lot of possible combination of DNA sequences that can be bound by FOXO3a. 
Overall, among 30 analysed sequences, there were only 2 sequences that contained 
the full 7 bp DNA motif. However, as there is no evidence that FOXO3a needs 
strictly the full 7 bp DNA, as well as there could be only parts of the FOXO3a DNA 
binding motif, the data set was analysed for a presence of 6 bp long motif and etc. 
Overall, there were 2 sequences out of 30 that contain the 6bp motif, 13 sequences 
that contain 5 bp motif and 19 sequences with 4 bp motif. Additionally, the MEME 
software was used to identify any significant motifs within the FOXO3a sequencing 
data set. Similarly to ABD2(C3) (search parameters were the same as for 
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ABD2(C3)) only one significant motif was found. The most significant motif was 
18 bp long and it was A/G/C-rich with a dominance of adenosines. Additionally, 
there were few couple of enriched adenosines in a row, which could resemble of the 
central “AA” core of the FOXO3a DNA binding motif. Overall, the SELEX 
procedure did not enrich the full FOXO3a DNA binding motif in 100%, however 






Figure 4.43 Binding experiment for the 1st and 8th cycle of SELEX. Increasing 
concentration of ABD2(C3) (1,10 and 20 µM) was incubated with 1 µM of 
amplified DNA from 1st or 8th cycle of SELEX and electrophoresed on an agarose 
gel. DNA from the 8th cycle of SELEX is bound stronger than DNA from the 1st 
cycle by ABD2(C3) indicating enrichment of the specific DNA sequences bound by 
ABD2(C3) throughout the whole SELEX procedure.  
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Figure 4.44 SELEX results for ABD2(C3). A). Alignment of the random region 
for the sequenced clones. Only one 5’-3’ strand is shown. B). DNA motif logo 
found for the sequences in A. 59 sequences were analysed using MEME. Only one 
significant motif was found. The search parameters were: a) minimum width – 4 









Figure 4.45 SELEX results for FOXO3a-DBD. A). Alignment of the random 
region for the sequenced clones, which contain at least 4 bp from the FOXO3a 
consensus DNA sequence. They were aligned according to the conserved, central 
“AA” motif. Only one 5’-3’ strand is shown. B). Alignment of the random region 
for the sequences clones, which do not contain at least 4 bp from the FOXO3a 
consensus DNA sequence (6 out of 30 sequences clones) C).  FOXO3a consensus 
DNA sequence. D). Occurrence of 4, 5, 6 and 7 bp long motifs within the 
sequencing data.  E). DNA motif logo found for the sequences in A and B. 30 
sequences were analysed using MEME. Only one significant motif was found. The 










4.9. Characterisation of the interaction between ABD2(C3) and the DNA motif 
found in SELEX 
 
To test whether ABD2(C3) binds to the most significant motif found in the SELEX, 
gel shift assay and NMR titration were used. As there was certain variability in the 
base composition of the final motif, it was necessary to define precisely the 
oligonucleotide content to be used for the binding experiment (Figure 4.44 B). 
From the SELEX experiment performed for FOXO3a it was clear that the SELEX 
protocol does not generate a fully enriched single motif, and that the procedure is 
compromised to some extent. It was shown that sometimes, only part of the target 
motif is present in the sequencing data, and that there might be sequences that do 
not have the target motif at all. Consequently, the most significant motif discovered 
using the MEME software may not represent the true motif bound by the protein in 
vivo. However, as parts of the FOXO3a target motif were still present in the best 
SELEX-identified motif there are high chances that the motif found for ABD2(C3) 
will bound to some extent.  
 
The MEME analysis performed for the SELEX data for ABD2(C3) yielded only 1 
significant motif, which was not well defined, although it was clear that it is 
CA/GT-rich with predominant A/T content. However, when analysing the data set 
manually, it was clear that within the whole data set, there are sequences that 
contain A/T-rich tracts, which consist of 3-5 adenosines/thymidine in a row (Figure 
4.44 A).  
 
Interestingly, some winged helix-turn-helix domains bind to a similar target 
sequence (Obsil and Obsilova 2011; Teichmann et al. 2012). Consequently, to begin 
a sequence named Wild type (WT) that contains a central 5’-CAAA-3’ motif, 
proceeded and followed by C or A bases was chosen. The hypothesis was that this 
central motif would be bound by helix 3 of the winged helix-turn-helix domain of 
ABD2(C3). To test it, an additional oligonucleotide, called A7G, which has a point 
mutation within its central motif, where the second adenosine was replaced with 
guanidine (5’-CAAA-3’ into 5’-CAGA’3’) was designed. Additionally, an AT-hook 
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target motif (5’-AATA-3’), which may be bound by the AT-hook from the extension 
of ABD2(C3) and, which was also present in some of the sequencing data was 
incorporated into the WT oligonucleotide sequence. Moreover, the WT 
oligonucleotide contains guanidine on both ends in order to improve the stability of 
the final ds oligonucleotide. Overall, the final WT DNA oligonucleotide sequence 
was: 5’-GACACAAACACAATAG-3’ (underlined are the central core motif 
hypothesised to be bound by helix 3 and the AT-hook target sequence, 
respectively).  
 
Additionally, an oligonucleotide called Scramble, which contains the same content 
of DNA bases as the WT oligonucleotide, but distributed in a random manner so 
they do not assemble the “CAAA” core and the AT-hook motif was designed. 
Moreover, binding of two additional oligonucleotides by ABD2(C3) will be tested: 
one will contain an extra AT-hook target sequence on its 5’- end (AT_WT) and one 
will contain the core “CAAA” sequence flanked by only G/C bases (WT_core). All 









 WT_core GCGCGCCAAAGCGCGC 
 
Table 4.3 WT sequence and its mutants used for ABD2(C3)-DNA interaction study. 






4.9.1 Characterisation of the ABD2(C3) binding of WT oligonucleotide and its 
mutants using EMSA 
 
First, to test the binding of the WT oligonucleotide by ABD2(C3) a gel shift assay 
was performed. As seen in Figure 4.46 the binding of the oligonucleotide was 
moderate as the protein started to shift the DNA at 1:10 [DNA:protein] ratio, whilst 
at 1:30 [DNA:protein] ratio almost all DNA was retarded. However, compared to 
the ABD2 binding of the motifs found in SELEX (Figure 4.18), where there was a 
very small shift of DNA at 1:30 [DNA:protein] ratio, it seems that the DNA binding 
properties of this construct were improved. Whether it is due to finding a better 
DNA sequence or due to extending the winged-turn-helix domain or both will be 
investigated later.  
 
The binding of the mutated wild type sequence (A7G), where one adenosine was 
replaced with a guanidine was also tested. It was done in order to test whether the 
core “CAAA” motif is significant for the binding. As seen in Figure 4.46, there 
was no noticeable difference in the binding between the WT and the A7G 
oligonucleotides and the binding was of a moderate affinity for both of them. 
However, it is worth to note that the gel shift assay is not the best quantitative 
method to determine protein-DNA affinities and during this study some technical 
difficulties arose, which affected the assay reproducibility (discussed in Discussion 
chapter). For example the complex band for WT-ABD2(C3) interaction starts to be 







Figure 4.46 WT and A7G binding by ABD2(C3) using  gel shift assay. 1 µM of 
each oligonucleotide was incubated with increasing concentration of ABD2(C3) (1, 
10 and  30 µM) and run on an agarose gel. Both oligonucleotides were bound with 
the same, moderate affinity as judged by a well-defined complex band at 1:30 
[DNA:protein] ratio. No significant differences were visible between the wild type 
and the mutated DNA sequence. M – DNA marker, FD – free DNA  
 
 
To further study the WT-ABD2(C3) interaction, the binding of the Scramble 
oligonucleotide by ABD2(C3) was tested (Figure 4.47). When compared to the 
binding of the WT by ABD2(C3), there was no characteristic shift for the protein-
DNA complex band. This suggested that either the binding is very low or there is 
no binding of this oligonucleotide at all, which indicates that ABD2(C3) can bind 






Figure 4.47 WT and Scramble binding by ABD2(C3) using  gel shift assay. 1 
µM of each oligonucleotide was incubated with increasing concentration of 
ABD2(C3) (1, 10, 30 and 50 µM) and run on an agarose gel. WT oligonucleotide is 
bound with a moderate affinity by ABD2(C3) as judged by formation of well-
defined complex band, starting at 1:10 [DNA: protein] ratio, whilst the complex 
band was absent when Scramble oligonucleotide was incubated with the 
ABD2(C3)., indicating very low or no binding.  This indicates that the DNA 
binding of ABD2(C3) is sequence-dependent.  
 
 
4.9.2 Characterisation of the ABD2(C3) binding of WT oligonucleotide and its 
mutants using NMR spectroscopy 
 
To test the interaction between ABD2(C3) and the WT oligonucleotide at the 
residue level, NMR titrations were performed. Figure 4.48 shows superimposition 
of all HSQC spectra from the titration experiments. The addition of the WT 
oligonucleotide causes significant changes to the position of some peaks (zoomed 
squares in Figure 4.48), which is consistent with detecting binding between 
ABD2(C3)-WT in gel shift assay. Most of the residues such as R292 and R347 
showed binding in a fast-exchange mode, which is often associated with moderate 
to low binding affinity interactions. Moreover, the CSPs are quite small, which 
would further suggest a modest binding affinity for the ABD2(C3)-WT interaction. 
The NMR data is also in a good agreement with the results obtained from the 




To roughly estimate the binding affinity of this interaction, the apparent KD values 
based on the titration curves for the most representative residues that exhibited the 
biggest CSPs were calculated (Figure 4.49). For example the binding affinity for 
E306, which is localised to the helix 1 was around 188 µM, whilst the KD value of 
R292, which is localised in the N-terminal extension of the ABD2(C3), was around 
2.1 µM. Although, this is just a potentially biased estimation of the local strength of 
the affinity (per residue) and one may argue that it should not be calculated for the 
residues that do not form specific contacts with the ligand (such as residues from 
helix 1) it still demonstrates the importance of the N-terminal extension in the DNA 
binding, which supports the hypothesis that it is necessary for the DNA binding of 
ABD2(C3). The binding affinity of R292 was almost 90 times higher than for E306, 
which may justify the importance of the N-terminal extension of the ABD2(C3).  
 
Also, when looking at residues from helix 3 it is worth noting that for example I344 
exhibit a slow-exchange mode of binding, which is often associated with a high 
affinity interaction. This further supports the hypothesis that part of this DNA is 
bound with a high affinity by residues from helix 3, which may indicate that this 
interaction is indeed sequence-specific. It is hypothesised that helix 3 binds to the 
“CAAA” core motif of the WT oligonucleotide, which will be later validated using 
point (A7G) and Scramble mutant. On the other hand, R349, which is also present 
in helix 3 exhibit a fast exchange mode of binding, which is often associated with 
moderate to low binding affinities. Consequently, it is possible that I344 is crucial 
for the interaction, however this has to be further validated using point mutation of 
ABD2(C3).  
 
Overall, the titration experiments showed that for the first time a DNA sequence 
(WT) that affects residues from helix 3 (such as I344 and R349) was found. In 
general, the helix 3 of winged helix-turn-helix domains binds a sequence-specific 
DNA, therefore it is highly likely that this sequence is specifically recognised by 
ABD2(C3). The interaction between ABD2(C3) and the WT oligonucleotide seem 
to be of moderate affinity and further experiments will be performed such as 




Figure 4.48 Binding between ABD2(C3) and WT oligonucleotide. Increasing 
concentration of the WT oligonucleotide was incubated with 15N-labelled 
ABD2(C3) and HSQC spectra were recorded at each titration point. 70 μM of 
ABD2 and 70, 140, 210 and 350 μM of the WT oligonucleotide were used. Some 
peaks experienced significant perturbation after addition of the ligand. It includes 
peaks, which belong to the N-terminus of ABD2(C3) (R292) as well as residues 
from helix 3 (R347 and I344). Most residues such as R292 and R347 exhibit fast-
exchange mode of binding and some such as I344 exhibit a slow-exchange mode of 
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Figure 4.49 Estimation of the apparent KD for the ABD2(C3)-WT 
oligonucleotide interaction. Apparent KD values were calculated based on the 
titration curves for E306 and R292 residues (top 2 squares). The inset squares 
contain titration spectra of 15N-labelled ABD2(C3) with increasing concentration of 
the WT oligonucleotide and the labeling is the same as in the Figure 4.48. The 
normalized chemical shift changes (ppm) were plotted against concentration of the 
added ligand (µM) and the binding affinity was calculated from the equation Y = 
{(Ltot + Kd + Ptot) – [(Ltot + Kd + Ptot)2 – 4 Ptot Ltot]0.5} / (2 Ptot), where P – [protein], 
L – [ligand]. The KD of E306 (located in helix 1) was 90 times lower than the KD of 
R292 (located in N-terminal extension). This demonstrates the importance of this 
added part in the protein for the DNA binding. I344 (located in helix 3) exhibits a 
slow-exchange mode during the binding, which is characteristic for a high affinity 
interaction. Fitting of R347 data, which also belong to helix 3, was unsuccessful 
due to the lack of the titration saturation. The difference in exchange regimes for 
I344 compared to other residues may suggest the presence of multiple binding 















4.9.2.1. Mapping of the DNA binding site of ABD2(C3) using NMR 
 
To map the DNA binding site of ABD2(C3), the final 1:5 [protein:DNA] ratio 
spectra was used (from Figure 4.48). To establish the binding site two strategies 
were used: 1. identification of residues that exhibit the biggest CSPs and 2. 
identification of residues, which experienced significant changes in their intensities. 
Those two methods were chosen due to fact that this interaction seemed to be of a 
modest affinity and any extra information about the nature of this interaction would 
be useful, especially knowing that the CSPs are relatively small. Figure 4.50 and 
4.51 show the binding site mapping results. The binding site comprises residues 
from the N-terminal extension, helix 1, helix 3 as well as the wing between helix 3 
and the second beta strand. Both methods shown the same residues being involved 
in the binding, as judged by CSPs and changes in peaks intensities. The binding site 
was mapped onto the solution NMR structure of ABD2 and the residues involved in 
the DNA binding form a cluster of neighbouring residues located around helix 3 
(Figure 4.51).  
 
 
Figure 4.50 Mapping of the DNA binding site of ABD2(C3). Plot of intensity ratio 
between free- and bound-state (+ WT oligonucleotide) spectra of ABD2(C3) vs. residue 
number. Residues with ratio below the dashed line (0.38) are considered to be involved in 
the binding of the WT oligonucleotide. These include residues from the N-terminal 
extension, some from helix 1, helix 3 as well as from the wing between helix 3 and the 
second beta strand. To simplify the graph, only two residues are labeled: R347 and A348 in 
order to show the involvement of helix 3 in this interaction. * - indicates unassigned 
residues (G279, K294, H299, Y301, H317, R318, R319, D320, R336, I337, E359); * - 
indicates residues invisible in HSQC (G281, P283, G286, S287, K288, T289).  
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Figure 4.51 Mapping of the DNA binding site of ABD2(C3).  A). Plot of chemical shift 
perturbation vs. residue number of ABD2(C3). Residues that show CSP higher than <Δδtot> 
are labeled in blue, whilst residues that have CSP higher than <Δδtot> + 1σ in black. * - 
indicates unassigned residues (G279, K294, H299, Y301, H317, R318, R319, D320, R336, 
I337, E359); * - indicates residues invisible in the apo HSQC (G281, P283, G286, S287, 
K288, T289) Some residues (e.g. R282, K284, E285, A290, E291, A293, A295) broadened 
beyond detection upon DNA addition B). Mapping of the residues that exhibit CSP higher 
than <Δδtot> (red patches) and higher than  <Δδtot> + 1σ (green) onto solution NMR 
structure of ABD2. Overall, the binding site of ABD2(C3) consists of residues that 
surround the helix 3. WT oligonucleotide is the first DNA ligand that has been found to 
affect residues from the helix 3 of ABD2.  
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4.9.2.2. Determination of the specificity of the ABD2(C3)-WT interaction using 
NMR 
 
To determine whether ABD2(C3) binds the WT oligonucleotide in a sequence-
dependent manner, 2 mutated forms of this oligonucleotide were used. One, called 
A7G has a point mutation in its central core “CAAA” motif, where the 2nd 
adenosine was replaced with guanidine (7th position in the whole oligonucleotide, 
therefore the label is A7G).  
 
We hypothesised, that the central core “CAAA” is bound by helix 3, therefore it is 
expected that replacing one base pair in this motif should reduce the affinity or 
cause a partial or complete loss of the binding by helix 3. In spite of the fact that the 
previous EMSA results (Figure 4.46) showed that there is no difference in binding 
of the WT and A7G oligonucleotide by ABD2(C3), this interaction was investigated 
further using NMR. It was done in order to identify, which residues are involved in 
the A7G oligonucleotide binding, as there was a possibility that the binding was 
mainly caused by the AT-hook target motif “AATA” present in the oligonucleotide. 
Also, it is worth noting that the gel shift assay is not the best quantitative method; 
so it is highly possible that the ABD2(C3) affinities and binding sites for WT and 
A7G oligonucleotide may differ.  
 
The second oligonucleotide, called Scramble, has the same DNA base content as 
the WT oligonucleotide, however they are assembled in a random manner, so they 
do not form the “CAAA” core nor the “AATA” motifs. Results from the previous 
EMSA experiment (Figure 4.47) shown that this oligonucleotide is bound weakly 
or not at all by ABD2(C3) as opposed to the WT oligonucleotide. This may already 
suggest a sequence-specific binding of the WT oligonucleotide by ABD2(C3). The 
NMR experiment was performed to determine whether the ABD2(C3)-Scramble 
interaction will be detectable in NMR, and if yes, which residues are involved in 





To begin, the HSQC spectrum of 70 µM of the 15N-labelled ABD2(C3) with and 
without 140 µM of the WT oligonucleotide was recorded, as the comparison 
between wild type sequence and its mutants will be performed at 1:2 
[protein:DNA] ratio in order to visualise any difference if present in the N-
terminal region (at 1:5 [protein:DNA] ratio most of the residues disappear as shown 
in Figure 4.50). 
 
Figure 4.52 shows the two superimposed spectra and the plot of chemical shift 
perturbations vs. residue number. The residues involved in the binding of the WT 
oligonucleotide at 1:2 [protein:DNA] ratio comprise of residues from the N-
terminal extension including the AT-hook motif, helix 1 and helix 3, which is in a 
good agreement with the binding site of ABD2(C3) presented in Figure 4.51 
derived from the previous full titration experiment.  
 
However, there are few additional residues in the loop (wing) between helix 3 and 
the second beta strand that experienced significant CSPs, and which were absent 
during the full titration experiment. We have repeated this experiment several times 
and noticed variability in the binding of the WT oligonucleotide by the wing 
residues. The reason why this is the case is still unclear, but perhaps it is due to fact 
that the experiments were not performed in exactly the same way e.g. different 
batch of protein or DNA sample were used, DNA samples were synthesises at 
different companies etc.  
 
However, it is worth noting that in the intensity ratio vs. residue number for the 
ABD2(C3)-WT interaction graph (Figure 4.50), there are some residues from the 
wing that experienced significant changes in their intensities. Interestingly, W362 is 
present in both experiments, which would suggest that indeed it is involved in the 
WT oligonucleotide binding. This will be exploited further in tryptophan 





To compare the binding of the mutated oligonucleotides with the WT 
oligonucleotide, HSQC of 70 µM of the 15N-labelled ABD2(C3) with and without 
140 µM of the A7G oligonucleotide was recorded. As seen in Figure 4.53, addition 
of the A7G oligonucleotide did not cause changes to the position of the peaks as big 
as WT oligonucleotide did. Interestingly, significant CSPs of residues belonging to 
the helix 3 were abolished. However, the most significant CSPs are still observed 
for residues located in the N-terminal extension including the AT-hook motif and 
helix 1. The peak intensity changes analysis (Figure 4.55 B)) confirms that the 
addition of the A7G oligonucleotide affects only those residues as shown by 
significant changes in their peak intensities. As the N-terminal residues disappear at 
this early titration point, as shown by both methods, and no other residues were 
affected, it may suggest that the binding of this DNA oligonucleotide is driven 
mainly by the AT-hook motif. It is also clear that the A7G oligonucleotide does not 
affect any residue from helix 3 as opposed to the WT oligonucleotide, which 
supports the hypothesis that ABD2(C3) binds to the “CAAA” core motif in a 
sequence specific manner using residues from helix 3. 
 
In case of the Scramble oligonucleotide the CSPs for residues from helix 3 are very 
small, well under the error level (Figure 4.54), which may further support the 
hypothesis about the specific binding to the “CAAA” core motif using helix 3 
residues. Overall, the binding site of the Scramble oligonucleotide involves residues 
from helix 1 and the N-terminus as confirmed by both methods: CSPs and peak 
intensity changes analysis (Figure 4.55 C)). One may argue that the oligonucleotide 
does not contain the AT-hook target motif within the sequence, therefore it is not 
expected to be bound by the AT-hook, however it can be seen that there is still one 
“AA” pair followed by a “CA” pair. This is due to the fact that the WT 
oligonucleotide contains a high A/T bases content and is was impossible to arrange 
the Scramble sequence so it does not have A/T sequences in a row. The results of 
this experiment suggest that the AT-hook of MS1 bind to any type of AT-rich 





Overall, the peak intensity changes analysis (Figure 4.55) confirms that the 
mutated forms of the WT oligonucleotide (A7G and Scramble) are bound mainly 
via residues from the N-terminus of ABD2(C3) as opposed to the WT 
oligonucleotide, whose binding involves helix 3 residues. In case of the A7G 
oligonucleotide the AT-hook motif and surrounding residues disappear at very early 
titration point (1:2 [protein:DNA] ratio) as opposed to when the WT 
oligonucleotide is added. The N-terminal residues, including the AT-hook residues 
are still significantly affected, however, they do not disappear at least not in the 
early titration point as in case of when the A7G oligonucleotide is added (they 
eventually do at the 1:5 [protein:DNA] ratio as shown in the full titration 
experiment in Figure 4.50). This suggests that the binding of the A7G 
oligonucleotide is exclusively a result of the AT-hook motif interaction.  
 
In case of the Scramble oligonucleotide, the AT-hook residues are not as much 
affected as in case of the A7G oligonucleotide, however the helix 1 residues seem 
to be more perturbed as shown by both methods (Figure 4.54 and 4.55 C)). This 
could be caused by the fact explained earlier, that the Scramble oligonucleotide 
does not contain the proper AT-hook motif target sequence, however it still contains 
some A/T stretch and as a result the binding seems to be shifted and very likely it is 
a result of a non-specific interaction with DNA. 
 
In conclusion, the earlier experiment (Figure 4.50) showed that the binding site of 
the WT oligonucleotide comprises of the AT-hook motif, N-terminal, helix 1 and 
helix 3 residues, however, this experiment showed that the binding of the WT 
oligonucleotide by helix 3 residues is visible at an early titration point and that the 
N-terminal residues are not as much perturbed as when titrated with the A7G or 
Scramble oligonucleotide. This seems to support the hypothesis that the “CAAA” 
core motif is bound specifically by helix 3 as in both cases when the mutated form 
of the “CAAA” motif (A7G and Scramble oligonucleotide) was titrated, the helix 3 






Figure 4.52 Binding between ABD2(C3) and the WT oligonucleotide  at 1:2 
[protein:DNA] ratio. A). Superimposition of HSQC of 15N-labelled ABD2(C3) 
with (green) and without (black) the WT oligonucleotide. 70 µM of ABD2(C3) and 
140 µM of DNA were used. B). Plot of Chemical Shift Perturbation vs. residue 
number. The first dashed line indicates <Δδtot> level and the second one <Δδ
tot> + 1σ level. For clarity residues only from helix 3 with CSPs higher than <Δδ
tot> (black) and with CSPs higher than <Δδtot> + 1σ (blue) are shown. * - 
indicates unassigned residues (G279, K294, H299, Y301, H317, R318, R319, 
D320, R336, I337, E359); * - indicates residues invisible in HSQC (G281, P283, 




Figure 4.53 Comparison between the WT and A7G oligonucleotides binding by 
ABD2(C3). A). The HSQC spectrum (top left corner) represents superimposition of HSQC 
spectra of 15N-labelled ABD2(C3) with (red) and without (black) A7G oligonucleotide. 
Residues I344 and L345, which belong to helix 3, are zoomed in the right squares and 
compared with HSQC spectrum of 15N-labelled ABD2(C3) + WT oligonucleotide (green). 
For all spectra 70 µM of ABD2(C3) and 140 µM of DNA were used (1:2 [protein:DNA] 
ratio). Addition of the single mutated DNA (A7G) does not affect the residues I344 and 
L345 as opposed to the WT oligonucleotide. B). Plot of CSP vs. residue number for 
ABD2(C3) + WT (black bars) and ABD2(C3) + A7G (red bars) spectra. For clarity 
residues only from helix 3 with CSPs higher than <Δδtot> (black), and with CSPs higher 
than <Δδtot> + 1σ (blue) are shown (from ABD2(C3) + WT spectrum). There is a loss of 
binding by the helix 3 of the A7G oligonucleotide as opposed to the WT oligonucleotide, 
which indicates sequence-specific binding of the WT oligonucleotide by ABD2(C3) using 
helix 3. * - indicates unassigned residues (G279, K294, H299, Y301, H317, R318, R319, 
D320, R336, I337, E359); * - indicates residues invisible in HSQC (G281, P283, G286, 
S287, K288, T289). Some residues, e.g. AT-hook T289, K284, G286 broadened beyond 





Figure 4.54 Comparison between the WT and Scramble oligonucleotides binding by 
ABD2(C3). A). The HSQC spectrum  (top left corner) represents superimposition of 
HSQC spectra of 15N-labelled ABD2(C3) with (blue) and without (black) Scramble 
oligonucleotide. Residues I344 and L345 are zoomed in the right squares and compared 
with HSQC spectrum of 15N-labelled ABD2(C3) + WT oligonucleotide (green). For all 
spectra 70 µM of ABD2(C3) and 140 µM of DNA were used (1:2 [protein:DNA] ratio). 
Addition of the Scramble oligonucleotide does not affect the residues I344 and L345 as 
opposed to the WT oligonucleotide. B). Plot of CSP vs. residue number for ABD2(C3) + 
WT (black bars) and ABD2(C3) + Scramble (blue bars) spectra. For clarity residues only 
from helix 3 with CSPs higher than <Δδtot> (black), and with CSPs higher than <Δδtot> 
+ 1σ  (blue) are shown (from ABD2(C3) + WT spectrum). Similarly to the A7G 
oligonucleotide, there is a loss of binding by helix 3 of the Scramble oligonucleotide as 
opposed to the WT oligonucleotide, which further indicates sequence-specific binding of 
the WT oligonucleotide by ABD2(C3) using helix 3. * - indicates unassigned residues 
(G279, K294, H299, Y301, H317, R318, R319, D320, R336, I337, E359); * - indicates 
residues invisible in HSQC (G281, P283, G286, S287, K288, T289). Experiment was 




Figure 4.55 Characterisation of the specificity of the ABD2(C3)-WT interaction. Plot 
of intensity ratio between free- and bound-state spectra of ABD2(C3) + either WT (A), or 
A7G (B) or Scramble (C) vs. residue number. Residues with ratio below the dashed line are 
considered to be involved in the binding of the particular oligonucleotide. The data shows 
that the addition of the mutated form of the WT oligonucleotide (A7G and Scramble) 
causes the most significant changes to the position of chemical shifts belonging to the N-
terminal residues of ABD2(C3), which include the AT-hook motif. In contrast, addition of 
the WT oligonucleotide at the same protein:DNA ratio does not cause such significant 
changes within this region but instead, it does cause changes in some helix 3 peaks 
intensities  * - indicates unassigned residues (G279, K294, H299, Y301, H317, R318, 
R319, D320, R336, I337, E359); * - indicates residues invisible in HSQC (G281, P283, 




4.9.2.3. Determination of the binding affinity for the interaction of ABD2(C3) 
with WT oligonucleotide and its mutants 
 
To determine the dissociation constants (KDs) for the interaction of ABD2(C3) with 
WT oligonucleotide and its mutants, initially a MST experiment was performed. It 
was the first method of choice due its relatively simple experimental set up (e.g. 
low protein concentration – 0.2 – 2 µM; low sample volume – 10 µl, max. 16 
titration points in one experiment, short experimental time – around 30 minutes per 
experiment etc.). It is also useful when the dissociation constant is unknown as in 
one experiment it is possible to cover a wide concentration range of the added 
ligand (in this case from 0.02 – 600 µM).  
 
For the MST experiment, constant concentration of the fluorescently labeled 
ABD2(C3) was incubated with increasing concentrations of DNA oligonucleotide 
(WT or its mutants) and subjected to thermophoresis. The MST measurement 
follows the fluorescence signal of the labeled molecule, which in the temperature 
gradient created by the IR-laser will migrate. The migration of the molecule can be 
affected by the addition of the ligand as a result of change in its shape, size or 
hydration shell.  The change of the migration properties is system dependent and 
usually involves a “positive thermophoresis”, where molecules migrate from higher 
to lower temperatures. However, sometimes they migrate in the opposite direction 
(from lower to higher temperatures), which is called a “negative thermophoresis”. 
The second type of thermophoresis is more favorable from the quantitative point of 
view as the difference between the apo- and bound-form is much higher than in the 
case of the “positive thermophoresis” and therefore it is easier to analyse the 
binding between two molecules.  
 
Figure 4.56 shows results from the MST experiments for ABD2(C3). Both WT and 
A7G oligonucleotide caused a “negative thermophoresis” behavior of ABD2(C3), 
which confirmed that the interaction happens under these experimental conditions. 
Surprisingly, the dissociation constants are lower than expected (based on EMSA 
and NMR data the KD for WT oligonucleotide was expected to be between 1 – 100 
µM). The calculated KD value from the MST experiment for the WT was 224 ± 5 
µM, whilst for the A7G is 508 ± 10 µM. Although, the KDs are quite low, there is a 
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significant difference between the dissociation constants for WT and A7G 
oligonucleotide (2 times), which supports the hypothesis that the binding is 
sequence-dependent. Moreover, the binding between the Scramble oligonucleotide 
and ABD2(C3) was not detectable at all. To explore the low KD numbers, the MST 
experiment for FOXO3a with its target DNA sequence was also performed (Figure 
4.56 E).). In contrast to ABD2(C3), FOXO3a shown a “positive thermophoresis”. 
The published KD for the FOXO3a-DNA interaction is 296 ± 26 nM (Tsai et al. 
2007; Obsil and Obsilova 2011), however the MST experiment gives a KD of 54000 
± 5000 nM. This shows that the MST experiment might have been biased to some 
extent, and that the real ABD2(C3) KDs  may be higher.  
 
To test it, a tryptophan fluorescence assay was performed. ABD2(C3) contains one 
tryptophan (W362), which is located in the wing between helix 3 and the second 
strand and it was previously shown in an NMR titration experiment to be affected 
by the addition of the DNA (Figure 4.52). The DNA binding domain of FOXO3a 
contains 4 tryptophans, where one tryptophan from the helix 3 (W234) forms 
hydrogen bonds with DNA backbone (Tsai et al. 2007). For both proteins, the 
tryptophan fluorescence signal was good and the addition of the DNA caused 
tryptophan quenching. First the KD for FOXO3a was measured and it was very 
similar to the published one (the calculated KD was 320 ± 130 nM vs. published one 
- 296 ± 26 nM), (Figure 4.57 A).). Then, the KDs for ABD2(C3) with WT, A7G and 
Scramble oligonucleotides were measured and the numbers were much higher than 
the numbers obtained from the MST experiment (Figure 4.57 A), B) and C), 
respectively). However, the tryptophan fluorescence revealed no difference in 
ABD2(C3) binding of WT and A7G oligonucleotide (17 ± 3 µM vs. 15 ± 3 µM, 
respectively), whilst the KD for the Scramble oligonucleotide was 29 ± 5 µM.   
 
At this, point it was suspected that the tryptophan fluorescence provide only local 
affinity, as there was no difference in binding between WT and A7G 
oligonucleotides by ABD2(C3) but from the  previous NMR and MST experiments 
it was clear that there must be a difference (e.g. A7G was not bound by helix 3, 2 
times lower affinity calculated by MST). Also, the fact that the Scramble 
oligonucleotide was bound with moderate affinity (around 30 µM, but there was no 
binding detected in MST and EMSA and lack of binding by helix 3 as shown in 
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NMR), suggests that the measured affinity comes from the AT-hook interaction 
with the target sequence.  
 
To test whether this interaction depends on the AT-hook sequence, an additional 
oligonucleotide, called AT_WT, which contains extra AT-hook target sequence (5’-
AATA-3’) at its 5’-end in addition to the WT sequence was designed. It was later 
tested for a binding by ABD2(C3) using NMR and the experiment revealed that 
binding site involves the same residues as in case with WT sequence (Figure 4.58 
C) and D)). In the fluorescence titration experiment the measured KD was slightly 
higher than for the WT oligonucleotide (13 ± 1 µM) indicating that the AT-hook 
interaction is important for the overall affinity (Figure 4.58 B.). All tryptophan 
fluorescence titration curves are shown in Figure 4.59, where the binding of 
AT_WT oligonucleotide by ABD2(C3) is the highest, and of Scramble 












Figure 4.56 Determination of the dissociation constant (KD) for the interaction 
of ABD2(C3) with the WT oligonucleotide and its mutants using MST. 2 µM or 
0.2 µM of fluorescently labeled ABD2(C3) and FOXO3a, respectively was titrated 
with increasing concentration of DNA oligonucleotide (range from 0.02 to 600 µM) 
and subjected to thermophoresis. Graphs A), B) and C) represent titration curves 
for the WT, A7G and Scramble oligonucleotides, respectively (the inset box 
contains raw MST data). The WT oligonucleotide (A) was found to be bound by 
ABD2(C3) 2 times stronger than the A7G (B), (224 ± 5 vs. 508 ± 10 µM). Scramble 
oligonucleotide (C) was not found to be bound by ABD2(C3). Graph D) represents 
titration curves for all 3 oligonucleotides. Graph E) shows titration curve for 
FOXO3a (positive control) with it target DNA sequence (5’-GCACAAACAACG-
3’). The calculated affinity from the MST measurement is 54000 ± 5000 nM, which 






Figure 4.57 Determination of the dissociation constant (KD) for the interaction 
of ABD2(C3) with WT oligonucleotide and its mutants using tryptophan 
fluorescence. A). Titration curve for FOXO3a with its target DNA sequence (5’-
GCACAAACAACG-3’). The calculated KD (320 ± 130 nM) corresponds to the 
published one (295 ± 26 nM; (Tsai et al. 2007). Graphs B), C) and D) show titration 
curves for ABD2(C3) with WT, A7G and Scramble oligonucleotides respectively. 
A7G oligonucleotide is bound with a very similar affinity to the WT (15 ± 3 vs. 17 
± 3 µM, respectively), whilst Scramble oligonucleotide has a binding affinitiy 






Figure 4.58 Binding between ABD2(C3) and the AT_WT oligonucleotide. A). Gel shift 
assay showing higher than for the WT affinity for the AT_WT of ABD2(C3) (in case of the 
AT_WT binding, there is more DNA shifted  at 1:50 [DNA:protein] ratio than for the WT 
DNA). B). Titration curve using tryptophan fluorescence. The dissociation constant (KD) 
for ABD2(C3)-AT_WT is 13 ± 1 μM. C). Plot of Chemical Shift Perturbation vs. residue 
number based on NMR titration of 70 μM of ABD2(C3) with 140 μM of AT_WT 
oligonucleotide (1:2 [protein:DNA] ratio). The dashed line indicates <Δδtot> + 1σ level. 
D). Plot of intensity ratio between free- and bound-state (+AT_WT oligonucleotide) 
spectra of ABD2(C3) vs. residue number. Residues with ratio below the dashed line (0.37) 
are considered to be involved in the binding of the AT_WT oligonucleotide. Experiment 
was performed at pH 7.2. Addition of AT_WT oligonucleotide affects residues from helix 
3, helix 1 and the N-terminal extension. The ABD2(C3) affinity for the AT_WT sequence 
is slightly higher than for the WT sequence, suggesting improvement of the DNA binding 
properties when the AT-hook target sequence is located on the 5’- end. * - indicates 
unassigned residues (G279, K294, H299, Y301, H317, R318, R319, D320, R336, I337, 





Figure 4.59 Titration curves for ABD2(C3) with all investigated 
oligonucleotides (WT, A7G, Scramble and AT_WT). Normalised fluorescence 
intensity was plotted against concentration of the added ligand. ABD2(C3) has the 
highest affinity for the AT_WT oligonucleotide and the lowest affinity for the 




4.9.3. Determination of the importance of the AT-hook and the N-terminal 
extension of the ABD2(C3) in the interaction between ABD2(C3) and WT 
oligonucleotide 
 
As the previous results suggested a role of the AT-hook motif in the binding of the 
WT oligonucleotide and its mutants by ABD2(C3), it was tested whether complete 
removal of the AT-hook motif target sequence from the WT oligonucleotide will 
abolish or reduce the binding.  
 
To test it, an additional oligonucleotide, called WT_core, which contains of a 
central “CAAA” motif flanked only by G or C base was designed. Figure 4.60 and 
Figure 4.61 show results from the NMR titration experiment. The addition of the 
WT_core oligonucleotide affected most of the same residues as in the case of the 
WT oligonucleotide. However, the binding by the AT-hook motif residues seems to 
be reduced as indicated by a small CSPs (smaller than the <Δδtot> + 1σ level) and 
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small changes in their peaks intensities, except for A280 and R282, whose peaks 
intensities are significantly changed. Based on the CSPs analysis one may 
hypothesise that the binding of this oligonucleotide by ABD2(C3) does not require 
the presence of the AT-hook target sequence as the binding site does not involve the 
AT-hook motif region, however, as the central AT-hook motif R282 experiences 
significant peak intensity change it is very likely that this region indeed is affected 
by the addition of this DNA oligonucleotide.  
 
It must be noted that in spite of the fact that the AT-hook motif target sequence was 
removed from the oligonucleotide and replaced by G or C bases, there is still an 
A/T rich sequence present in the “CAAA” core motif. It is therefore very likely that 
the observed changes in the A280 and R282 peak intensities are a result of the 
interaction between the “CAAA” core motif and the AT-hook motif residues. 
 
Figure 4.60 shows the NMR titration of ABD2(C3) with the WT_core 
oligonucleotide and comparison with the titration of ABD2(C3) with the WT 
oligonucleotide (in zoomed squares) shows that still the same residues from helix 3 
are affected by the addition of the WT_core oligonucleotide, however the chemical 
shift perturbations are slightly smaller than in the case of the WT oligonucleotide. It 





Figure 4.60 Binding between ABD2(C3) and the WT_core oligonucleotide at 1:3 
[protein:DNA] ratio and comparison between the WT and WT_core oligonucleotides 
binding by ABD2(C3). A). The HSQC spectrum  (top left corner) represents 
superimposition of HSQC spectra of 15N-labelled ABD2(C3) with (red) and without (black) 
WT_core oligonucleotide. Residues I344 and L345 are zoomed in the right squares and 
compared with HSQC spectrum of 15N-labelled ABD2(C3) + WT oligonucleotide (green) 
at the same protein:DNA ratio. For all spectra 70 μM of ABD2(C3) and 210 μM of DNA 
were used (1:3 [protein:DNA] ratio). Addition of the WT_core oligonucleotide does 
affect the residues I344 and L345 similarly to the WT oligonucleotide. B). Plot of CSP vs. 
residue number for ABD2(C3) + WT_core spectra. Addition of the WT_core 
oligonucleotide still affects residues from helix 3, helix 1 and some from the N-terminal 
extension. The AT-hook motif residues CSPs are reduced when compared to those caused 
by the addition of the WT oligonucleotide * - indicates unassigned residues (G279, K294, 
H299, Y301, H317, R318, R319, D320, R336, I337, E359); * - indicates residues invisible 




Figure 4.61 Plot of intensity ratio between free- and bound-state spectra of 
ABD2(C3) + WT_core vs. residue number. Residues with ratio below the dashed 
line are considered to be involved in the binding of the oligonucleotide. Residues 
that experience the biggest intensity changes are almost the same, which 
experienced the biggest chemical shifts perturbations (N-terminus, helix 1 and helix 
3 residues). * - indicates unassigned residues (G279, K294, H299, Y301, H317, 
R318, R319, D320, R336, I337, E359); * - indicates residues invisible in HSQC 




To test whether the N-terminal extension of ABD2(C3) is necessary for the 
interaction with the WT oligonucleotide, the binding experiments were repeated for 
the original ABD2 domain. First, a gel shift assay was performed and as seen in 
Figure 4.62 ABD2 failed to shift the WT and A7G oligonucleotides as opposed to 
the ABD2(C3). This indicates a very important role of the N-terminal extension in 
mediating the ABD2(C3)-WT interaction. Further, NMR titration of ABD2 with the 
WT sequence was performed and the results revealed that addition of the WT 
oligonucleotide to ABD2 did not cause significant chemical shift perturbations 
(Figure 4.63) Comparing this result with the NMR result for ABD2(C3) + WT at 
the same [protein:DNA] ratio, it is clear that ABD2 does not interact with this 
oligonucleotide in the same manner as ABD2(C3). As the chemical shift 
perturbations are significantly increased for ABD2(C3) (Figure 4.64), it further  
confirms that the N-terminal extension of ABD2 is very crucial for the DNA 
binding properties of the domain.   
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Overall, those experiments provided evidence that the N-terminal extension is very 
important for the ABD2(C3)-WT interaction, however, the AT-hook target sequence 
is not required for the binding.  It is very likely, that the N-terminal extension 
influences the stability of the complex, where addition of the AT-hook target 






Figure 4.62 Comparison between ABD2(C3) and ABD2 binding of WT and 
A7G oligonucleotides. 1 µM of each oligonucleotide was incubated with 
increasing concentration of ABD2(C3) or ABD2 (1, 10 and  30 µM) and run on an 
agarose gel. Both oligonucleotides were bound with the same, moderate affinity as 
judged by a well-defined complex band at 1:30 [DNA:protein] ratio by ABD2(C3), 
however ABD2 failed to bind those two oligonucleotides.  
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Figure 4.63 Binding between ABD2(C3) and the WT oligonucleotide  at 1:5 
[protein:DNA] ratio. A). Superimposition of HSQC of 15N-labelled ABD2 with (red) and 
without (black) WT oligonucleotide. 70 µM of ABD2 and 350 µM of DNA were used. B). 
Plot of Chemical Shift Perturbation vs. residue number. The first dashed line indicates <Δ
δ tot> level and the second dashed line  <Δδ tot> + 1σ  level. Addition of WT 
oligonucleotide causes mild changes to the position of some peaks. * - indicates unassigned 
residues (G291, A292, H299, Y301, R318, R319, R336, I337, E359). Experiment was 





Figure 4.64 Comparison between ABD2(C3) and ABD2 binding of WT 
oligonucleotide. Plots of CSPs vs. residue number for ABD2(C3) + WT (blue) and 
ABD2 + WT (red) interaction at 1:5 [protein:DNA] ratio were superimposed in 
order to visualise the differences in CSPs for ABD2(C3) and ABD2. The N-
terminal extension of the ABD2(C3) is important for the ABD2(C3)-WT 
interaction as without it ABD2 is not able to bind the WT oligonucleotide with the 
same affinity. For clarity, residues only from helix 3 showing CSP higher than 
<Δδtot> + 1σ level are shown (above the dashed line). * - indicates unassigned 
residues (G279, K294, H299, Y301, H317, R318, R319, D320, R336, I337, E359); 
* - indicates residues invisible in HSQC (G281, P283, G286, S287, K288, T289). 
Some residues (e.g. R282, K284, E285, A290, E291, A293, A295) broadened 





4.10. Characterisation of the interaction between ABD2(C2) and WT 
oligonucleotide and its mutants 
 
As mentioned earlier in Chapter 3, two new phosphorylation sites within MS1 were 
identified. One of them, Y280 is localised in the C-terminus of the ABD1 part of 
MS1. Interestingly, it is localised next to the identified AT-hook sequence: 
LHKGDEGYGRPKEGT (red is the Y280, the AT-hook is underlined). It is possible 
that Y280 may be involved in regulation of the DNA or actin binding properties of 
MS1. For example, phosphorylation of Y280, which will result in introduction of a 
negative charge, may cause destabilisation the MS1-DNA contacts, therefore 
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reduces or inhibits the interaction. The construct ABD2(C3) studied previously in 
this thesis started at G287, as at the time of designing the new domain boundaries 
and choosing the protein construct for a subsequent DNA-binding studies, there 
was no information about the possible phosphorylation sites.  
 
However, the construct ABD2(C2), which was previously characterised in point 4.6 
and which was shown to bind random library of dsDNA with an affinity similar to 
ABD2(C3) was available (Figure 4.37). ABD2(C2) starts at D270 (it contains 11 
residues prior ABD2(C3) sequence) and it may have a slightly different 
conformation in the N-terminus than ABD(C3), as the comparison of the HSQCs of 
ABD2(C3) and ABD2(C2) shows significant differences in the position of the 
peaks from the N-terminal extension, and especially the helix 1 (Figure 4.65).  
 
To test whether ABD2(C2) has a higher affinity than ABD2(C3) for DNA first a gel 
shift assay using AT_WT oligonucleotide was performed. It was chosen due to fact 
that it has been previously shown to be bound with the highest affinity by 
ABD2(C3). As seen in Figure 4.66 ABD2(C2) bound AT_WT oligonucleotide with 
a higher than ABD2(C3) affinity as at 1:10 [DNA:protein] ratio, there was more 
DNA shifted than in the case of ABD2(C3). Subsequently, the NMR titration 
experiment was performed and the results showed that some residues reached the 
saturation point at a lower [protein:DNA] ratio as opposed to ABD2(C3) (Figure 
4.67). For example residues I344 and R349 in ABD2(C2) reached saturation at 1:2 
[protein:DNA] ratio as opposed to ABD2(C3) where those residues were still 
unsaturated at 1:5 [protein:DNA] ratio. The estimation of the KDs for some residues 
e.g. R349 confirms that the binding affinities may be higher for this construct as 
they were found in the range of 0.1 – 26 µM. It must be noted that that due to not 
efficient number of points the KDs estimation are potentially biased and it is used 
here only to compare it with earlier estimated KDs for the ABD2(C3) in the same 
way.  
 
Mapping of the residues involved in the binding of AT_WT by ABD2(C2) 
confirmed a binding site similar to ABD2(C3), which included the AT-hook motif, 
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N-terminal extension, helix 1 and helix 3 residues (Figure 4.68). The peak intensity 
changes analysis confirmed the same residues being involved in the binding of this 
oligonucleotide as indicated by a significant changes in the same peaks, except of 
helix 3 residues (Figure 4.70 A)). It was later shown that ABD2(C2) binds 
specifically to the “CAAA” core motif  using residues from helix 3, as the A7G 
(which contains mutation in the “CAAA” core motif: CAAA – CAGA) did not 
cause any changes to the position of those peaks (Figure 4.69) as shown by a drop 
in CSPs for this region. The peak intensity changes analysis confirmed that the A7G 
oligonucleotide is bound by ABD2(C2) mainly via interaction with the AT-hook 
motif and surrounding residues as they disappeared during the early point of the 
titration (Figure 4.70 B)). ABD2(C3) interacted with these oligonucleotides in a 
similar manner.  
 
Finally, tryptophan fluorescence titration (Figure 4.71 and 4.72) indicated that 
ABD2(C2) has the highest affinity for AT_WT oligonucleotide (KD = 7 ± 0.9 µM), 
which was slightly higher than for WT oligonucleotide (KD = 10 ± 1 µM). The 
dissociation constants for A7G and Scramble oligonucleotides were 29 ± 5 and 27 ± 
4  µM, respectively.  
 
Table 4.4 shows comparison of dissociations constants between ABD2(C3) and 
ABD2(C2). Overall, ABD2(C2) has a higher than ABD2(C3) affinity for both the 
AT_WT and WT sequence, which suggest that this construct may be more 









Figure 4.65 Influence of the addition of the ABD2(C2) extension on the 
ABD2(C3) conformation. Plot shows chemical shift perturbation vs. residue 
number of the ABD2(C3) after addition of the ABD2(C2) extension. To plot the 
graph CSP were calculated between ABD2(C3) and ABD2(C2) spectra. The dashed 
line indicates <Δδtot> + 1σ level. Residues above the dashed line show significant 
changes to the peaks position. * - indicates unassigned residues (G279, K294, 
H299, Y301, H317, R318, R319, D320, R336, I337, E359); * - indicates residues 





        
 
 
Figure 4.66 Comparison between ABD2(C3) and ABD2(C2) binding of AT_WT 
oligonucleotide. 1 µM of oligonucleotide was incubated with increasing 
concentration of ABD2(C3) or ABD2(C2) (1, 10 and  30 µM) and run on an 
agarose gel. ABD2(C2) has a higher than ABD2(C3) affinity for the AT_WT as the 
shifts bigger than for the ABD2(C3) (e.g. at 1:10 [DNA:protein] ratio ABD2(C2) 





Figure 4.67 NMR titration of ABD2(C2) with the AT_WT oligonucleotide. A). HSQC 
spectra were recorded after each addition of the ligand. Black spectrum represents 
reference spectrum of ABD2(C2) (no added ligand). The spectrum moves from black to red 
throughout the titration, reaching saturation for some peaks e.g I344 and R347 (residues 
from helix 3) as there are no further movements of those peaks with additional addition of 
the ligand. This may suggest that the affinity of ABD2(C2) for this sequence is higher than 
of ABD2(C3). B). Estimation of the apparent KD for the ABD2(C2)-AT_WT 
oligonucleotide interaction. Apparent KD values were calculated based on the titration 
curves for R347, E306 and R307 residues. The normalized chemical shift changes (ppm) 
were plotted against concentration of the added ligand (µM) and the binding affinity was 
calculated from the equation Y = {(Ltot + Kd + Ptot) – [(Ltot + Kd + Ptot)2 – 4 Ptot Ltot]0.5} / (2 
Ptot), where P – [protein], L – [ligand]. The estimated KDs for ABD2(C2) are higher than for 
the ABD2(C3)-DNA interactions, suggesting improvement in the DNA binding properties 
of this construct.  Some peaks such as R295 or E303 (red squares) disappear at a very early 
titration point. For clarity, only part of the spectrum is shown. Experiment was performed 






Figure 4.68 Binding between ABD2(C2) and the AT_WT oligonucleotide A). 
Superimposition of HSQC of 15N-labelled ABD2(C2) with (red) and without 
(black) AT_WT oligonucleotide. 80 µM of ABD2(C2) and 160 µM of DNA were 
used B). Plot of Chemical Shift Perturbation vs. residue number. The dashed line 
indicates  <Δδtot> + 1σ level. Addition of the AT_WT oligonucleotide causes 
changes to the position of peaks from N-terminal extension, helix 1 and helix 3. * - 
indicates unassigned residues (G279, K294, H299, Y301, H317, R318, R319, 
D320, R336, I337, E359); * - indicates residues invisible in HSQC (G281, P283, 
G286, S287, K288, T289). Some residues (e.g. E285, A290, E291, A293, A295) 





Figure 4.69 Comparison between the AT_WT and A7G oligonucleotides binding by 
ABD2(C2). A). The HSQC spectrum  (top left corner) represents superimposition of 
HSQC spectra of 15N-labelled ABD2(C2) with (blue) and without (black) A7G 
oligonucleotide. Residues I344 and L345 are zoomed in the right squares and compared 
with HSQC spectrum of 15N-labelled ABD2(C2) + AT_WT oligonucleotide (red). For all 
spectra 80 μM of ABD2(C2) and 160 μM of DNA were used (1:2 [protein:DNA] ratio). 
Addition of the A7G oligonucleotide does not affect the residues I344 and L345 as opposed 
to the AT_WT oligonucleotide. B). Plot of CSP vs. residue number for ABD2(C2) + 
AT_WT (red bars) and ABD2(C2) + A7G (blue bars) spectra. For clarity residues only 
from helix 3 with CSPs higher than <Δδtot> + 1σ (blue) are shown (from ABD2(C2) + 
AT_WT spectrum). There is a loss of binding by the helix 3 of the A7G oligonucleotide, as 
opposed to the AT_WT oligonucleotide, which indicates sequence-specific binding of the 
AT_WT oligonucleotide by ABD2(C2) using helix 3. * - indicates unassigned residues 
(G279, K294, H299, Y301, H317, R318, R319, D320, R336, I337, E359); * - indicates 
residues invisible in HSQC (G281, P283, G286, S287, K288, T289). Experiment was 





Figure 4.70 Comparison between the AT_WT and A7G oligonucleotides binding by 
ABD2(C2). Plot of intensity ratio between free- and bound-state spectra of ABD2(C2) + 
either WT (A) or A7G (B) vs. residue number. Residues with ratio below the dashed line 
are considered to be involved in the binding of the particular oligonucleotide. The data 
confirms that the binding site of the WT and A7G oligonucleotides by ABD(C2) comprises 
of residues from the N-terminus and helix 1. However, in case of the WT oligonucleotide, 
residues from the helix 3 are not affected by any significant peak intensity changes as in 
case of the ABD2(C3). * - indicates unassigned residues (G279, K294, H299, Y301, H317, 
R318, R319, D320, R336, I337, E359); * - indicates residues invisible in HSQC (G281, 





Figure 4.71 Determination of the dissociation constant (KD) for the interaction 
of ABD2(C2) with WT oligonucleotide and its mutants using tryptophan 
fluorescence. Graphs A), B), C) and D) show titration curves for ABD2(C2) with 
WT, AT_WT, A7G and Scramble oligonucleotides respectively. ABD2(C2) binds 













         
 
 
Figure 4.72 Titration curves for ABD2(C2) with all investigated 
oligonucleotides (WT, A7G, Scramble and AT_WT). Normalised fluorescence 
intensity was plotted against concentration of the added ligand. Similarly to 
ABD2(C3), ABD2(C2) has the highest affinity for the AT_WT oligonucleotide and 
the lowest affinity for the Scramble oligonucleotide. However, the binding affinities 
are higher for ABD2(C2) than for ABD2(C3) (e.g. affinities for AT_WT sequence 








DNA oligonucleotide KD (µM) DNA oligonucleotide KD (µM) 
WT 17 ± 3 WT 10 ± 1 
AT_WT 13 ± 1 AT_WT 7 ± 0.9 
A7G 15 ± 3 A7G 29 ± 5 
Scramble 29 ± 5 Scramble 27 ± 4 
 
Table 4.4 Dissociation constants (KD) for ABD2(C3) and ABD2(C2) calculated 



















5.1. General overview 
 
MS1 has been shown to play a very important role in cardiac and skeletal muscle 
function and development (Koekemoer et al. 2009; Chong et al. 2012; Wallace et 
al. 2012; Wallace and Russell 2013). Since its discovery, the whole understanding 
of MS1 function was based on its actin-binding properties (Arai et al. 2002; Fogl et 
al. 2011). Several studies demonstrated that it binds and stabilises F-actin and/or 
stimulates its polymerisation (Arai et al. 2002; Fogl et al. 2011). 
 
In line with these studies, it was shown that MS1 localises to the cytoplasm, where 
in non-muscle cells it co-localises with actin fibres, whilst in muscle cells it 
partially co-localises with alpha-actinin in the I-band of the sarcomere (Arai et al. 
2002; Barrientos et al. 2007). Although, there were several reports stating that MS1 
was seen in the nucleus, the finding was not followed up and the data was not 
shown (Arai et al. 2002; Troidl et al. 2009; Lamon et al. 2009).  
 
In this thesis, evidence that MS1 can act as a DNA binding protein and therefore, 
potentially, it can be directly involved in gene expression regulation was shown. 
MS1 has previously been shown to be indirectly involved in gene expression 
regulation, via stimulation of SRF transcriptional activity (Arai et al. 2002). It is 
believed that MS1 together with RhoA stabilises polymerised actin and/or 
stimulates its polymerisation, and hence reduces the available pool of G-actins in 
the cytoplasm. Consequently this removes the inhibitory effect of G-actins on 
MRTFs, which are SRF’s co-activators. As a result, MRTFs translocate to the 
nucleus, where they associate with SRF and stimulate its transcriptional activity 
(Kuwahara et al. 2005).  
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The main motivation for this thesis was the identification of a winged helix-turn-
helix domain within the MS1 structure, which is a typical DNA binding domain 
present in transcription factors. The initial biophysical study of MS1 revealed that 
most of the protein is unfolded in solution, and that only the C-terminal part is 
folded. Moreover, this C-terminal part has been shown to be evolutionary 
conserved amongst different species as well as to have actin-binding properties 
(Arai et al. 2002; Fogl et al. 2011).   
 
The NMR solution structure of ABD2 was solved (pdb code: 2KRH) and since no 
other structures solved within the MS1 family were determined, in order to gain 
more insights into the function of this domain, DALI software (Holm et al. 2008) 
was used to identify proteins with similar to ABD2 fold. Interestingly, none of the 
100 identified proteins had actin binding properties, however they all had DNA 
binding function. The analysis of their DNA binding domains revealed that they 
belong to a subfamily of helix-turn-helix domains, called winged helix-turn-helix 
domains (Brennan 1993; Aravind et al. 2005). ABD2 possesses all the characteristic 
features of the typical winged helix-turn-helix domain, including the three-
dimensional structure and the conservation of positive residues within helix 3, 
which acts as a recognition motif in a sequence-specific interaction with DNA 
(Aravind et al. 2005). As the winged helix-turn-helix domains are mainly DNA 
binding domains present in transcription factors, a hypothesis that MS1 can act as 
one of them has emerged. Transcription factors (TFs) are proteins involved in gene 
expression regulation via direct binding of specific DNA sequences within the 
genome. They can either bind to promoter regions of certain genes or into 
regulatory sequences, called enhancers, where they can either stimulate or repress 
transcription of related genes. One of the distinctive features of TFs is that they 
bind DNA in a sequence specific manner using their highly specialised DNA 
binding domains (Vaquerizas et al. 2009).  
 
The NMR solution structure of ABD2 together with the DALI analysis 
demonstrated that MS1 contains a DNA binding domain, however in order to 
classify a protein as a transcription factor it has to fulfil three additional criteria: it 
has to be present in the nucleus, at least at some stage, it has to bind DNA in a 
sequence specific manner and it has to have an effect on a gene transcription. 
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5.1.1.  Subcellular localisation of MS1  
 
To verify the hypothesis that MS1 is a transcription factor, first its subcellular 
localisation was investigated. Interestingly, it was found that under appropriate 
conditions, MS1 could localise to the nucleus. The localisation appears to be tightly 
regulated. In neonatal rat cardiomyocytes, the endogenous MS1 was localised to the 
nucleus regardless of whether hypertrophic or non-hypertrophic conditions were 
applied. However, when MS1 was overexpressed, it localised to the nucleus only 
under hypertrophic conditions, whilst under non-hypertrophic conditions it 
localised to the cytoplasm. On the other hand, in adult rat cardiomyocytes, MS1 
localised only to the I-band of the sarcomere. This suggests, that MS1 localisation 
regulation may be taking place via a complex mechanism, in which during 
embryogenesis or during early development, MS1 is directed into the nucleus, 
where potentially it could be involved in expression of genes involved in muscle 
development, whilst in adult muscle cells it is retained in the cytoplasm to serve as 
a stress sensor protein. The overexpression data, where MS1 was localised to the 
nucleus only under hypertrophic conditions and under non-hypertrophic conditions 
it was found in the cytoplasm, suggests that there could be a specific mechanism 
that controls MS1 localisation in response to a stress signal.  
 
Previous data revealed that MS1 was one of the genes, that were upregulated during 
the early stage of pressure induced LVH (left ventricular hypertrophy) in a rat 
model of aortic banding. MS1 mRNA level was increased 3 fold 4 hours after aortic 
banding, and even before the early response genes were expressed. It returned to its 
basal level within 24 hours (Mahadeva et al. 2002). Combining results from these 
experiments with the previous overexpression data, one may speculate that in adult 
muscle cells, in response to stress signal MS1 translocates to the nucleus, where 
potentially it could regulate gene transcription. In fact, we identified a predicted 
nuclear localisation sequence (NLS) within the N-terminus of MS1, which is 
present in many transcription factors and which is involved in nuclear shuttling of 
many proteins. The predicted NLS of MS1 was later shown to be functionally 
relevant and important in the process of nuclear shuttling of MS1 as mutation of 
part of the NLS abolished the nuclear localisation of transiently transfected MS1 
under hypertrophic conditions.  
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Additionally, using the RegPhos and PhosphoSitePlus servers (Lee et al. 2011; 
Hornbeck et al. 2004) a potential phosphorylation site at S150, located next to the 
NLS of MS1 (predicted NLS starts at R153) and possibly a p38 kinase target was 
identified. Interestingly, p38 MAPK is a stress-activated kinase, which has been 
shown to play a role in cardiac hypertrophy where both p38-alpha and p38-beta 
levels have been increased during its progression (Zarubin and Han 2005; Tamura 
et al. 2000).  Additionally, it is well known that phosphorylation of residues near 
NLS can serve as a regulatory mechanism of the subcellular localisation of 
transcription factors (activation or deactivation of NLS) (Li et al. 2013). One of the 
examples is the regulation of the subcellular localisation of FOXO4 by PKB kinase, 
which via phosphorylation of the near-NLS residue creates a binding site for the 
14-3-3 protein. Consequently, 14-3-3 masks the binding site for the nuclear 
translocation machinery proteins and FOX04 is retained in the cytoplasm. In the 
absence of PKB (no phosphorylation of the near-NLS residue) FOXO4 translocates 
to the nucleus (Obsilova et al. 2005).  
 
To test whether S150 has an affect on MS1 localisation, it was mutated into alanine 
and overexpressed in Hela cells. Hela cells do not express endogenous MS1 and it 
was previously shown that transient overexpression of wild type MS1 in Hela cells 
results in cytoplasmic localisation. The aim of this experiment was to determine 
whether abolishing of this potential phosphorylation site would result in MS1 
translocation to the nucleus, which would mean that S150 is involved somehow in 
the nuclear translocation of MS1. The overexpression results showed that there was 
no difference in the phenotype between the wild type and the S150A mutant, which 
both localised to the cytoplasm. Consequently, one may speculate that this 
phosphorylation site is not involved in the NLS regulation. However, in order to 
further verify this, additional experiments should be performed. First of all, it must 
be tested whether these predicted phosphorylation sites indeed get phosphorylated 
in vivo as it was not done yet. It could be achieved by combining overexpression 
studies of wild type and variety of phospho-mutants (S150A, S150D, Y280A, 
Y280D) of MS1 with phos-tag gels as well as kinases inhibitor analysis. Second of 
all, as the overexpression of MS1 in NRCs demonstrated that MS1 localisation is 
stress signal-dependent, it is possible that S150 is phosphorylated in response to a 
stress signal, so phosphorylation of those residues must be studied under stressed 
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vs. unstressed conditions.  The previous experiments in Hela cells were performed 
under normal (unstressed) conditions, therefore it is possible that what was seen 
there as a wild type localisation, was actually a result of non-phosphorylated MS1. 
To verify it, a phospho-mimicking mutant (e.g. S150D) of MS1 should be used for 
the overexpression studies in Hela cells. Also it would be interesting to look at the 
subcellular localisation of the wild type, S150A and S150D MS1 mutants in Hela or 
other cell line type which do not express MS1, under stressed and non-stressed 
conditions, if those can be established.  
 
Additionally, the whole set of experiments (wild type, S150A and S150D) should 
be performed in NRCs or in some other type muscle cells as it is possible that in the 
whole process of the regulation of MS1 subcellular localisation, other muscle-
specific proteins, which may be absent in Hela cells, are involved. 
 
Furthermore, another phosphorylation site within MS1 sequence was identified at 
Y280, which is very likely a Src-like kinase target as predicted by RegPhos and 
PhosphoSitePlus. Interestingly it is localised next to the DNA binding site of MS1 
and particularly next to the predicted AT-hook motif, which starts at G281. It is 
known that the cellular/nuclear localisation of transcription factors can also be 
regulated by phosphorylation of residues near or in the DNA-binding domain. For 
example in FOXO1 phosphorylation of S249 by CDK2 in its second wing results in 
cytoplasmic sequestration and inhibition of FOXO1 function (Brent et al. 2008; 
Obsil and Obsilova 2011) Phosphorylation of residues near the DNA binding 
domain can also cause a reduction or loss of DNA binding as a result of introducing 
a negative charge into the DNA binding surface.   
 
In case of MS1, phosphorylation at Y280 may serve as yet another regulatory 
mechanism of its function. In adult muscle cells during the rest state, MS1 is 
localised to the sarcomere, where it associates with actin. The actin binding site of 
MS1 is comprised of residues located within the C-terminus of MS1, which 
includes Y280.  It is possible that in response to a stress signal, phosphorylation at 
Y280 may cause dissociation of MS1 from actin, and subsequently it may promote 




Mutation of Y280 into alanine caused nuclear translocation of MS1, indicating the 
involvement of this predicted phosphorylation site in the regulation of its 
subcellular localisation. This suggests that the regulation of MS1 localisation may 
be more complex than anticipated and that there may be  more than one mechanism 
that regulates its nuclear translocation. Depending on the signals received by the 
cell, different pathways and therefore different phosphorylation sites may be 
targeted. S150 might be phosphorylated in response to a stress signal, which is in 
agreement with the fact that it is a predicted target of p38 MAP kinase, which is a 
stress-activated kinase shown to be upregulated during cardiac hypertrophy 
(Tamura et al. 2000). However, what is the exact role of Y280 
phosphorylation/dephosphorylation needs to be further investigated.  
 
Overall, it would be interesting in the future to see whether these predicted 
phosphorylation sites indeed get phosphorylated in vivo as well as to establish the 
conditions under which they get phosphorylated/dephosphorylated. It could be 
achieved by combining overexpression studies of wild type and variety of phospho-
mutants (S150A, S150D, Y280A, Y280D) of MS1 under stressed and non-stressed 
conditions with phos-tag gels as well as kinases inhibitor analysis. Preferably the 
analysis should be performed on muscle cells, as it is very likely that in the whole 
process of MS1 subcellular localisation other, muscle-specific proteins are 
involved. Additionally, it would be interesting to look at the subcellular localisation 
of phospho-mutants of MS1 in NRCs as they should provide more relevant than 
Hela cells information about the regulation of MS1 subcellular localisation.  
 
Additionally, as Y280 was shown to be important for the regulation of MS1 
subcellular localisation it would be interesting to study the effect of Y280 (Y280A, 
Y280D) mutation on in vitro DNA binding properties of MS1. It is knows that 
phosphorylation of residues near or within the DNA binding domains of 
transcription factors may affect their DNA binding and subsequently their nuclear 
export (Brent et al. 2008; Obsil and Obsilova 2011). It is therefore possible that via 
introducing a negative charge around the DNA binding domain as a result of 
phosphorylation, the DNA binding of MS1 may be much weaker or completely 
abolished. Consequently MS1 may be free to interact with some other proteins, 
which would control its nuclear export. For the in vitro studies ABD2_C2 construct 
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should be used as it contains the winged helix-turn-helix domain as well as the AT-
hook motif and Y280. It would be interesting to see whether the charge state of 
Y280 can affect the overall DNA binding affinity of this construct. If this is the 
case, then phosphorylation of Y280 may provide another mechanism of the 
regulation of MS1 function.  
 
 
5.1.2. DNA binding properties of MS1  
 
Consequently, as the localisation studies of MS1 showed that it indeed can localise 
to the nucleus its DNA binding properties in vitro were subsequently characterised. 
Initial studies have shown that the winged helix-turn-helix domain of MS1 (ABD2) 
may need specific DNA sequence as its binding to variety of DNA samples (e.g. 
pETM11 plasmid, 46 bp fragment of BACH1 gene or random dsDNA library) was 
very weak. Those DNA samples were chosen randomly, as there was no predicted 
DNA targets for MS1, and it was also performed in order to see whether ABD2 
would bind to those sequences with a high affinity or not. If the binding to those 
sequences was high, it would mean that ABD2 most probably binds DNA in a non-
specific manner. However, the results indicated that most probably it binds specific 
DNA sequence, which supported the hypothesis that MS1 may function as a 
transcription factor.  
 
To identify the DNA sequence bound by ABD2, SELEX assay was performed. It 
yielded a set of sequences, which were CA/GT-rich, however the exact DNA motif 
bound by ABD2 was not clearly defined. A set of the most representative sequences 
were chemically synthesised and they were tested for the binding by ABD2 using 
gels shift assay and NMR titration. None of the sequences were bound with a high 
affinity, which meant that the right DNA motif had not been found yet or that this 
domain binds DNA with a low affinity probably via non-specific interaction with 
DNA. 
 
Using sequence analysis, it was later found that MS1 contains an additional DNA 
binding motif called an AT-hook motif, which is located in the very near proximity 
to its winged helix-turn helix domain. The functionality of this motif was confirmed 
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using NMR titration, which identifies the amino acids involved in the binding of a 
ligand. The NMR experiment confirmed that during titration with AT-rich DNA 
sequence, only residues from the predicted AT-hook sequence were involved in the 
binding, indicating that the predicted AT-hook motif of MS1 is functional. 
 
It is known that AT-hook motifs can be present in proteins with other DNA binding 
domains and that they can be necessary for their DNA binding properties. For 
example, deletion of the AT-hook motif in human Estrogen Releated Receptor-2 
protein (hERR2) abolishes DNA binding of its core DNA binding domain (DBD) 
(Gearhart et al. 2003). Recently it was demonstrated that the presence of the AT-
hook increased the affinity for DNA of TdIF1, which contains a helix-turn-helix 
domain as a core DBD (Kubota et al. 2013). It is therefore highly likely, that the 
AT-hook of MS1 provides a very important regulatory function in the process of 
DNA binding of MS1. The AT-hook of MS1 may anchor the protein on AT-rich 
DNA sequence and then it may “pull” the winged HTH domain to its target 
sequence. This could have an important implication in the gene expression 
regulation and search of the target sequence within the genome. Also, it is possible 
that the AT-hook may help to stabilise the entire ABD2-DNA complex as typically, 
the winged helix-turn-helix domains bind DNA as dimers while ABD2 exist in 
solution only as a monomer (Fogl et al. 2011).  
 
Interestingly, at the time of performing these experiments an NMR solution 
structure of a human homolog of MS1 called COSTARS (Pang et al. 2010) was 
solved and similarly to our results, the structure contained a winged helix-turn-helix 
domain (Lin et al. 2011). The DNA binding experiment revealed that this domain 
failed to bind DNA, which may suggest that the winged helix-turn-helix domain of 
MS1 is not fully functional without the AT-hook, suggesting further the implication 
of an allostery-like binding mechanism. A similar situation was observed for 
hERR2, where the zinc finger domain was not able to bind DNA, unless the AT-
hook was present (Gearhart et al. 2003).  
 
For further experiments, extended versions of ABD2 were prepared and the initial 
gel shift assay indicated that the N-terminal extension may be crucial for the DNA 
binding as two of the extended constructs (ABD2(C3) and ABD2(C2)) bound 
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random dsDNA library with a much higher affinity than ABD2. Initially, ABD2(C3) 
was chosen for a further characterisation. It contains the predicted AT-hook motif, 
the amino acid backbone assignment for this fragment was performed during the 
AT-hook verification and ABD2(C3) showed higher affinity than ABD2 alone and 
comparable to FOXO3a - a well characterised transcription factor (used as a 
positive control in DNA binding experiments).  
 
To identify the DNA sequence bound by ABD2(C3) a SELEX experiment was 
performed. It yielded a DNA motif, which was also CA/GT-rich, however it was 
still not completely clear what the exact motif is. At this stage, it also seemed quite 
obvious that the SELEX assay is ineffective to some extent, as it did not enrich to 
100% the full 7bp target motif of FOXO3a (FOXO3a was used as a positive control 
in SELEX). Some sequences did not contain the FOXO3a motif at all, whilst some 
contained only part of that motif. The MEME software was used to identify any 
significant motifs within the FOXO3a sequencing data set and the most significant 
motif was 18 bp long and it was A/G/C-rich with a dominance of adenosines. 
Additionally, there were few couple of enriched adenosines in a row, which could 
resemble of the central “AA” core of the FOXO3a DNA binding motif. Overall, the 
SELEX procedure did not enrich the full FOXO3a DNA binding motif in 100%, 
however there are part of it in the sequencing data.  
 
One of the possible explanations to why this happened could be due to fact that the 
number or conditions of the performed selection rounds were not enough to remove 
the non-specific DNA sequences and consequently, to enrich the single motif. In 
spite of the fact that the binding experiment before sequencing the final round 
(round 8) indicated an enrichment of the specific sequence, perhaps it was still not 
enough to remove non-specifically bound DNA sequences. It is also possible that 
during the selection and partitioning step of SELEX, the protein-specific DNA 
complex band, which was cut out, purified and used for the next round of selection, 
could have been contaminated by some non-specific DNA sequences, especially as 
no competitor DNA was used in EMSA (Materials and Methods). For example, as 
mentioned in the Chapter 4, there was a DNA band outside the well during the 
electrophoresis, which very likely represented some oligomers of ABD2 with some 
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non-specific DNA. As this non-specific DNA might have been incorporated to the 
next cycle of the SELEX, the final result could contain some of those non-specific 
DNA sequences. However, this error was corrected for the ABD2(C3) and FOXO3a 
when used in the SELEX and only bands from the gel were chosen for a subsequent 
cycle of the SELEX.  
 
Although, the gel shift assay has been previously used for the selection and 
partitioning step of the SELEX, our set up experienced some issues, which could 
have affected the overall SELEX result (Kubota et al. 2013; Cui and Leng 2007; 
Zykovich et al. 2009; Overdier et al. 1994). For example, it was noted that during 
the electrophoresis there were changes in the band numbers at different times of the 
electrophoretic run. For example, as shown in Figure 5.1, after 15 minutes of the 
electrophoresis, at 1:30 [DNA:protein] ratio there is no band visible in the gel lane 
and only small smear of DNA in the gel pocket. However, after additional 15 
minutes of the electrophoresis, one band is visible and further 15 minutes of the run 
result in appearance of one more band.  The reason why this is the case is unclear, 
but it may have been caused by the reduction in the background during the 
electrophoresis of the ethidium bromide from the gel. The changes in visualised 
DNA band numbers during electrophoresis could also have an implication on the 
overall SELEX result, as bands with different affinities could have been selected for 
a further SELEX cycle. The differences of affinities between them should not be 
large, but there is a possibility that some bands contained some non-specific DNA 
sequences, which affected the final SELEX result.   
 
Additionally, although the gel shift assay is a good technique to study protein-DNA 
binding, our set up showed some issues with the reproducibility when performing 
the titration experiments (sometimes for the same protein, under the same 
conditions a complex band started to be visible at different [protein:DNA] ratio). 
Overall, the gel shift assay results were carefully analysed, especially when 
comparing small differences in DNA binding e.g. during analysis of the DNA 
mutants binding and all results were verified using another methods such as NMR, 





                          
 
 
Figure 5.1 Visualisation of the complex band during gel shift assay. The gel was 
run for a total of 45 minutes at 80V and at every 15 minutes the DNA was 
visualised under UV light using the same exposure time. The complex band starts 
to be visible at the highest 30:1 [protein:DNA] ratio after 15 minutes of run and 
















5.1.2.1 Specificity and affinity of the MS1-DNA interaction 
 
Based on the sequence alignment from the SELEX results for ABD2(C3), one 
sequence named Wild type (WT) was chosen for further studies. It contained a 
“CAAA” core motif, which based on the sequencing results alignment was 
hypothesised to be bound specifically by helix 3 of the winged helix-turn-helix 
domain of ABD2(C3). The NMR titration confirmed that this sequence is indeed 
bound by ABD2(C3) and furthermore that residues from helix 3 are affected by the 
addition of this oligonucleotide. As in general, helix 3 of winged helix-turn-helix 
domains bind DNA in a sequence-specific manner, it was hypothesised that the WT 
oligonucleotide is bound by ABD2(C3) specifically.  
 
The mapped DNA binding site of ABD2(C3) contained residues from the AT-hook, 
N-terminal extension, helix 1, helix 3 and to some extent also the wing. It was later 
mapped onto the ABD2 structure and it revealed that indeed only residues that face 
the DNA molecule were affected by the binding of the WT oligonucleotide, with 
the exception of residues from helix 2.  
 
Using point mutant (A7G) as well as the Scramble oligonucleotide it was shown 
that the “CAAA” core motif is recognised by helix 3 as the CSPs in this region 
were significantly reduced for the mutated oligonucleotides when probed by NMR. 
The tryptophan fluorescence titrations showed that the KD of ABD2(C3) for the WT 
oligonucleotides is moderate (17 ± 3 µM) and that for the Scramble one is roughly 
two times lower (29 ± 5 µM). The calculated affinity for the point mutant, A7G was 
similar to the WT (15 ± 3 vs. 17 ± 3 µM for A7G and WT, respectively). The reason 
why this is the case is at present unclear as the NMR titration showed that helix 3 is 
definitely not involved in the binding of A7G oligonucleotide and therefore we 
would expect a much lower KD for the A7G oligonucleotide. However, in case of 
the longer construct ABD2(C2) the KD for the A7G oligonucleotide is around 3 
times lower that for the WT (10 ± 1 vs 29 ± 5 µM for WT and A7G, respectively). 
Also the ABD2(C2) affinity for the Scramble oligonucleotide is around 3 times 





The ABD2(C2) construct was used at the end of this investigation as it was later 
found that it contains a potential phosphorylation site just right next to the AT-hook 
motif (YGRPK, bold is the AT-hook, Y – the potential phosphorylation site) and 
therefore it could possibly be crucial for the regulation of MS1 DNA binding. 
Additionally, the phosphorylation site mutant (Y280A_MS1) showed a changed 
phenotype as compared to the wild type in a transient transfection experiment in 
Hela cells. Therefore, it is highly likely that it is functionally relevant, however 
further studies are necessary e.g. whether the charge state of the Y280 would affect 
the DNA binding in vitro. Overall, the DNA binding properties of the ABD2(C2) 
were slightly improved when compared to the ABD2(C3). Their DNA binding sites 
when bound to WT oligonucleotide involved the same residues, however the 
calculated KDs slightly differ (15 ± 3 vs. 10 ± 1 µM for ABD2(C3) and ABD2(C2), 
respectively). It is also consistent for the binding of the AT_WT oligonucleotide (13 
± 1 vs. 7 ± 0.9 µM ABD2(C3) and ABD2(C2), respectively). 
 
The binding of the AT_WT oligonucleotide was investigated as it was hypothesised 
that it enhances the DNA binding of the main winged helix-turn-helix domain. The 
KD values measured by tryptophan fluorescence titration support this hypothesis as 
in both cases for ABD2(C3) and ABD2(C2) the KDs were higher than for the WT 
oligonucleotide (for ABD2(C3) 15 ± 3 vs. 13 ± 1 µM for WT and AT_WT 
respectively; and for ABD2(C2) 10 ± 1 vs. 7 ± 0.9 µM for WT and AT_WT 
respectively). 
 
Table 5.1 shows a summary of all characteristics for the ABD2(C3)/ABD2(C2) 
interaction with the studied oligonucleotides. Overall, the results show that the 
binding of the WT/AT_WT oligonucleotide is more or less 2-3 times (ABD2(C3)) 
or 4 times (ABD2(C2)) stronger than the mutated forms. Whether this indicates 
specificity of the binding and whether it is physiologically relevant is not 
completely clear. However, what is clear is that when helix 3 residues are involved 
in the binding as in case for the WT/AT_WT oligonucleotide (which usually are 
involved in sequence-specific interaction with DNA), the affinity is improved. As 
the binding affinity for the best DNA motif is moderate, it is possible that the best 
SELEX-identified motif is not in 100% the motif, which could by bound by MS1 in 
vivo. Some studies show that substitution of one or more of the DNA bases can 
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drastically change the binding affinity (Knosp et al. 2006; Zhang et al. 2011; Cui 
and Leng 2007), so there is a possibility that the base composition in the found 





NMR titration Tryptophan 
fluorescence KD (µM) Binding site Helix 3 binding 
































- YES - - - 
AT_rich AT-hook 
only 
- NO - - - 
 
Table 5.1 Summary of DNA binding characteristics for ABD2(C3) and ABD2(C2). 
It describes residues involved in binding (Binding site) of certain oligonucleotide 
(DNA) by ABD2(C3) or ABD2(C2) as probed by NMR and it indicates whether 
helix is involved in the binding (Helix 3 binding). Binding affinities are shown as 
determined by a tryptophan fluorescence  (Tryptophan fluorescence KD (µM)). 
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Based on the assumption that the helix 3 drives sequence-specific DNA interaction 
and that indeed when helix 3 residues of MS1 are involved in the binding the 
affinity is improved (as judged by NMR and tryptophan fluorescence) it could be 
concluded that the ABD2(C3)/(C2)-WT/AT_WT interaction at least aims toward 
being specific. However, as the binding affinities are in 2-3 or 4- fold change range 
(for ABD2(C3) and ABD2(C2), respectively), one may argue that they may not be 
physiologically relevant, which seems logical in the context of a cell. However, to 
conclude it, more experiments are needed and ideally study of a position base 
change could be useful in order to see whether a change in a base composition (one 
by one) can affect the overall affinity in a positive way (improve the binding).  
 
Throughout the studies it was found that the newly discovered AT-hook motif 
within the MS1 sequence is important for its DNA binding properties. It was shown 
during NMR titration that addition of every oligonucleotide (WT, AT_WT, A7G, 
Scramble) affected the AT-hook motif and surrounding residues. One may argue 
that the observed ABD2(C3)/ABD2(C2)-DNA interaction may be primarily a result 
of the AT-hook binding, however the experiment with the WT_core oligonucleotide 
indicates that this is not the case. The WT_core oligonucleotide was designed not to 
contain the flanking AT-rich motifs, only the central “CAAA” core motif, which 
was flanked by G or C bases. The NMR titration confirmed that in the binding of 
this oligonucleotide only residues from helix 1 and helix 3 + wing were involved as 
judged by chemical shifts perturbations analysis. This suggests that the binding of 
this oligonucleotide is driven mainly via helix 1 and helix 3. However, the peak 
intensity changes analysis showed that R282, which is the central residues in the 
AT-hook motif experienced significant changes in its peak intensity, indicating an 
involvement in the binding of this oligonucleotide. It is very likely that there are 
two binding events, one as a result of the winged helix-turn-helix domain binding to 
the core motif and second of the AT-hook motif also to the central “CAAA” core, as 
there are still present A/T bases and from the previous experiment it is known that 
the AT-hook motif will bind to any A/T pairs.  
 
Also it is worth noting that in the experiment with the AT-rich oligonucleotide 
(Figure 4.32 and 4.35) peaks only from the AT-hook motif experienced significant 
changes, and no other residues were affected. It is therefore, very likely that the 
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observed changes for the ABD2(C3)/ABD2(C2)-WT/WT_AT interaction, whether 
in CSPs or peak intensities, are a result of some sort of specific interaction between 
the DNA and the winged helix-turn-helix domain of MS1. If the binding was a 
result of interaction between only the AT-hook motif and the AT-hook target 
sequence in the WT/AT_WT oligonucleotide it would be expected to observe 
changes only in the AT-hook part, as shown in the experiment with the AT-rich 
DNA oligonucleotide. Overall, it seems that the addition of any A/T pairs on sides 
of the “CAAA” core motif promotes binding of the DNA sequence, but the 
observed overall binding (for the WT/AT_WT oligonucleotide) itself is not only a 
result of the AT-hook motif interaction.  
 
Additionally, although the removal of the flanking AT-hook motif target sequences 
caused slight changes to the residues involved in the binding of that oligonucleotide 
(WT_core), the removal of the AT-hook + linker part significantly reduced the 
binding. Titration of ABD2 with the WT sequence caused, although consistent with 
ABD2(C3), very small CSPs of the residues involved in the WT oligonucleotide 
binding.  
 
Overall, the AT-hook motif seems to be very important for the 
ABD2(C3)/ABD2(C2)-DNA interactions and it is very likely that the AT-hook via 
attaching to AT-rich sequences may help to stabilise the ABD2-WT complex. The 
possible mechanism of the binding between ABD2(C3)/ABD2(C2) and WT 
sequence may involve binding to AT-rich sequence by the AT-hook to the inserted 
“AATA” sequence (WT sequence is 5’-GACACAAACACAATAG-3, the AT-hook 
target sequence is highlighted) or, as it seems that the AT-hook binds to any AT-rich 
sequence, it can possibly fold over the DNA molecule and bind back to the 
“CAAA” core motif in the minor groove (technically to the “AAA” from the 
“CAAA motif”). This would explain the chemical shift perturbation within helix 1, 
which does not face the DNA molecule, however they are still affected by the 
addition of the DNA as observed in the NMR titration experiment. It can also 
explain why the AT-hook binding residues peaks broadened beyond detection in the 
NMR titration experiment, as possibly the AT-hook may exist in two 
conformations: one bound to its target “AATA” sequence and one to the core 
“CAAA” sequence. Moreover, the binding into the “CAAA” core motif of the AT-
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hook seems possible due to relatively long linker between the AT-hook and the 
helix 1. Figure 5.2 shows possible binding modes of the WT oligonucleotide by 
ABD2 + the extended part containing the AT-hook motif. For the modeling a linker 
containing AT-hook from HMG-I(Y) was used ((Huth et al. 1997). Figure 5.2 A) 
and B) show two possible positions of ABD2 on the WT molecule (A) – 5’-3’; B) – 
3’-5’).  The model suggests that only the 3’-5’ DNA variant is able to accommodate 
two conformations of the AT-hook (Figure 5.2 C) and D)), whilst the 5’-3’ can 
accommodate only the “flipped AT-hook” model conformation. In the 5’-3’ 
direction the inserted AT-rich sequence is too far for the AT-hook to reach it 
(Figure 5.3 E) and F)). This can explain why the addition of the extra AT-rich 
sequence on the other side of the “CAAA” core motif in the AT_WT 







Figure 5.2 Possible binding modes of the WT oligonucleotide by ABD2(C3) or 
ABD2(C2). A) and B) two possible positions of the ABD2 on the WT molecule (A) 
– 5’-3’; B) – 3’-5’). C), D) two possible conformations of the AT-hook-containing 
linker on the 3’-5’ DNA. E), F) 2 possible conformations of the AT-hook-
containing linker on the 5’-3’ DNA. The model suggests that only the 3’-5’ DNA 
variant is able to accommodate two conformations of the AT-hook whilst the 5’-3’ 
can accommodate only the “flipped AT-hook” conformation. For the model AT-
hook containing linker from (?) was used. Images were created in Pymol. 
Interacting residues are shown in red and orange. Red indicates residues that exhibit 
CSP higher than <Δδtot> + 1σ, whilst orange higher than  <Δδtot> level.  
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5.2. Conclusions and future perspectives  
 
In conclusion, this study shows that MS1 exhibits all features and properties of a 
DNA binding protein. Under appropriate conditions, it can localise to the nucleus in 
a stress response and development-dependent manner. It contains a DNA binding 
domain, namely winged helix-turn-helix domain, which in combination with a 
nearby AT-hook binds a DNA sequence with a moderate affinity, as the best binding 
affinity of ABD2(C2)-AT_WT interaction was 7 ± 0.9 µM.  
 
Although, most of the transcription factors bind their target DNA sequence with 
nanomolar affinities (Risner et al. 2013; Vacha et al. 2013; Pham et al. 2013), there 
are also known cases where their binding affinities are in similar range to that of 
MS1 (low micromolar range). One of the examples could be AsH2L protein, whose 
X-ray crystal structure revealed also a presence of the winged helix-turn-helix 
domain. Its DNA target motif was identified using SELEX assay and the measured 
KD for this sequence was 3.7 ± 0.9 µM. Moreover, this sequence was later validated 
in vivo by performing chromatin immunoprecipitation experiment, where genes 
associated with this motif were found to be upregulated by AsH2L protein (Sarvan 
et al. 2011; Chen et al. 2011).  
 
Although the best DNA sequence bound by MS1 was identified, genes associated 
with this motif, potentially regulated by MS1, were not found. It was due to the fact 
that the best motif bound by MS1 was too short (“CAAA”) and any search through 
known databases would generate an enormous number of potential genes associated 
with this motif. Moreover, although, residues from helix 3 were specifically 
involved in binding of this motif, the differences in affinities between the mutated 
forms is too small to speculate that this motif is specific and any search of genes 
associated with this motif could yield a high number of false positives.  
 
This work demonstrated the excellent performance of the aABD2ch antibody 
against MS1, which allowed us to establish the conditions under which MS1 goes 
to the nucleus. Its good performance in immunofluorescence and on blots means 
that it is now possible to perform a chromatin immunoprecipitation (ChiP) 
experiment, which identifies DNA sequences bound by a protein under in vivo 
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conditions and which should ultimately provide us with answers as to whether MS1 
is a transcription factor and to which DNA sequence and therefore genes it binds. In 
case of MS1, ChiP-on-chip or ChiP-seq should be performed. ChiP-on-chip is a 
combination of ChiP and microarray technology, while Chip-seq combines ChiP 
with high throughput sequencing. They are both used when DNA targets of the 
investigated protein are completely unknown. In case of ChiP-on-chip, DNA 
microarrays, which contain thousands of DNA fragments are used. DNA 
microarrays are commercially available and they are specifically designed to 
contain well-defined DNA fragments e.g. whole genome arrays or only promoter 
arrays. In order to identify the immunoprecipitated DNA, it is later denaturated, 
fluorescently labelled and hybridised with the microarray. Scanning of the 
microarray reveals, to which DNA spot the immunoprecipitated DNA hybridised 
and the sequence is identified. In case of the ChiP-seq the immunoprecipitated 
DNA is sequenced. (Aparicio et al. 2004; Ho et al. 2011). 
 
Another way of further studying MS1 function could be by gene expression 
profiling using DNA microarrays or by performing RNA-seq, which is a recently 
developed approach to transcriptome profiling that uses deep-sequencing 
technologies. It would be interesting to perform the experiment on muscle tissues 
and under different conditions (e.g. overexpressed vs. non-overexpressed MS1, 
stressed vs. non-stressed conditions etc) and to see whether and what changes are 
caused by the overexpression of MS1 in muscle cells and under different 
conditions. In case when possible targets are identified, it could be easier to perform 
chromatin immunoprecipitation coupled with real-time PCR to verify, whether MS1 
binds directly to those genes, which would be more cost effective than performing 
ChiP-on-chip or ChiP-seq.   
 
In the future it would be very useful to identify possible interacting partners of 
MS1. This could be achieved via pull-down assay coupled with mass spectrometry 
analysis or yeast two-hybrid assay. So far only three interacting partners of MS1 are 
known: actin, ABLIM1 and ABLIM2. It is highly likely that there are additional 
interacting partners, especially knowing that different cellular localisations of MS1 
have been observed. It is very likely that there are specific mechanisms involving 
different proteins that control the subcellular localisation of MS1.  
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Also, as the measured affinity of ABD2(C3)/ABD2(C2) for DNA is quite moderate 
(assuming that indeed MS1 is a transcription factor and the low affinity is not a 
result of a binding to a wrong binding motif) it is possible that it may need some 
additional interacting partners, which  may  induce a better positioning of the DNA 
binding site of MS1 on the DNA molecule, which consequently may increase its 
DNA binding affinity. It is possible that such interactions could induce changes in 
MS1 secondary structures or may help to stabilise the whole complex. It is also 
known that transcriptional complexes contain a variety of proteins so it is unlikely 
that MS1 would act alone. It may need for example co-activators like SRF needs 
MRTFs in order to be activated (Miralles et al. 2003) it may be part of a 
transcriptional complex and it may require prior binding of an activator protein to 
enhancer regions. Activator proteins bind to enhancers, which may be located far 
away from promoter regions. They can cause bending of DNA molecule, and in 
order to recruit RNA polymerase and subsequently facilitate the transcription, they 
require interaction with additional transcription factors, which would bind to them 
and to the promoter region of the regulated gene. MS1 may have this function, 
however this has to be further investigated.  
 
In summary, this thesis shows that MS1 possesses all the necessary attributes of a 
DNA binding protein and potentially, it could act as a transcription factor in the 
context of stress related cell modelling, e.g. in cardiac hypertrophy. It can 
translocate to the nucleus and the nuclear translocation is mediated by its NLS as 
well as it binds with moderate affinity to a defined DNA motif. The newly found 
function of MS1 seems to be relevant in the context of stress-mediated hypertrophic 
response and moreover, it suggests a novel mechanism of MS1 involvement in 
muscle hypertrophy. The current model of MS1 involvement in the development of 
muscle hypertrophy is based on its actin binding properties, where via interaction 
with actin it stimulates MRTFs translocation to the nucleus and subsequent SRF 
activation. However, based on the results found in this thesis it maybe possible that 
MS1 is involved in the development of muscle hypertrophy much earlier, via its 
direct DNA binding properties and subsequent gene expression regulation. It is 
worth noting that in the aortic banding experiment MS1 mRNA level has been 
upregulated times 1 hour after aortic banding, with a peak expression before day 1 
(3-times increase), which is when the early hypertrophic response takes place. The 
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possible mechanism may involve p38 kinase, which can be activated in response to 
a mechanical stress such as high pressure and which has been predicted to 
phosphorylate S150 of MS1. Therefore, it could be hypothesise that in response to a 
stress signal S150 is phosphorylated by p38, which subsequently causes 
translocation of MS1 to the nucleus where it may affect expression of specific 
genes. It could be genes that regulate MS1 expression or MS1 gene itself as the 
MS1 level is upregulated 1 hour after applying the stress signal in the model of 
aortic banding. The increased MS1 may later act in the MRTFs-SRF pathway using 
its actin binding properties and in the mechanism that has previously been well 



















































































No. PDB code Z-score Function/Description 
1  3Q5F-A 4.9 Transcriptional regulator SLYA 
2  4LMY-A 4.6 Peroxide regulator PERR, FUR family 
3  1G3T-A  4.6 Diphtheria toxin repressor 
4  1Q1H-A 4.5 Transcription factor E 
5  4HX8-A  4.5 Transcriptional regulator MNTR 
6  4ETS-B  4.5 Ferric uptake regulation protein 
7  4BGR-O 4.5 Proteasome subunit beta type-1 
8  1P6R-A 4.4 Penicillinase repressor 
9  2RGV-B 4.3 Peroxide operon regulator 
10  1YQA-A 4.3 Histone 1 
11  2QWW-A 4.2 Transcriptional regulator MARR 
12  LU6G-A 4.2 Cullin homolog 1 
13  2XV4-S 4.2 DNA-directed RNA polymerase III subunit 
14  3EYI-B 4.2 Z-DNA-binding protein 1 
15  3NQO-A 4.1 MARR-family transcriptional regulator 
16  1DPU-A 4.1 Replication protein A (RPA32) 
17  LOKR-A 4.1 Methicillin resistance regulatory protein MECI 
18  1W1W-H 4.1 Structural maintenance of chromosome 1 
19  3R4K-A 4.1 Transcriptional regulator, ICLR family 
20 3CTA-A 4.1 Riboflavin kinase 
21 2IT0-D 4.1 Iron-dependent repressor IDER 
22  4CR4-O 4.1 Proteasome component PRE3 
23  3DV8-A 4.0 Transcriptional regulator CRP/FNR 
24  1HST-B 4.0 Histone H5 
25  2QLZ-C 4.0 Transcriptional factor PF0095 
26  2QXB-B 4.0 Double-stranded RNA-specific adenosine deaminase 
27  4BGR-O 3.9 HTH-type transcriptional regulator MGRA 
28  2JT1-A 3.9 PEFI protein 
29  4L9T-B 3.9 MEPR protein 
30  4HQM-A 3.9 Transcriptional regulator QSRR 
31  2ZME-A 3.9 Vacuolar sorting protein SNF8 
32  1WQ2-B 3.9 DSVD protein 
33  2HYE-C 3.8 DNA damage-binding protein 1 
34  2WA0-A 3.8 Melanoma-associated ANTIGEN-4 
35  3EUH-A 3.8 Chromosome partition protein MUKF 
36  1WSU-D 3.8 Selenocysteine-specific elongation factor 
37  3JSO-A 3.8 LEXA repressor 
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38  1X1D-A 3.8 CRTF-related protein 
39  4GYI-A 3.7 RIO2 kinase 
40 2WTE-A 3.7 CSA3 protein 
41  3IZB-V 3.7 Cadmium efflux system accessory protein 
42  3HRM-A 3.7 HTH-type transcriptional regulator SARZ 
43  2PFB-B  3.7 Transcriptional regulator OHRR 
44  1ZHF-A 3.7 Isoflavanone 4’-O-methyltransferase 
45  2FRH-A  3.6 Staphylococcal accessory regulator A 
46  4EJU-B  3.6 Transcriptional regulator TCAR 
47  4BGR-O 3.6 Proteasome subunit beta type-1 
48  2OZ6-A 3.6 Virulence factor regulator 
49 4I99-D 3.6 Chromosome partition protein SMC 
50 4AD9-C 3.6 Beta-lactamase-like protein 2 
51  3DQV-C 3.6 NEDD8 
52  3PQK-B  3.5 Biofilm growth-associated repressor 
53  2CO5-B 3.5 Viral protein F93 
54  4CR2-A  3.5 Proteasome component PRE3 
55  3DP7-B 3.5 Sam-dependent methyltransferase 
56  LI5Z-B 3.5 Catabolite gene activator protein 
57  2VLU-A 3.5 Cell division control protein 6 homolog 
58 3LFK-B 3.5 Marr-like protein TVG0766549 
59  2NRI-B 3.5 Replication protein O 
60  3OV8-A 3.4 Protein AF_1382 
61  3OOP-A 3.4 LIN2960 protein 
62  2LSO-A 3.4 Histone H1X 
63  2QEN-A 3.4 Walker-type ATPase 
64  3LST-B 3.4 CALO1 methyltransferase 
65  3NW0-A 3.4 Melanoma-associated antigen G1 
66  1Z6T-B 3.4 Holliday junction atp-dependent DNA helicase RUVB 
67  1W1W-H 3.3 Apoptotic protease activating factor 1 
68  3DPT-A 3.3 RAB family protein 
69 2XRN-B 3.3 HTH-type transcriptional regulator TTGV 
70 2NOV-B 3.3 DNA topoisomerase 4 subunit A 
71 3HRT-A 3.3 Metalloregulator SCAR 
72 1HXD-A  3.3 BIRA bifunctional protein 
73  1Z91-A 3.3 Organic hydroperoxide resistance transcriptional 
regulator 74  3XGO-D 3.3 MMCR 
75  1W5T-C 3.3 ORC2 
76  2MLG-A 3.3 Sulfolobus transcription factor 76 
77  3MQ0-B 3.2 Transcriptional repressor of the BLCABC operon 
78  1FT9-B 3.2 Carbon monoxide oxidation system transcription factor 
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79  3QYF-A 3.2 CRISP-associated protein 
80 1BBY-A 3.2 RAP30 
81  3JTH-A 3.1 Transcription activator HLYU 
82 1R23-A 3.1 Transcriptional repressor SMTB 
83  4EVI-B 3.1 Coniferyl alcohol 9-O-methyltransferase 
84  3U21-A 3.1 Nuclear factor related to KAPPA-B-binding protein 
85  1DPU-A 3.1 Replication protein A (RPA32) 
86  3W6J-B 3.0 SCPA 
87  3ZEC-A 3.0 Adenosine monophosphate-protein transferase 
88 1S3J-B 3.0 YUSO protein 
89  1KYW-A 3.0 Caffeic acid 3-O-methyltransferase 
90 1YG2-A 3.0 Gene activator APHA 
91 1XNP-A 2.9 Transcriptional regulatory protein ARSR family 
92  1SFU-A 2.9 34L protein 
93 1STZ-A 2.9 Heat-inducible transcription repressor HRCA homolog 
94  1BJA-A 2.9 Transcription regulatory protein MOTA 
95  3LA7-A 2.9 Methionine aminopeptidase 2 
96 1DPU-A 2.9 Global nitrogen regulator 
97  2PBI-A 2.9 Regulator of G-protein signaling 9 
98  2F2E-B 2.8 PA1607 
99 3RIR-A 2.8 Biotin-[acetyl-COA-carboxylase] ligase 
100  1R00-A 2.8 Aclacinomycin-10-hydroxylase 
 
 


























Media name Media Ingredients [1L] 
Luria Broth Agar 5 g Yeast Extract, 10 g Tryptone, 10 g NaCl, 15 g Agar 










M9 Salts (42 mM Na2HPO4, 22 mM KH2PO4, 8.5 mM 
NaCl, pH 7.4),  
Micronutrient solution (stock solution contains: 3 µM 
NaMoO4, 400 µM H3BO3, 30 µM CoCl2, 10 µM CuSO4, 
80 µM MnCl2, 10 µM ZnSO4) dilute 1/1000, 
Vitamins solution (stock solution contains: 0.4 g choline 
chloride, 0.5 g folic acid, 0.5 g pantothenic acid, 0.5 g 
nicotineamide, 1.0 g myo-inositol, 0.5 g pyridoxal-HCl, 
0.5 g thiamine-HCl, 0.05 g riboflavin, 1.0 g biotin) 
Dilute 1/1000, 
2 mM MgSO4, 10 µM CaCl2, 6 g glucose, 1 g NH4Cl 
Transfection medium 68% DME, 16% medium M199, 10% horse serum, 5% 
fetal calf serum, 4 mM glutamine 
Maintenance medium 
 
78% DME, 20% medium M199, 4% horse serum, 1% 
penicillin–streptomycin, 4 mM glutamine, 0.1 mM 
phenylephrine  
Mounting medium 0.1 M Tris-HCl/glycerol (3:7) and 50 mg/ml N-
propylgallate, pH 9.5. 
 













Buffer name Buffer Ingredients [1L] 
FF6 Wash buffer 20 mM NaPO4, 500 mM NaCl, 10 mM 
Imidazole, 0.02% NaN3, pH 7.5 
FF6 Elution buffer 20 mM NaPO4, 500 mM NaCl, 500 mM 
Imidazole, 0.02% NaN3, pH 7.5 
TEV Wash buffer 20 mM NaPO4, 500 mM NaCl, 10 mM 
Imidazole, 0.02% NaN3, 10% glycerol, pH 7.5 
TE buffer 10 mM Tris, 1 mM EDTA 
Klenow buffer 50 mM Tris-HCl, 5 mM MgCl2, 1 mM DTT 
EMSA/SELEX buffer A 20 mM PO4, 100 mM NaCl, 0.01 % Triton X-
100, pH 7.5 
SELEX buffer B 20 mM PO4 , 150 mM NaCl, 0.01 % Triton X-
100, pH 7.5 
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